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Post-operative adhesion is a common complication after abdominal surgery, with 
high impact on patient wellbeing and healthcare costs. The repair of peritoneum is a 
complex process involving orderly phases which share some common features to 
normal wound healing. These include coagulation, infiltration of inflammatory cells, 
cell proliferation, extracellular matrix (ECM) deposition and remodelling, often with 
overlap between phases. The unique feature of peritoneal repair is that both small 
and large peritoneal wounds heal in a similar time. The peritoneum is a monolayer of 
elongated, flattened, squamous-like peritoneal mesothelial cells (PMC). Local 
mesothelial cell proliferation, centripetal cell migration from the wound edge, as well 
as incorporation of free-floating mesothelial cells may all contribute to repair of 
injured peritoneum. To date, the only well-characterised pathologic mechanism 
underlying post-operative adhesion formation at the molecular level is the formation 
of the fibrin layer and regulation of peritoneal fibrinolytic capacity. However, the 
contributions of collagen deposition and ECM remodelling to the peritoneal repair 
mechanism are not well understood. This thesis focuses on the role of PMC in the 
regulation of ECM deposition and remodelling in response to inflammatory stimuli 
in both in vivo and in vitro models, aiming to identify other key pro-fibrotic factors 
involved in the development of post-operative adhesion.  
 
We first identified that lysyl oxidase (LOX) played a key role in the progression of 
peritoneal fibrosis by regulating collagen cross-linking and deposition in vivo. The 
inhibition of LOX enzyme activity prevented the formation of fibrotic tissue by 
reducing collagen deposition. Meanwhile, dexamethasone (DEX) treatment also 
minimized the fibrotic response. Furthermore, in vitro studies showed that the 
induction of collagen deposition factors in PMC, including LOX and pro-collagen I, 
required both IL-1 and TGF-β signalling pathways. Thus, the combination of IL-1 + 
 iv
TGF-β was adopted in an in vitro model to mimic the inflammatory environment 
during peritoneal repair. Treatment of PMC with IL-1+TGF-β caused an 
epithelial-to-mesenchymal transition (EMT). These transformed PMC had enhanced 
cell motility and were more adherent to fibronectin. Finally, a real-time quantitative 
PCR-based microarray was used for genomic analysis of ECM-adhesion-related 
PMC genes in response to IL-1 and TGF-β treatment. The results showed that IL-1 
was more involved in regulating ECM degradation by inducing expression of matrix 
metalloproteinase (MMP) genes, whereas TGF-β mainly affected genes involved in 
ECM deposition, including collagens and other ECM components. However, both 
cytokines were shown to regulate some key genes involved in the development of 
adhesion, including COL16A1, COL7A1, FN1, ITGA5, and TGFB1. Moreover, IL-1 
was shown to reduce ITGA4 and ITGB6 expression affecting adherence of PMC to 
basement membrane, while TGF-β increased MMP14 and MMP16 expression, 
which could facilitate invasion of EMT-transformed PMC to the site of tissue repair.  
 
In summary, this thesis indicates that LOX plays an important role in peritoneal 
fibrosis. Secondly, a combination of IL-1 and TGF-β1 treatment demonstrates how 
these factors can act in concert to orchestrate tissue remodelling during peritoneal 
repair. Finally, genomic analysis of ECM-adhesion genes increases our 
understanding of aspects of the pathology of post-operative adhesion and identifies 
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The aim of this thesis is to examine the central role of mesothelial-cell-secreted 
Lysyl Oxidase (LOX) in the fibrotic response associated with peritoneal fibrosis 
following inflammatory injury, using in vivo and in vitro models. Other factors 
involved in the fibrotic process will be identified using a PCR-based microarray 
to analyse cytokine-induced effects on a panel of ECM-associated genes. 
Understanding the factors regulating peritoneal fibrosis may inform the 
development of therapeutic agents to limit the development of fibrosis 
associated with surgery and disease. This review of the relevant literature sets a 
background to the experimental studies described in subsequent chapters of the 
thesis. 
 
1.1 Clinical aspects of peritoneal fibrosis and adhesion within the abdominal 
cavity 
 
Post-operative peritoneal adhesions are very common complications after abdominal 
surgery (Parker et al., 2005) (Figure 1.1). They can cause bowel obstruction, 
infertility, and extreme pelvic pain that dramatically impact quality of life and 
healthcare costs (Parker et al., 2005). Although the problem has been extensively 
studied in vitro and in vivo, to date the pathology is still not fully understood. 
Clinically oriented guidelines for the diagnosis, treatment and options for reducing 
adhesion still need further investigation. Intra-abdominal adhesions may be 
congenital or acquired. Congenital adhesions can be attributed to abnormal 
physiological organogenesis or embryonal development of the abdominal cavity. For 
example, a frequent observation is the attachment of the sigmoid colon to the left 
abdominal wall. Fortunately they are rare and usually asymptomatic (Liakakos et al., 
2001). Patients who have not undergone surgery still may develop post-inflammatory 
adhesions (Weibel and Majno, 1973). These are mainly caused by intra-abdominal 
inflammation linked to diseases such as endometriosis, peritonitis, radiotherapy, 
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Chlamydia trachomatis infection (Taylor-Robinson et al., 2009), or long-term 
peritoneal dialysis (Liakakos et al., 2001; Cheong et al., 2001; Monk et al., 1994).  
 
 
Figure 1.1. Postoperative adhesions following open surgery 
 
Although there can be many causes for intra-abdominal adhesions as mentioned 
above, the major cause is associated with surgery. The incidence of such peritoneal 
adhesion in patients following general abdominal surgery ranges from 63% to 97% 
(Menzies and Ellis, 1990; Group., 1991). They develop as a result of unusual wound 










Table 1.1. Overview of factors that influence the formation of adhesions. 
Adapted from (Bruggmann et al., 2010). 
 
Factors influence the formation of adhesions  
● Complexity of operation (DeCherney and diZerega, 1997) 
● Extent of peritoneal trauma  (Dijkstra et al., 2000; Menzies, 
1993) 
● Previous illness (e.g., diabetes) (Liakakos et al., 2001) 
● Poor nutritional status  (Liakakos et al., 2001) 
● Intra-abdominal placement of foreign bodies (e.g. meshes) (Liakakos et al., 2001) 
● Excessive coagulation with tissue necrosis  (Drollette and Badawy, 1992) 
● Accompanying bacterial infection (Liakakos et al., 2001) 
● Laparoscopy 
– Dehydration owing to high insufflation pressure and 
compression of capillary flow  
(Yesildaglar and Koninckx, 2000; 
Molinas and Koninckx, 2000) 
● Laparoscopy 
– Dehydration owing to dry gas  
(Ott, 2008) 
● Laparoscopy 
– Mesothelial hypoxia owing to use of CO2  
(Molinas et al., 2001) 
● Laparotomy 
– Dehydration owing to light and heat  
(Drollette and Badawy, 1992) 
● Laparotomy 
– Exposure to foreign material (e.g., glove powder) 
(Torre et al., 2002; Luijendijk et 
al., 1996) 
● Laparotomy 
– Mesothelial dehydration and abrasion from use of dry 
abdominal drapes  
(Dijkstra et al., 2000; Menzies, 
1993) 
 
A considerable number of these patients experience serious complications, including 
bowel obstruction (Menzies, 1993; Beck et al., 1999), female secondary infertility 
(Hershlag et al., 1991) and re-operative complications (Holmdahl and Risberg, 1997). 
The greater omentum is involved in 80% of cases of postoperative intra-abdominal 
adhesion and around 50% with the bowel (Menzies and Ellis, 1990). The symptoms 
caused by these adhesions include meteorism, digestive disorders, infertility, 
intestinal obstruction, irregular bowel movements, and chronic abdominal pain. 
Ovarian (Pittaway et al., 1985) and peritubal (Stovall et al., 1989; Molloy et al., 1987) 
adhesions can also be found in over 90% of patients after gynaecological adnexal 
surgery. These can reduce mobility, cause mechanical blockage of the Fallopian 
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tubes, and eventually lead to follicular entrapment. Such adhesions may also interfere 
with oocyte transport, increasing the risk of ectopic pregnancy (Molloy et al., 1987). 
Readmission for patients who have had postoperative abdominal adhesion is another 
huge problem in terms of both patient morbidity and healthcare costs. Awareness of 
such problems has increased in recent years. A comprehensive epidemiological study 
was undertaken in Scotland in 1986 to determine the frequency of adhesion-related 
complications in patients undergoing open lower abdominal surgery (Parker et al., 
2001) . The study showed that over a 10 year period, up to 33% of patients were 
readmitted to hospital for an average of 2.2 occasion, due to a disorder directly or 
possibly related to adhesions, or for surgery complicated by adhesions. Over £500 
million was spent in UK over 10 years for adhesion-related readmission following 
lower abdominal surgery (Wilson et al., 2002). In a more recent study (Parker et al., 
2004), the rates of adhesion-related readmissions following colorectal surgery were 
found to be very similar between 1986 and 1996-1997. The rate of directly or 
possibly related readmissions 4 years after colorectal surgery was 25.5% in the 
former and 29.7% in the latter. This suggested there was no improvement in 
reduction of adhesion-related readmission despite advances in surgical technique that 
had occurred. In order to address the problem more specifically, another study 
(Parker et al., 2005) investigated the risk of adhesions associated with specific types 
of abdominal surgery and with patient characteristics. In this study, researchers used 
data from the Scottish National Health Service medical record linkage database to 
assess the risk of the adhesion-related readmissions following open lower abdominal 
surgery between April 1996–March 1997. They found a nearly 5% risk of 
readmission directly related to adhesions in the 5 years following surgery among 
patients undergoing lower abdominal surgery (excluding appendectomy). 
Panproctocolectomy and ileostomy surgery appear to be associated with the greatest 
risk of an adhesion-related readmission. Previous surgery (within 5 years) and patient 
age (< 60 years) were also identified as important risk factors, as double readmission 
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risk was found in patients who had had undergone abdominal or pelvic surgery 
within the previous 5 years and in the patients aged < 60 years as well. This study 
will help to identify the patients who might have a high risk to get an adhesion 
related readmission.  
 
Based on pathophysiological mechanisms of origin, various strategies have more 
recently been taken to reduce adhesions (Table 1.2). Nowadays anti-inflammatory 
agents, fibrinolytics, and antibiotic solutions are used to prevent adhesion formation 
(Metwally et al., 2006; Kamel, 2010). Moreover other solutions, such as colloids 
(dextran) or crystalloid solutions (Ringer lactate or saline), have been used to 
separate peritoneal surfaces either alone or with corticosteroids or heparin. However, 
clinical data have yet to demonstrate a clear benefit of these substances in adhesion 
reduction (Metwally et al., 2006). Other materials have also been employed that form 
a physical barrier between the peritoneum and organs. For example, cross-linked 
esters of hyaluronic acid form a viscous gel that is applied to traumatized peritoneal 
surfaces after abdominal pelvic surgery to keep them separate during the healing 
process (Mais et al., 2006); carboxymethyl cellulose and polyethyleneoxide form a 
gel-like resorbent barrier for sealing peritoneal surfaces and preventing future 
adhesions (diZerega et al., 2007); oxidized regenerated cellulose is used as a 
resorbant membrane applied to injured surfaces (Ahmad et al., 2008). In summary, 
however despite many developments in adhesion prevention, there is no consensus 
on a reliable, consistent method for the prevention/reduction of adhesion formation. 







Table 1.2. Practical tips: general strategies for reduction of adhesions. Table 
adapted from (Parker et al., 2005) 
 
●Preference for tissue-sparing and micro-invasive surgical techniques 
●Minimization of operating time and of heat and light 
●Avoidance of peritoneal trauma by superfluous contact and coagulation 
●Limited placement of intra-abdominal foreign bodies such as patches, meshes, and suture 
material 
●Use of moistened abdominal drapes and swabs and occasional application of saline solution to 
minimize dehydration of mesothelial surfaces 
●Irrigation of the abdominal cavity to remove residual intra-abdominal blood depots 
●Reduction of infection risk by ensuring sterile working conditions and giving antibiotics as 
required 
●Laparotomy: preferential use of latex- and powder-free gloves 
●Laparoscopy: use of humidified gases at appropriately low insufflation pressure 
●High-risk patients: use of barrier techniques or peritoneal instillation after appropriate 
explanation 
 
1.2 Biological function of mesothelium and peritoneal mesothelial cells in the 
peritoneal cavity 
 
The mesothelium was first described by Bichat in 1827 (Whitaker et al., 1982), as a 
single layer of flattened cells lining the serous cavities. In embryological studies, 
mesothelium was found to develop from the mesodermal tissue between 8 and 18 
days of gestation, depending on species (Tiedemann, 1976; Hesseldahl and Larsen, 
1969). In humans, this occurs around day 14. The mesothelium has been shown to 
cover three serosal cavities: pleural, pericardial and peritoneal cavities. In the male, it 
also lines the sac that surrounds the testes. The mesothelium is further defined as 
visceral mesothelium and parietal mesothelium. The former mainly covers the 
internal organs, whereas the later is referred to that which lines the body wall. Both 
morphological and histochemical studies have confirmed that the mesothelium is 
essentially similar, irrespective of species or anatomical site (Whitaker et al., 1982; 
Kluge and Hovig, 1967a; Kluge and Hovig, 1967b; Baradi and Rao, 1976; Baradi 
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and Hope, 1964; Tsilibary and Wissig, 1977; Gaudio et al., 1988; Raftery, 1973a; 
Whitaker et al., 1980). Despite the longstanding acknowledged existence of the 
mesothelium, its importance has only recently been recognised. Not only is the 
mesothelium a protective layer for preventing organs from sticking together, but it 
also plays an important role in regulating serosal response to injury, infection and 
disease. 
 
The mesothelium consists of a monolayer of elongated, flattened, squamous-like 
mesothelial cells (Figure 1.2). The terminology arose because these cells not only 
display many epithelial characteristics including a polygonal cell shape, cytokeratin 
expression, and the ability to secrete a basement membrane, but also share some 
features of mesenchymal cells including expression of vimentin, desmin and, upon 
stimulation, alpha smooth muscle actin (Czernobilsky et al., 1985; Afify et al., 2002). 
These cells are approximately 25μm in diameter and rest on a thin basement 
membrane with underlying connective tissue. The predominant mesothelial cells 
present a squamous-like cell phenotype; but they can also present a cuboidal 
morphology which can be found in some areas, including the parenchymal organs 
(liver, spleen), the ‘milky spots’ of the omentum and the peritoneal side of the 
diaphragm (Wang, 1974; Michailova et al., 1999). Although they are both described 
as mesothelial cells, ultrastructural analysis has shown some differences between 
these two types of cells. Squamous-like cells have a round or ovoid nucleus, which is 
usually larger than that of the cuboidal cells and contain a prominent nucleolus 
(Baradi and Hope, 1964; Wang, 1974; Baradi and Campbell, 1974). In addition, 
squamous-like cells have few mitochondria, a poorly developed Golgi apparatus and 
little rough endoplastic reticulum (RER); whereas cuboidal cells contain abundant 
mitochondria, RER, and a well developed Golgi apparatus. A greater number of 
microfilaments are also found in the cuboidal cells compared to squamous ones 
(Baradi and Hope, 1964; Wang, 1974; Baradi and Campbell, 1974; Kluge and Hovig, 
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1967a). These features indicate that the cuboidal cells may be more metabolically 
active than the squamous ones. Interestingly, cuboidal cells, or morphologically 
similar ones, can be found after injury or stimulation of the serosal surfaces, which is 
suggestive of a more active role of cuboidal cells during serosal repair (Whitaker and 




Figure 1.2. Phase contrast image showing a monolayer of peritoneal mesothelial 
cells in primary cell culture.  
 
The luminal surface of the mesothelial cells has a well developed microvillous 
border, projecting from the apical surface. The microvilli are up to 3μm in length; but 
vary in shape, length and density between adjacent cells and between different 
organs (Andrews and Porter, 1973; Tsilibary and Wissig, 1977; Michailova et al., 
1999). They help to trap protein from peritoneal fluid and to minimize the shear 
between neighbouring mesothelial surfaces. Interestingly, the number of microvilli 
expressed on each cell is also shown to depend on the surrounding physiological 
situation, that could be a functional adaptation of the microvilli (Madison et al., 
1979). The mesothelial cells also have a well-developed system of vesicles and 
vacuoles. Most of them are micropinocytic; but a few multivesicular bodies and large 
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vacuoles can also be found. It has been shown that visceral mesothelium has more 
vesicles than the parietal mesothelium. These vesicles are often found along the 
luminal cell surface, in contact with the plasmalemma (Fukata, 1963; Kluge and 
Hovig, 1967a; Fedorko and Hirsch, 1971; Cotran and Karnovsky, 1968), and 
function in transporting fluids and particulates through the mesothelium by pinocytic 
transport (Cotran and Karnovsky, 1968; Leak and Rahil, 1978; Fedorko and Hirsch, 
1971).    
 
Mesothelial cells have well-developed cell-cell junctional complexes including tight 
junctions, adherens junctions, gap junctions and desmosomes (Kluge and Hovig, 
1967b; Pelin et al., 1994). Tight junctions are thought to be important for the 
formation of cell surface polarity, as well as the development and maintenance of a 
semi-permeable diffusion barrier. Adherens junctions are crucial to form the 
structural and adhesive support of the cell layer, while gap junctions contribute to the 
establishment of aqueous inter-cellular channels. A number of protein components 
are involved in the build up of these junctional complexes, including E-, N- and P- 
cadherins (Yap et al., 1997; Simsir et al., 1999). N-cadherin has been shown to 
predominate (Simsir et al., 1999). Mesothelial cells also express 
membrane-associated zonula occludens-1 (ZO-1) (Foley-Comer et al., 2002). At the 
junctions between mesothelial cells, another important functional construction called 
‘stomata’ has been described (Wang, 1975). It is postulated that these stomata may 
help the movement of fluid and particulate matter to and from the serous cavities. 
These stomatal openings are normally 3-12 μm in diameter and are controlled by 
actin filaments (Tsilibary and Wissig, 1983), but their size can increase during 
inflammation (up to more than 20μm). The stomata are generally found in the areas 
where cuboidal mesothelial cells are present, such as the peritoneal side of the 
diaphragm or the omental milky spots. The opening of stomata allow rapid removal 
of fluid, cells, bacteria and other particles from the serosal cavities to the underlying 
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submesothelial lymphatic system; indicating an important role of stomata in 
peritoneal clearance. In the meantime, it also provides a direct link between the 
pleural and abdominal cavities (Ohtani et al., 1995; Ohtani and Ohtani, 1997), which 
may account for the entry of inhaled materials into the abdominal cavity leading to 
fibrosis or malignant mesothelioma.   
 
Not only can the stomata aid the transport of the fluid within the cavities, but 
mesothelium itself also plays an important role in transport across the serosal cavities. 
It has been shown that microvilli can bind fluids and aid adsorption by their 
glycosaminoglycan covering (Wang, 1974). Many tracing studies have also 
demonstrated that particulates and solutes can be actively transported across the 
mesothelium by pinocytic vesicles (Fukata, 1963; Fedorko and Hirsch, 1971; Leak 
and Rahil, 1978). In addition, mesothelial cells can increase the number of 
plasmalemmal vesicles, which facilitates clearance of extracellular fluid under 
elevated fluid pressure (Shumko et al., 1993).   
 
Mesothelial cells also play an important role in inflammatory responses within the 
serosal cavities. It has been shown that mesothelial cells can secret various pro-, 
anti-inflammatory and immunomodulatory factors. These include prostaglandins, 
prostacyclin, nitric oxide (NO) and reactive nitrogen and oxygen species, 
chemokines, anti-oxidant enzymes, cytokines and growth factors, extracellular 
matrix (ECM) molecules and products of the coagulation cascade.  
 
The production of these factors is mainly due to a variety of stimuli including 
bacterial endotoxins, cytokines, asbestos, or instilled agents, with the purpose of 
restoring normal mesothelial architecture and function (Antony et al., 1993; Boylan 
et al., 1992; Antony et al., 1995). For example, it has been shown that 
lipopolysaccharide (LPS) and zymosan can stimulate tumour necrosis factor (TNF)-α, 
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interleukin (IL)-1β, and IL-10 production from cultured rat peritoneal mesothelial 
cells (Yao et al., 2004). Disorder of production of these cytokines might further 
contribute to peritonitis (Yao et al., 2004). Studies also show that mesothelial cells 
can eliminate bacteria by phagocytosis resulting in IL-8 release (Visser et al., 1995; 
Visser et al., 1996). Phagocytosis also occurs during engulfment of asbestos fibres by 
these cells (Antony et al., 1995). Furthermore, talc and asbestos have been shown to 
stimulate mesothelial cells to secrete IL-8 and monocyte chemoattractant protein-1 
(MCP-1), production of which can be further increased in the presence of IL-1β or 
TNF-α (Tanaka et al., 2000; Nasreen et al., 1998). Neutralizing studies, using 
specific MCP-1 and IL-8 antibodies, have demonstrated that cell-derived MCP-1 and 
IL-8 play important roles in chemotactic activity (Antony et al., 1995). Other 
chemotactic factors are also produced by mesothelial cells including stromal 
cell-derived factor-1 (SDF-1) (Coulomb-L'Hermin et al., 1999) and eotaxin 
(Katayama et al., 2002). The former can stimulate the growth of B lymphocyte 
precursors and account for the accumulation of B1 lymphocytes in the cavities 
(Coulomb-L'Hermin et al., 1999; Foussat et al., 2001). Eotaxin can be produced by 
mesothelial cells in response to TNF-α and IL-4, and is considered as a chemokine 
for eosinophils (Katayama et al., 2002; Georas et al., 2002). Studies have also shown 
that mesothelial cells can produce IL-6 and macrophage colony stimulating factor 
(M-CSF). Elevated levels of IL-6 are expressed by mesothelial cells in response to 
TNF-α and IL-1β (Topley et al., 1993). The expression of endogenous IL-6 can 
regulate the levels of pro-inflammatory factors in both local and systemic acute 
inflammatory responses (Xing et al., 1998). In addition, release of transforming 
growth factor-β (TGF-β) isoforms 1 and 2 from mesothelial cells is found in 
response to IL-1β (Offner et al., 1996). Furthermore, mesothelial cells also secret NO 
and other reactive radical species in response to cytokines, bacterial products and 
asbestos, including O2-·, NO· and H2O2 (Chen et al., 2000; Choe et al., 1998; Owens 
and Grisham, 1993). Such reactive species can cause cell death to occur when the 
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mesothelial cells are challenged by other toxic elements, which allow the cells to 
initiate a self-clean and regeneration process. 
 
As discussed above, mesothelial cells produce a variety of chemokines during serosal 
inflammation. Interestingly, these chemokines were found to be secreted more in the 
apical side of mesothelial cells than that of the basolateral side (Zeillemaker et al., 
1995; Nasreen et al., 2001). Such polarized secrtion by mesothelial cells forms a 
chemotactic gradient from the basolateral to apical side of the cells (Zeillemaker et 
al., 1995; Nasreen et al., 2001). This accounts for the recruitment of inflammatory 
cells into the serosal cavities from underlying tissue, such as vascular and lymphatic 
vessels (Li et al., 1998). Studies have shown that blocking such gradients, with 
antibodies for respective chemokines, can inhibit the transmesothelial migration of 
neutrophils and monocytes through the mesothelial monolayer (Li et al., 1998; 
Nasreen et al., 2001). In addition to secreting chemokines for inflammatory cell 
recruitment, mesothelial cells also produce specific integrins and adhesion molecules 
to facilitate the migration of inflammatory cells. For example, mesothelial cells can 
express intercellular adhesion molecule (ICAM-1), which interacts with lymphocyte 
function-associated antigen-1 (LFA-1) on the surface of leucocytes (Nasreen et al., 
2001; Jonjic et al., 1992). The interaction leads to cell-cell adherence and contributes 
to the transmigration of leucocytes through mesothelial cell monolayers (Liberek et 
al., 1996). It was shown that ICAM-1 is only expressed on the microvilli of 
mesothelial cells (Liang and Sasaki, 2000). This suggested another important role of 
microvilli in regulating leucocytes migration through the mesothelium. 
 
Finally, mesothelial cells secrete a variety of growth factors and ECM molecules that 
are critical for tissue repair. For example, TGF-β 1/2 are synthesized by mesothelial 
cells and regulated by IL-1β (Offner et al., 1996). Hypoxia, which is normally caused 
by tissue ischemia after injury, is also found to increase TGF-β 1/2 mRNA levels 
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(Offner et al., 1996). TGF-β2 can further stimulate mesothelial cells to produce 
vascular endothelial growth factor (VEGF) (Gary Lee et al., 2002), an important 
factor involved in angiogenesis. The inflammatory factors produced by mesothelial 
cells; including TGF-β, platelet-derived growth factor (PDGF), fibroblast growth 
factor (FGF), TNF-α and IL-1; are mitogenic for human mesothelial cells in vitro 
and in vivo (Gabrielson et al., 1988; Laveck et al., 1988; Mutsaers et al., 1997). 
These indicate an active autocrine regulation mechanism of mesothelial cell 
contribution to tissue repair. In addition, mesothelial cells can synthesize a variety of 
ECM components. Studies have shown that cultured rat mesothelial cells can 
produce collagen types I, III and IV, elastin, fibronectin and laminin (Rennard et al., 
1984; Laurent et al., 1988; Owens and Grimes, 1993), which is likely the same in 
human cells. Furthermore, mesothelial cells can organize these components into 
complex structures that reassemble to form the ECM in vivo (Rennard et al., 1984). 
The production of these molecules from mesothelial cells is regulated by many 
cytokines and growth factors, including IL-1β, TGF-β, TNF-α, epidermal growth 
factor (EGF) and PDGF (Owens and Grimes, 1993; Owens and Grisham, 1993; 
Kuwahara et al., 1994; Perfumo et al., 1996). Other studies have shown that collagen 
synthesis is increased in the cells in response to peritoneal effluents obtained from 
patients with acute peritonitis (Perfumo et al., 1996). This indicates an important role 
of peritoneal fluid in the regulation of tissue repair. Mesothelial cells also contribute 
to tissue remodelling by secreting matrix metalloproteinases (MMPs) and tissue 
inhibitors of metalloproteinases (TIMPs) (Marshall et al., 1993; Rougier et al., 1997; 
Ma et al., 1999), which are very important factors involved in collagen degradation 
(see section 1.5.4). It has been proposed that the regulation of the balance of these 
inflammatory molecules, together with the ECM factors, leads either to normal tissue 
repair or to fibrosis and adhesion formation. A summary of the factors produced by 
human mesothelial cells is listed in Table 1.3, with their respective stimuli.  
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Table 1.3. Factors produced by human mesothelial cells. Table adapted from (Mutsaers, 2002).  
Molecules Stimulus References 
Cytokines 
IL-1 EGF, TNF-α, LPS (Demetri et al., 1989; Lanfrancone et al., 1992) 
IL-6 TNF-α, IL-1 (Fujino et al., 1996; Topley et al., 1993) 
CSF (G,M,GM) IL-1, TNF-α, EGF, LPS (Demetri et al., 1989; Lanfrancone et al., 1992) 
Chemokines 
IL-8 IL-1, TNF-α, LPS, macrophage CM, asbestos, talc (Visser et al., 1995; Betjes et al., 1993) 
MCP-1 IL-1, TNF-α, IFN-γ, LPS (Visser et al., 1998a; Haslinger et al., 2001) 
RANTES IL-1, TNF-α, IFN-γ (Visser et al., 1998a) 
GRO-α IL-1, TNF-α, IFN-γ (Visser et al., 1998a) 
IP-10 IL-1, TNF-α, IFN-γ (Visser et al., 1998a) 
Eotaxin IL-4, TNF-α (Katayama et al., 2002) 
Growth factors 
TGF-β IL-1, hypoxia (Offner et al., 1996; Saed et al., 2000) 
FGF IL-1 (Cronauer et al., 1999) 
HB-EGF IL-1, TNF-α (Jayne et al., 2000; Faull et al., 2001) 
VEGF IL-1, TNF-α, TGF-β (Jayne et al., 2000; Gary Lee et al., 2002) 
HGF N/A (Warn et al., 2001) 
ECM-related molecules 
Collagen I IL-1, TNF-α, EGF, PDGF (Owens and Grimes, 1993; Saed et al., 1999; Yang et al., 1999) 
Collagen III TGF-β, EGF, PDGF, hypoxia (Saed et al., 1999; Harvey and Amlot, 1983; Rennard et al., 1984) 
Fibronectin IL-1 (Yang et al., 1999; Rennard et al., 1984) 
Hyaluronan IL-1, EGF, PDGF (Yung et al., 2000; Heldin and Pertoft, 1993) 
Surfactant N/A (Beavis et al., 1994) 
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Molecules Stimulus References 
Biglycan N/A (Yung et al., 1995) 
Decorin N/A (Yung et al., 1995) 
MMP TGF-β, PMA (Ma et al., 1999; Rougier et al., 1997; Marshall et al., 1993) 
TIMP TGF-β, PMA (Ma et al., 1999; Rougier et al., 1997; Marshall et al., 1993) 
Integrin (α1-6, β1, 
β3, α4β3) 
EGF (Liaw et al., 2001; Leavesley et al., 1999) 
Coagulation cascade proteins 
Tissue factor N/A (Bottles et al., 1997) 
tPA TNF-α (Idell et al., 1992; Sitter et al., 1995; Sitter et al., 1999) 
uPA TGF-β (Rougier et al., 1998; Falk et al., 2000) 
PAI IL-1, TNF-α, TGF-β, thrombin, LPS (Sitter et al., 1999; Sitter et al., 1995; Rougier et al., 1998) 
Adhesion molecules 
ICAM IL-1, TNF-α, IFN-γ (Jonjic et al., 1992; Cannistra et al., 1994; Liberek et al., 1996) 
VCAM IL-1, TNF-α, IFN-γ, LPS (Jonjic et al., 1992; Cannistra et al., 1994; Liang and Sasaki, 2000) 
E-cadherin N/A (Simsir et al., 1999) 




IL-1, TNF-α, thrombin, macrophage CM (Baer and Green, 1993; Topley et al., 1994; Hott et al., 1994) 
HSP IL-1, TNF-α (Lopez-Cotarelo et al., 2000) 
NO Combination of IL-1, TNF-α, IFN-γ, LPS (Chen et al., 2000) 
Reactive species 
scavengers 
Asbestos (Janssen et al., 1994) 
 
 20 
Abbreviation: IL, interleukin; EGF, epidermal growth factor; HB-EGF, heparin-binding EGF; VEGF, vascular EGF; TNF-α, tumour necrosis factor-α; LPS, 
lipopolysaccharide; IFN-γ, interferon-γ; G-, M-, GM-CSF, granulocyte, macrophage and granulocyte–macrophage colony stimulating factor, respectively; 
MCP-1, monocyte chemoattractant protein-1; GRO-a, growth-related oncogene-a; IP-10, IFN-g-inducible protein-10; PDGF, platelet-derived growth factor; 
FGF, fibroblast growth factor; HGF, hepatocyte growth factor, respectively; PMA, phorbol myristate acetate; MMP, matrix metalloproteinases; TIMP, 
tissue-specific inhibitors of metalloproteinases; PAI, plasminogen activator inhibitors; tPA, uPA, tissue and urokinase plasminogen activators, respectively; 
ICAM, intercellular adhesion molecule; VCAM, vascular cell adhesion molecule; HSP, heat shock protein; NO, nitric oxide. 
 21
1.3 Mechanism of peritoneal repair and post-operative adhesion 
 
1.3.1 Normal wound healing, scar formation and fibrosis 
Injury to cells and tissue is common to almost every accident and disease. The 
damage will normally initiate the healing process, which can be broadly separated 
into tissue regeneration and tissue repair. Tissue regeneration normally involves a 
complete reconstitution of lost or injured tissue and helps to restore normal tissue 
function. In contrast, tissue repair could lead to dysfunction in the original tissue, as 
it may restore the original tissue with inclusion of aberrant components, such as scar 
tissue. Tissue regeneration, such as the growth of an amputated limb in amphibians 
or liver regeneration, can be found in mammals but happens rarely. It has been 
shown that the regrowth process always involves compensatory growth, e.g., in 
kidney repair (Mene et al., 2003). Growth factors and stem cells also play very 
important roles in this process. Tissue repair is a much more common event that 
occurs during the healing process. Since most tissues cannot heal solely by 
self-regeneration, the healing is always associated with a mix of self-regeneration 
and replacement of other components, including connective tissue. Thereby, tissue 
repair can lead to the formation of a scar at the injury site. In post-operative repair, it 
may provoke adhesion formation. Fibrotic tissue will cause dysfunction of the 
original tissue and lead to many further problems. Therefore, a deeper understanding 
of the healing process, particularly the tissue repair process, will help to find a 
resolution for tissue fibrosis.     
 
As the repair process is more or less the same in different tissues, cutaneous wound 
healing is used as an example to introduce the general process of tissue repair. The 
healing process can be generally divided into sequential phases, commonly with 
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overlap between each phase (Hunt et al., 2000). First, the injury causes rapid 
activation of a coagulation process, which results in the formation of a blood clot at 
the injured site (Robson et al., 2001). The clot is formed by entrapped blood cells, 
fibrin, fibronectin and other complement components. It not only helps to stop 
bleeding, but also serves as a scaffold for the recruitment of inflammatory cells 
(Robson et al., 2001; Lawrence, 1998). For example, neutrophils are shown to appear 
on the injured site within 24 h to clean up the damaged tissue and invading bacteria 
(Werner and Grose, 2003). Subsequently granulation tissue is formed by the 
proliferation of fibroblasts and vascular endothelial cells (Witte and Barbul, 1997; 
Zhang et al., 1997). The granulation tissue progressively invades the injured space 
and replaces lost tissue, a hallmark of tissue repair. One of the notable features of 
granulation tissue is that it is often edematous, due to the leakage of newly forming 
blood vessels. This might assist however more ready access of other components to 
the injury site, facilitating the repair. In the meantime, neutrophils are replaced by 
macrophages from 48 to 96 h after injury (Hart, 2002). As the key inflammatory cells 
in the healing process, macrophages are capable of clearing the damaged tissue, 
fibrin and other foreign material (Werb et al., 1980). In addition, macrophages can 
produce a series of factors including PDGF, EGF, TGF-β, FGF, VEGF, IL-1 and 
TNF (Lingen, 2001; Delavary et al., 2011). These factors can promote fibroblast 
migration and proliferation, angiogenesis and ECM deposition. ECM deposition 
follows after granulation tissue formation. The ECM components can be produced by 
a variety of cells presenting in the injured site, including fibroblast cells (Myllyharju 
and Kivirikko, 2001), macrophages (Delavary et al., 2011), and epithelial cells  
(Myllyharju and Kivirikko, 2001). A predominant ECM is found within the injury 
area replacing the granulation tissue, with re-epithelialization beginning later on the 
surface of the tissue. The mediators for the epithelialization are thought to be HGF, 
HB-EGF, FGF-7 and IL-6 (Werner and Grose, 2003). In large wound areas, wound 
contraction helps to close the wound by decreasing the gap between the edges of the 
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wound. This process is mediated by myofibroblasts at the edge of the wound (Clark 
et al., 1989; Montesano and Orci, 1988). These cells have similar ultrastructual 
characteristics to smooth muscle cells. They contract the wound physically and also 
secrete large amounts of ECM components, including collagen I, fibronectin and 
tenascin-C (Darby and Hewitson, 2007). Myofibroblasts are thought to originate 
from tissue fibroblasts (Quan et al., 2006), promoted by factors secreted by 
macrophages at the wound sites, including TGF-β, PDGF and FGF-2. However, 
some studies suggest they may also originate from bone marrow precursors known as 
fibrocytes, or from epithelial cells through the epithelial-to-mesenchymal transition 
(Zeisberg et al., 2007; Kalluri and Neilson, 2003). The last step involved in tissue 
repair is the remodelling of connective tissue. Repair of injured tissue always leads to 
large amounts of ECM components being deposited at the wound site to replace lost 
tissue (Velnar et al., 2009). Therefore, the balance between ECM synthesis and 
degradation mediates in the remodeling of the connective tissue, a very important 
process for the completion of tissue repair. We already know that many growth 
factors contribute to ECM synthesis including TGF-β (Buck et al., 1996). The 
mediators of the ECM degradation involve the MMP family of enzymes. (Nagase 
and Woessner, 1999). The MMP family has more than 20 members, all having a 
conserved 180-residue zinc-protease domain (Visse and Nagase, 2003). They include 
interstitial collagenases (MMP-1, -2,-3), gelatinases (MMP-2 and -9), and 
stromelysins (MMP-3, -10, and -11) (Visse and Nagase, 2003).  
 
MMPs can act on a variety of ECM components, such as collagen types I, II, III, 
fibronectin and laminin. Most MMPs are produced by fibroblasts, macrophages, 
neutrophils and some epithelial cells (Vu and Werb, 2000). Their production can be 
up-regulated by growth factors (PDGF, FGF), cytokines (IL-1, TNF) and 
phagocytosis in macrophages (Werb et al., 1980; Circolo et al., 1991; Goetzl et al., 
1996), but be inhibited by TGF-β (Sporn and Roberts, 1992) and steroids (Green and 
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Friedland, 2007). They can readily degrade the ECM components because of their 
high enzymatic activity. Therefore, tight regulation of the high activity of the MMPs 
is maintained by tissue inhibitors of metalloproteinases (TIMPs). TIMPs are 
produced by most mesenchymal cells and can prevent uncontrolled action of the 
MMPs (Brew et al., 2000). More details about the MMPs and TIMPs will be 
discussed in section 1.5.4. We can conclude that the key feature involved in tissue 
remodelling is the regulation of ECM synthesis and degradation. This process seems 
to be mostly mediated by growth factors, MMPs and TIMPs present at the area of 
injury.   
 
The final process of repair involves scar formation at the injured site. This is 
composed of spindle-shaped fibroblasts, dense collagen, fragments of elastic tissue, 
small vascular vessels and other ECM components (O'Kane, 2002). Fibrosis is 
defined by the overgrowth, hardening, and/or scarring of various tissues and is 
attributed to excess deposition of extracellular matrix components, mainly collagen 
(Wynn, 2008). Although the terms scarring and fibrosis are interchangeable, fibrosis 
mainly relates to severe collagen deposition in chronic disease. The pathology of 
fibrosis associated with chronic disease is quite similar to the mechanisms of skin 
wound healing discussed above. However, the skin wound healing is always 
completed by orderly healing steps, which are promoted by acute inflammatory 
responses. In contrast, the chronic diseases caused by infections, autoimmune 
reactions and severe trauma always lead to chronic inflammation. The persistant 
stimulus in the chronic inflammatory response can lead to a disorderly repair process 
with much longer periods in each healing phase. Adverse chronic inflammation will 
be discussed later in section 1.4.2. The cellular and molecular mechanisms of fibrosis 
involve various cell types and inflammatory factors. One of the key cellular 
mediators of fibrosis are myofibroblasts, as they can promote wound contraction and 
produce a large quantity of ECM components (Quan et al., 2006; Follonier Castella 
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et al., 2010). Other cellular mediators including lymphocytes and monocytes also 
contribute to fibrosis, as these cells sustain the production of growth factors and 
fibrogenic cytokines during the chronic inflammatory process (Wynn and Barron, 
2010; Wynn, 2004). Therefore, the molecular mechanism(s) of fibrosis is relative to 
the persistant presence of various growth factors and fibrogenic cytokines, including 
TGF-β, PDGF, IL-4 and IL-13 (Wynn, 2008). 
 
TGF-β has been recognized as the most important factor contributing to fibrosis. 
Studies have shown that inhibition of TGF-β can suppress fibrosis in many disease 
models (Lee et al., 2001; Daniels et al., 2004). The function of TGF-β and its 
signalling pathway(s) will be discussed in more detail in section 1.4.3.3. Additionally, 
cytokines IL-4 and IL-13 also have distinct roles in the regulation of fibrosis. For 
example, studies indicate that IL-4 is another potent profibrotic cytokine which is 
nearly twice as effective as TGF-β (Fertin et al., 1991). Receptors for IL-4 are found 
on many human and mouse fibroblast cells (Sempowski et al., 1994; Doucet et al., 
1998). The activation of these receptors can increase the production of ECM factors, 
including types I and III collagen and fibronectin (Sempowski et al., 1994; Doucet et 
al., 1998). Blocking IL-4 led to a significant reduction in the development of hepatic 
fibrosis in mice (Cheever et al., 1994). IL-13 is another cytokine that has been 
identified as a predominant factor in several experimental models of fibrosis (Blease 
et al., 2001; Kumar et al., 2002; Keane et al., 2007; Kolodsick et al., 2004). On the 
other hand, over-expression of IL-13 in the lung induced significant subepithelial 
airway fibrosis in mice without any other additional inflammatory stimulus (Zhu et 
al., 1999), while anti-IL-13 treatment markedly reduced collagen deposition in the 
lungs of animal challenged with A. fumigatus conidia (Blease et al., 2001) or 
bleomycin (Belperio et al., 2002).  
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In summary, tissue repair is a complex process normally including orderly phases as 
we discussed above. Development of scar after tissue repair is quite common, since 
the injured tissue has always been replaced with a large amount of ECM components, 
mainly collagen. Fibrosis is most often linked to chronic inflammation, with 
persistant activation of profibrotic cells and factors. The resolution of inflammatory 
responses, as well as the balance between ECM synthesis and degradation, is critical 
to prevent tissue fibrosis. 
 
1.3.2 Peritoneal repair 
Peritoneal repair shares some common features to normal wound healing, including 
an inflammatory response, cell proliferation, extracellular matrix (ECM) deposition, 
angiogenesis and the fibrinolytic system. The unique feature of peritoneal repair is, 
however, that both small and large peritoneal wounds heal in a similar amount of 
time (Hubbard et al., 1967). Irrespective of the size of the wound area, peritoneal 
repair is normally completed within 7-10 days of the initial injury, being complete 
when the wound area is covered by cells displaying all the characteristics of 
mesothelial cells. It is suggested that unlike normal wound healing, such as that 
occurring in epithelium, peritoneum does not repair solely by proliferation and 
centripetal migration of cells from the wound edge. Many studies have been 
undertaken to address the mechanism regulating the peritoneal repair process. The 
general process has been defined (Hubbard et al., 1967). In this study, a midline 
incision was made and defects in the parietal peritoneum were created in Wistar rats, 
albino rabbits, and mongrel dogs. The healing process was investigated at 12 hours, 
and at daily intervals up to 7 days. The findings were quite similar in dogs, rabbits, 
and rats. At 24 hours the injury tissue was covered by a thin layer of fibrin. 
Infiltration of inflammatory cells including polymorphonuclear cells, eosinophils, 
lymphocytes and monocytes was found across the injured area (see Figure 1.3A). 
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Injured muscle fibres in the depths of the wound were removed by phagocytosis. By 
day 2 occasional fibroblasts were found within the injury area but mononuclear cells 
predominated in the whole injury site indicating a continued inflammatory response 
(Figure 1.3B). On day 3 most inflammatory cells had disappeared except for a few 
macrophages which indicated that the main inflammatory response was complete. 
Fibroblast-like cells replaced the fibrin layer to cover the surface of injury tissue 
(Figure 1.3C). Numerous mitoses were seen indicative of a regenerative process. 
From 4 to 6 days (Figure 1.3D-E), the number of fibroblasts decreased. Regeneration 
of peritoneum was found on the surface of the injury area and collagen deposition 
was found to replace the underlying fibroblasts. At 7 days (Figure 1.3F) the repair 
process was generally complete with an intact peritoneal mesothelium on the surface 
and underlying connective tissue consisting of mainly fibroblasts and collagen. The 
repaired tissue was quite similar to the normal tissue (Figure 1.3G) except for fewer 
fibroblasts in the deeper layers and a greater amount of collagen. In summary, the 
sequential peritoneal repair process includes the following steps: (1) A coagulation 
phase covering injured tissue with fibrin; (2) An inflammation phase with 
inflammatory cell infiltration; (3) A fibroplasias phase with fibroblast-like cells 
infiltration; (4) ECM remodelling phases with ECM deposition and degradation; and 











Figure 1.3. Sections of peritoneal tissues during wound repair. A. The centre of a 
peritoneal defect at 24 hours (X450); B. The centre of a peritoneal defect at 2 days. 
(X 450); C. The centre of a peritoneal defect at 3 days. (X 450); D. The centre of a 
peritoneal defect at 5 days. (X 450); E. The centre of a peritoneal defect at 6 days, 
collagen shown by Masson staining. (X 450); F. The centre of a peritoneal defect at 7 




























A (24 h)                        B (2 days) 
   
             C (3 days)                        D (5 days) 
   
E (6 days)                          F (7 days) 
    
            G (normal)                                    
   
 30
Although the general repair process discussed above appeared quite similar to a 
normal healing process, the regeneration of peritoneal mesothelium was still 
undefined since both small and large defects in the mesothelium were found to heal 
at the same rate. It has been shown that mesothelial cells at the edge of injured areas 
undergo cell proliferation and temporarily transform into spindle-shaped cells that 
migrate on to the denuded wound area (Whitaker and Papadimitriou, 1985; Mutsaers 
et al., 2000). The normal mesothelium is a slowly renewing tissue with 0.16-0.5% of 
cells undergoing mitosis at any one time (Mutsaers et al., 2000; Fotev et al., 1987). 
However, they can be stimulated to divide by many agents as well as by direct 
physical damage. Furthermore, kinetic studies using [3H]-thymidine as a marker for 
DNA synthesis confirmed that around 28% of mesothelial cells at the wound edge 
and on the opposing surface were dividing 24-48 h after injury (Figure 1.4A, B) 
(Mutsaers et al., 2000; Whitaker and Papadimitriou, 1985), whereas the centre of the 
wound reaches the maximum number by day 4 (Figure 1.4C). This suggested that 
local mesothelial cells proliferation and centripetal migration from the wound edge 
plays a very important role in peritoneal mesothelium healing. However it is clear 
that this is not the only mechanism accounting for the peritoneal repair. 
Irradiation(Whitaker and Papadimitriou, 1985; Fotev et al., 1987) and cell labelling 
studies (Fotev et al., 1987; Foley-Comer et al., 2002; Raftery, 1973b) have shown 
that macrophage transformation and a possible circulating bone marrow-derived 
mesothelial precursor are not involved. However, Campbell’s group showed that 
bone marrow origin cells can differentiate into myofibroblasts within the peritoneal 
cavity in response to irritation from foreign bodies (Campbell et al., 2000). Several 
pro-fibrotic genes were found up-regulated in these myofibroblasts which can 
contribute to peritoneal repair (Le et al., 2010). In addition, other studies suggest that 
regenerating mesothelium might originate either from a sub-mesothelial 





Figure 1.4. Surface imprints of [3H]-TdR labelled serosal lesions at (A) 24 h, (B) 
2 days, and (C) 4 days. Letter c: The centre of the lesion; Thick arrows: the margin 
between the centre and edge of the lesion; Small arrows: dark nuclei are labelled 
with silver grains (magnification X16). Bar 125 μm. Figure adapted from (Mutsaers 
et al., 2000).  
 
The nature of the sub-mesothelial mesenchymal precursor remains controversial. 
One theory was advanced by researchers on discovering the presence of cells with 
epithelial-like characteristics in the subserosal layer of biopsies from various 
pathological conditions (Bolen et al., 1986; Bolen et al., 1987; Davila and Crouch, 
1993; Dobbie, 1990). Bolen and co-workers have shown the best evidence for the 
existence of such precursor cells (Bolen et al., 1986; Bolen et al., 1987). They 
demonstrated that normal surface mesothelial cells expressed low and high molecular 
weight cytokeratins whereas submesothelial cells only expressed vimentin. However, 
submesothelial cells lost vimentin expression and acquired high and low molecular 
weight cytokeratins in the injured serosa. This suggested that the sub-mesothelial 
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cells were differentiating towards a mesothelial cell phenotype and thereby 
accounting for the regeneration of surface mesothelium. However, in a similar study, 
Whitaker and co-workers (Whitaker et al., 1992) could not reproduce these findings 
and doubted that the pattern seen by Bolen was a result of mature mesothelial cells 
migrating into the subserosal connective tissue. In addition, a kinetic study of 
mesothelial repair demonstrated that subserosal cells were not essential for 
mesothelial healing (Mutsaers et al., 2000). The study was suggestive that the 
surrounding uninjured mesothelial cells were more likely to contribute to 
mesothelium regeneration. 
 
Furthermore, it has been suggested that the epithelial-like cells in the subserosal layer 
might originate from mesothelial cells through an epithelial-mensenchymal transition 
(EMT). EMT is a characteristic loss of the epithelial markers E-cadherin, ZO-1, and 
desmoplakins I and II; and acquisition of a mesenchymal phenotype, with 
up-regulation of the mesenchymal marker fibronectin and reorganization of actin 
stress fibres and vimentin (Miettinen et al., 1994). Thus, EMT changes an epithelial 
cell to one with a fibroblastic nature (Figure 1.5). EMT has a role in many fibrotic 
diseases by increasing cell migration, invasion and cell-ECM adhesion, such as in 
kidney fibrosis (Higgins et al., 2007) and biliary atresia fibrosis (Diaz et al., 2008). It 
has been shown that various growth factors, including EGF (Leavesley et al., 1999) 
and TGF-β (Miettinen et al., 1994), can induce mesothelial cells to change phenotype 
and express many mesenchymal markers. In culture, mesothelial cells present both 
mesenchymal and epithelial characteristics throughout early passages. Thus, these 
findings have been suggested that the inflammatory response can direct the 
phenotype of mesothelial cells at different stages of wound healing by the production 
of inflammatory factors, particularly TGF-β. The mechanism of TGF-β induced 
EMT will be further discussed in a later section (1.4.3.3)  
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Figure 1.5. Epithelial-mesenchymal transition. EMT occurs when epithelial cells 
lose their epithelial cell characteristics, including dissolution of cell-cell junctions, i.e. 
tight junctions (black), adherens junctions (blue) and desmosomes (green), and loss 
of pical- basolateral polarity, and acquire a mesenchymal phenotype, characterized 
by actin reorganization and stress fibre formation (red), migration and invasion. 
Figure adapted from (Xu et al., 2009).  
 
In a number of studies, free-floating mesothelial cells were proposed to contribute to 
peritoneal repair (Watters and Buck, 1973; Whitaker and Papadimitriou, 1985). A 
12-fold increase in the number of viable free-floating mesothelial cells was found in 
the peritoneal lavage fluid recovered from experimental animals following injury to 
mesothelium compared to controls (Fotev et al., 1987). These cells were thought to 
originate from proliferative mesothelial cells adjacent to, or opposing, the serosal 
injury. Furthermore, it was shown that mesothelium healing was delayed following 
postoperative peritoneal lavages, possibly due to the removal of the free-floating 
cells (Tolhurst Cleaver et al., 1974). The most reliable evidence for the incorporation 
of free-floating mesothelial cells during serosal healing was presented by 
Foley-Comer and co-workers (Foley-Comer et al., 2002). The study used an in vivo 
cell tracking dye (1, 1’-dioctadecyl-3, 3, 3’, 3’-tetramethylindo-carbacyanine 
perchlorate; DiI) to label cultured mesothelial cells, peritoneal lavage cells and 
control fibroblasts. The labelled cells were injected into experimental animals 
immediately following mesothelial injury. Labelled cultured mesothelial and 
peritoneal lavage cells, but not cultured fibroblasts, implanted onto the wound 
surface and began to proliferate. Furthermore, the implanted cells were shown to 
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incorporate into the regenerated mesothelium and form junctional complexes. These 
studies have clearly shown that free-floating mesothelial cells may play an important 
role in peritoneal mesothelium healing. They proposed that the free-floating cells 
might move down chemotactic gradients and attach to ECM components exposed 
beneath the mesothelium. The attached cells would then proliferate and reconstitute 
an intact mesothelial monolayer. However, how these cells become detached from 
the basement membrane and remain viable in the peritoneal fluid still requires further 
investigation.   
 
In summary, peritoneal repair requires recruitment of inflammatory cells to the 
injured area and production of various inflammatory factors including growth factors 
and cytokines. The wound surface becomes covered by a fibrin layer, which is 
followed by the appearance of proliferative fibroblast cells to replace the fibrin layer 
as well as the underlying tissue. Meanwhile, collagen deposition is initiated to build 
up connective tissue. The repair process is completed on formation of an intact 
mesothelial cell layer on the surface. The regeneration of mesothelium may well be a 
consequence of both local mesothelial cell proliferation and centripetal migration 
from the wound edge, as well as the attachment of free-floating mesothelial cells in 
the peritoneal fluid.  
 
1.3.3 Pathology of post-operative adhesion 
So far, the well-established pathologic mechanism of post-operative adhesion 
involves the formation of the fibrin layer and the regulation of the peritoneal 
fibrinolysis capacity (Holmdahl et al., 1996). As discussed above, defects in the 
peritoneum are immediately covered by a thin layer of fibrin. This arises because 
damage to the peritoneum is followed by increased vascular permeability with 
exudation of fibrinogen and plasma fibronectin. The fibrinogen is then cleaved into 
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fibrin by the serine protease thrombin (Blomback et al., 1978). Fibrin is cross-linked 
by fibrin-stabilizing factor and binds to the tissue fibronectin at the wound sites, as 
well as plasma fibronectin, to form a fibrin clot (Blomback et al., 1978; Smith et al., 
2007). The fibrin clot acts mainly to help close the wound and form a wound bed for 
the recruitment of inflammatory cells (Hermans and McDonagh, 1982). In normal 
peritoneal repair, the fibrin layer will be degraded by the endogenous fibrinolytic 
activity of the mesothelial cells within 72h (Sulaiman et al., 2002). At this stage, the 
mesothelial cells produce fibrinolytic mediators - plasminogen activators (PA), 
including the urokinase PA (uPA) and tissue PA (tPA) (Sulaiman et al., 2002). The 
PAs are serine proteases that catalyze the conversion of plasminogen to plasmin 
(Vassalli et al., 1991). Plasmin is responsible for fibrinolysis, direct degradation of 
extracellular matrix, and activation of MMPs (Vassalli et al., 1991). Meanwhile, 
mesothelial cells have been shown to produce fibrin stabilizing plasminogen 
activator inhibitor-1 and -2 (PAI-1 and PAI-2) (Idell et al., 1992; Rougier et al., 
1998). It is suggested a fine balance between fibrin deposition and breakdown, that, 
if not regulated appropriately, can cause reduced fibrin clearance and result in 
adhesion formation (Holmdahl et al., 1998). 
 
It has been shown that the balance between normal and fibrotic healing is regulated 
by the inflammatory response. The inflammatory factors (LPS, TNF-α, and IL-1) 
(Sitter et al., 1996; Whawell and Thompson, 1995) and fibrogenic mediators (TGF-β 
and thrombin) (Rougier et al., 1998; Falk et al., 2000; Mandl-Weber et al., 1999) 
have been shown to reduce production of PA by mesothelial cells while increasing 
the synthesis of PAI-1. Therefore, during chronic inflammation, a significant delay in 
fibrinolysis can be caused by a persistent inflammatory response. The undigested 
fibrin will easily conglutinate the opposite site of the mesothelium to the wound. 
Further, fibrin-rich adhesions become organized with invading fibroblasts, 
endothelial cells and macrophages with consequent collagen deposition and 
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angiogenesis. This will lead to permanent fibrous adhesions formed within a week in 
the injured areas (Figure 1.6).  
 
 
Figure 1.6. Fibrinolysis inter-relationships involved in the origin of 
post-operative adhesion. Figure adapted from (Bruggmann et al., 2010). 
 
Other factors are also proposed to be involved in post-operative adhesion formation, 
including hypoxia. It has been shown that hypoxia can increase the production of 
lactate through the anaerobic glycolysis process (Shavell et al., 2009). The study 
demonstrated an elevated lactate concentration in the wound space immediately after 
injury. Lactate can act as an important stimulus for collagen formation and 
angiogenesis, and can then be a potent factor to promote adhesion formation by 
excessive collagen deposition and rapid angiogenesis. In addition, other studies have 
demonstrated that a specific neurokinin-1 receptor (NK-1R) antagonist, CJ-12,255 
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(Pfizer), can reduce adhesion formation in an experimental animal surgical model by 
increasing MMP activity in the peritoneum 24 hours after surgery (Cohen et al., 
2007). These data also support the role of MMPs in post-operative adhesion 
formation. Although there are a number of studies regarding the pathology of 
post-operative adhesion formation, an understanding of its underlying mechanism is 
incomplete.    
 
1.4 Inflammation and tissue fibrosis 
 
1.4.1 Inflammatory response induced by tissue damage.  
In a tissue repair process, the inflammatory response is commonly induced by 
infections at wound sites and sites of tissue damage, with the aim of eliminating both 
the initial cause of cell injury (e.g., microbes, toxins) and the consequences of these 
injuries (e.g., cell death and damaged tissue). Cellular response, as a consequence of 
inflammatory cells infiltration, plays a very important role in the inflammatory 
process. For example, neutrophils can help to clear microbes through phagocytosis 
and express proteinases that are involved in matrix degradation, enabling further 
cellular infiltration by macrophages and fibroblasts (Lingen, 2001). Macrophages 
have a variety of effects in damaged tissue clearance, fibroblast proliferation, and 
tissue remodeling. In addition, lymphocytes can migrate to the inflammatory site by 
chemotaxis, and interact with macrophages by producing the main macrophage 
activator – interferon-γ (IFN-γ). They are also capable of producing EGF, FGF and 
MMPs (Blotnick et al., 1994; Xia et al., 1996). Mast cells, which are widely 
distributed in connective tissues are also recruited to the wound site and can be 
activated to produce IL-4, a cytokine that stimulates fibroblast proliferation 
(Trautmann et al., 2000). However, the requirement for inflammatory cells in wound 
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repair may be not as essential as initially thought. Animal studies shows that 
neutrophil- or mast cells- knockdown mice are capable of completing normal wound 
repair (Simpson and Ross, 1972; Dovi et al., 2003; Egozi et al., 2003). In contrast, 
depletion of macrophages with antisera and steroids results in a serious disturbance 
in the repair process (Leibovich and Ross, 1975). It has been shown that debridement, 
the clearance of dead cells, fibrin and tissue debris from the wound, is compromised 
in the absence of macrophages, suggesting an essential role of macrophages in 
wound healing. However, in neonatal PU.1-knockout mice, a mouse model of 
neutrophil and macrophage knockout, an enhanced rate of re-epithelialization was 
found with absence of fibrosis (Martin et al., 2003). These findings suggest that 
inflammatory cells might disturb re-epithelialization by secondary tissue damage. 
Therefore, the effects of macrophages might represent a “double-edged sword” in 
wound repair. For example, a recent study showed that macrophage depletion 
blocked fibrosis in mouse liver after CCl4-induced damage, whereas the same 
depletion disturbed matrix degradation and slowed down scar resolution during the 
recovery phase (Duffield et al., 2005).    
 
In parallel with the cellular response, the inflammatory response also contains an 
orchestrated effect from other molecular mediators. The list of these inflammatory 
mediators includes, but is not limited to, cytokines, growth factors, proteases, kinins, 
and cellular metabolites. These mediators are soluble factors released by resident 
cells or by platelets and leukocytes infiltrating from blood vessels. The main factors 
in wound healing are considered to be cytokines and growth factors. Cytokines are 
recognized as the core factors involved in formation of post-operative adhesion 
including IL-1, TNF-α, and TGF-β. Therefore, as a focus of interest in this project, 
the functions and effects of these three cytokines will be discussed in more detail in 
section 1.4.3.  
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Growth factors also play an essential role in tissue repair. For example, connective 
tissue growth factor (CTGF) is an important downstream mediator for several 
inflammatory factors, including TGF-β (Leask, 2008; Schultz Jel et al., 2002). The 
role of CTGF is strongly associated with angiogenesis and ECM remodeling (Kular 
et al., 2011; Leask and Abraham, 2006). As a cofactor for TGF-β induced 
fibrogenesis, CTGF appears to create a favorable environment for fibrogenic stimuli 
to act (Mori et al., 1999; Shi-wen et al., 2006). In contrast, CTGF on its own is found 
to only weakly promote fibrosis (Kennedy et al., 2007). Functions of other growth 
factors involved in tissue repair are presented in Table 1.4. Although growth factors 
are equally important as cytokines, the effect of growth factors involved in 
post-operative adhesion is beyond the scope of this thesis.  
 
Table 1.4. Growth factors involved in wound healing. Table adapted from (Kumar 




In an ideal situation, the inflammatory response should be concluded, termed 
resolution, after the elimination of the injurious stimuli and restoration of the 
damaged tissue. Resolution involves neutralization of inflammatory mediators; 
restoration of normal vascular permeability; cessation of leukocyte infiltration; and 
removal of fluid, protein, leukocytes, and foreign agents from the site.  
 
 
1.4.2 Chronic inflammation and tissue fibrosis 
As discussed above, acute inflammation is thought to benefit the repair process. 
However, a persistent inflammatory response, i.e., a chronic inflammation, can 
frequently occur in many repair situations. Active inflammation of prolonged 
duration results in tissue destruction and repair proceeding simultaneously, and leads 
to tissue fibrosis. Chronic inflammation arises from persistent infection, prolonged 
exposure to potentially toxic agents, or very rarely autoimmunity. In post-operative 
adhesion formation, sutures or serious tissue damage at the site of incision are the 
principal contributors promoting adhesion formation. The features of chronic 
inflammation can be classified as follows: (1) infiltration of mononuclear cells, 
mainly macrophages but also lymphocytes and plasma cells; (2) Tissue destruction, 
due to the persistent offending factors; (3) replacement of damaged tissue by 
connective tissue, accompanied by growth of small blood vessels (Kumar et al., 
2005b).  
 
Macrophages are the dominant cells in chronic inflammation. They are part of the 
mononuclear phagocyte system, and derive from the bone marrow (Hume, 2006). In 
addition, tissue-resident macrophages also play an important role in local 
inflammatory response (Mosser and Edwards, 2008). As we discussed before, 
macrophages start to appear at the wound sites within 48h of insult and become the 
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predominant cell type. They can be activated by a variety of factors, including 
cytokines (e.g., IFN-γ and TNF-α), bacterial endotoxins and other chemical 
mediators (Mosser and Edwards, 2008). The activated macrophage can not only 
function as a phagocyte, but also produce several inflammatory factors (Lingen, 2001; 
Mosser and Edwards, 2008; Huybrechts-Godin et al., 1985), including IL-1, TNF-α, 
FGF, and MMPs. These mediators play an essential role in body defence and tissue 
remodelling. However, over a long period they can also induce the tissue destruction 
that is one of the hallmarks of chronic inflammation.  
Another hallmark of chronic inflammation is granulomatous inflammation (Adams, 
1976). This is a consequence of failed attempts to eliminate foreign bodies and 
particles, such as bacteria, toxic materials and suture fragments. It is a distinctive 
pattern of chronic inflammation reactions characterized by focal accumulations of 
activated macrophages, which often develops an epithelial-like (epithelioid) 
appearance. It leads to the formation of granuloma, a microscopic aggregation of 
macrophages that are transformed into epithelium-like cells surrounded by a collar of 
mononuclear leukocytes, principally lymphocytes (Williams and Williams, 1983). 
These epithelioid cells can fuse to form giant cells, which can be found in the 
periphery or centre of granulomas (Figure 1.7). Granulomas can be divided into two 
types by their different pathogeneses. One type are called foreign body granulomas 
and caused by inert foreign bodies, such as talc, sutures or other fibres. These 
materials are too large to be phagocytosed by a single macrophage, but do not incite 
any specific inflammatory or immune response. Therefore, the epithelioid or giant 
cells are formed with the purpose of simply encompassing the foreign body. The 
other granuloma type is called immune granuloma and is caused by insoluble 
particles, typically microbes. These particles are capable of inciting a cell-mediated 
immune response. In these responses, macrophages engulf these foreign particles and 
present them to respective T lymphocytes. T lymphocytes are activated and start to 
produce cytokines, such as IL-12 and IFN-γ. IL-12 can activate other T cells to 
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perpetuate the response, whereas IFN-γ can activate macrophages and transform 
them into epithelioid cells and multinucleate giant cells. Therefore granulomatous 
inflammation is seen in a wide variety of diseases, and frequently associated with 
tissue fibrosis (Woodard et al., 1982; Hartel et al., 2010; Mukhopadhyay and Gal, 
2010).  
 
Figure 1.7. Non-necrotizing granuloma in a lymph node (20x objective lens). 
Figure taken from Mutley Smith (Wikimedia Commons) 
1.4.3 Inflammatory cytokines and post-operative adhesion 
As discussed above, production of cytokines is one of the key characteristics of the 
inflammatory response. They can mediate and regulate inflammatory responses in 
various aspects, including cell infiltration, ECM remodelling and angiogenesis. 
However, persistent production of cytokines can cause a sustained inflammatory 
response, which will lead to tissue fibrosis. The role of cytokines involved in 
post-operative adhesion has been widely studied. For example, serum levels of IL-1 
and TNF-α are found to correlate with peritoneal adhesion grades in patients 
following major abdominal surgery (Saba et al., 1998). In addition, a pilot study of 
peritoneal fluid obtained from patients following laparoscopy has demonstrated that 
IL-1, IL-6 and TNF-α concentrations in the fluid are dramatically increased in the 
initial 48 h. High concentrations of IL-1 and IL-6, but not TNF-α, are associated with 
significant adhesion formation (Cheong et al., 2002). Furthermore, levels of TGF-β1 
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are also raised in peritoneal scar tissue compared to normal peritoneal tissue (Chegini 
et al., 1994). An overview of cytokine effects in post-operative adhesion formation is 
presented in Table 1.5. The most common cytokines studied in post-operative 
adhesion are IL-1 and TNF-α and TGF-β. Therefore, in this thesis, the effects of 
cytokines on adhesion formation will focus on these three cytokines.  
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Table 1.5. Overview of current literature regarding cytokine orchestration in postoperative adhesion formation. Table adapted from 






Effect on adhesion formation Referrence 
HGF Rat  
(both) 
Cecal abrasion Local HGF gene transfer enhance PMC migration and prevent postoperative peritoneal 
adhesions 
(Liu et al., 2006) 
IFN-γ, HGF Mouse 
(both) 
cecal cauterization Diminishing IFN-γ production can prevent adhesions by regulating PAI-1 and tPA, 
which is enhanced by HGF 
(Kosaka et al., 
2008) 
IL-1, TNF-α Human  
(in vivo) 
Adhesion samples Serum levels of IL-1 and TNF-α correlate with peritoneal adhesion grades in humans 
after major abdominal surgery 








Adhesion associated with IL-6 and IL-1 (Cheong et al., 
2002) 
IL-10, IL-4 Mouse 
(in vivo) 

















Exacerbated by IL-6, attenuated by monoclonal Ab to IL-6 (Saba et al., 
1996) 




Attenuated by combined TGF-β1 and TGF-β2 mAb, exacerbated by exogenous 
addition of TGF-β3 
(Gorvy et al., 
2005) 
TGF-β Rat Cecal abraision TGF-β mRNA increased by trauma and expressed higher in injured tissue that healed (Freeman et al., 
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(in vivo) with adhesion 2003) 












Adhesion associated with reduced MMP-9 but elevated MMP-9/TIMP-1 ratio (Cheong et al., 
2003) 
TGF-β Human  
(in vitro) 
Biopsy samples TGF-β protein is higher in scar tissue than normal tissue (Hobson et al., 
2003) 
TGF-β1 Rat  
(in vivo) 
Cecal ligation and 
puncture 
Peritonitis upregulates TGF-β1 expression (Ghellai et al., 
2000) 
TNF-α Rat  
(in vivo) 
Cecal abraision or 
small bowel 
resection 
Identify TNF-α as a good biological marker for adhesion formation (Kaidi et al., 
1995a) 
TNF-α, IL-1 Rat  
(in vivo) 








No effect of MMP & TACE inhibition, TNF-α may not be adhesiogenic (Mirastschijski 
et al., 2005) 
VEGF Mouse  
(in vivo) 
Peritoneal injury Adhesions attenuated by antiserum and monoclonal antibody (Saltzman et al., 
1996; Cahill et 
al., 2006) 
VEGF Mouse  
(in vivo) 
Lap. Uterine horn 
model 
Exacerbated by overexpression of VEGF  (Molinas et al., 
2003) 
MCP-1 Mouse  
(in vivo) 
Peritoneal injury Adhesions significantly attenuated by anti-MCP-1 Abs (Zeyneloglu et 
al., 1998) 
Abbreviation: HGF: Hepatocyte growth factor; IFN-γ: Interferon-gamma; IL: Interleukin; TNF-α: Tumour necrosis factor-alpha; TGF-β: Transforming growth 
factor-beta; GM-CSF: Granulocyte macrophage colony stimulating factor; MMP: Matrix metalloproteinase; TIMP: Tissue inhibitor of metalloproteinase; 
VEGF: Vascular endothelial growth factor; MCP: Monocyte chemotactic protein. 
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1.4.3.1 Interleukin-1 family and signalling networks 
The principal function of IL-1 is to mediate the host inflammatory response to 
infections and other stimuli due to its ubiquitous and pleiotropic role in the human 
body. The IL-1 family includes two members, IL-1α and IL-1β (Clark et al., 1986; 
Furutani et al., 1986). They share less than 30% amino acid homology in the same 
species. However, closer relations of the individual IL-1 forms are found between 
species. Thus, about 88% homology is found between human and mouse IL-1β, and 
approximately 70% between the various species of IL-1α. Each of the IL-1 forms is 
encoded by separate genes located on chromosome 2, which leads to the synthesis of 
a 33-kDa precursor. The precursor is further processed into a 17-kDa mature protein 
by serine proteases (particularly elastase and plasmin) and cysteine protease 
caspase-1 (also called IL-1β-converting enzyme) (Fenton et al., 1987). In the cell, 
IL-1 is associated with lysosomes rather than endoplasmic reticulum, indicating a 
nonclassical pathway of IL-1 secretion compared to other secreted proteins 
(Matsushima et al., 1986). A wide variety of cells are shown to synthesize IL-1 
including fibroblasts, macrophages and mesothelial cells. The level of IL-1β mRNA 
predominates over that of IL-1α, possibly due to a second promoter-like sequence 
contained in the IL-1β gene but not found in the IL-1α one (Libby et al., 1986). Both 
IL-1α and IL-1β bind equally to the same receptors and induce the same downstream 
signalling pathway (Bankers-Fulbright et al., 1996). However, the activities of the 
forms do demonstrate differences. IL-1β is only active after it has been processed to 
the mature form, whereas IL-1α is active either as the precursor or as the mature 
product (Mosley et al., 1987). Cells contain active membrane-associated IL-1 
(MA-IL-1), which may account for the immunostimulatory effects of IL-1 in local 
tissues such as lymph nodes, joints, and skin (Dinarello, 1988; Niki et al., 2004). The 
evidence suggests that most of the membrane-associated IL-1 is IL-1α, because 
IL-1β needs to be cleaved and secreted into the body system (Dinarello, 1988; Niki et 
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al., 2004). Therefore IL-1 can participate in autocrine and paracrine responses locally 
through MA-IL-1α, as well as inducing IL-1β systemic effects. Another member 
involved in the IL-1 system is a competitive inhibitor of IL-1, IL-1 receptor 
antagonist (IL-1ra). IL-1ra is an endogenous inhibitor secreted by the same types of 
cells (Arend et al., 1998). It can inhibit both IL-1α and IL-1β activity by binding to 
the cell surface IL-1 receptors. There are two types of cell surface receptors: IL-1 
receptor type1 (IL-1R1) and IL-1 receptor type2 (IL-1R2) (Sims et al., 1993). They 
belong to the toll-like/IL-1 receptor (TIR) superfamily and share a 22% homology 
(Sims et al., 1988). These two receptors have a key conserved TIR cytoplasmic 
domain that contains at least 200 amino acids and an extracellular ligand-binding Ig 
domain. It has been shown that the main functional receptor is IL-1R1, whereas 
IL-1R2 likely acts as a ‘decoy’ that competitively inhibits IL-1 binding to IL-1R1 
(Stylianou et al., 1992). The main biologic effect of IL-1 is to stimulate cells to 
produce other inflammatory mediators including surface adhesion molecules, 
cytokines, growth factors, ECM components and mitogens (Stylianou et al., 1992). 
IL-1 mediates these effects by triggering several transcriptional pathways in the cells 
through the binding to the IL-1R1 (Stylianou et al., 1992; O'Neill and Dinarello, 
2000) (Figure 1.8). After binding to the extracellular Ig domains of the receptor, the 
external stimulated signal recruits an adapter protein MyD88 to the TIR domain 
(Wesche et al., 1997). MyD88 then phosphorylates IL-1 receptor-associated kinase-4 
(IRAK4) that in turn phosphorylates IRAK-1. The phosphorylation of IRAK-1 
further activates another adapter protein, TNF receptor-associated factors-6 (TRAF6), 
by ubiquitinating at lysine 63 chains of TRAF6 (Chen, 2005). This also leads to the 
unbiquitination of TGF-β activated kinase-1 (TAK1) through the assembly of 
TAK1-TAB complex and K-63 ubiquitinated TRAF6 (Sun et al., 2004). TAK-1 can 
further induce the NF-κB pathway by activating the IκB kinases (IKKs) (Mercurio et 
al., 1997). In addition, TAK-1 can also induce activation of mitogen-activated 
protein kinases (MAPKs), including JNK/p38 pathways, resulting in the activation of 
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activating protein-1 (AP-1) (Sato et al., 2005). The activation of AP-1, together with 
the NF-κB pathway, could dominate the production of inflammatory mediators from 
almost all cell types (Kawai and Akira, 2006). 
 
 
Figure 1.8. IL-1 signalling network. Binding of IL-1 to the IL-R heterodimer 
induces sequential phosphorylation of serine/threonine kinases that in turn activates 
NF-κB and AP-1 transcription. Figure adapted from (Krishnan et al., 2007; O'Neill 
and Dinarello, 2000). 
 
In summary, IL-1 contributes to the inflammatory response both locally and 
systematically by inducing the production of other inflammatory mediators. The 
effect of IL-1 can be modulated by its specific endogenous inhibitor IL-1ra, as well 
as by the regulatory NF-κB and AP-1 transcriptional pathways.  
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1.4.3.2 TNF-α signalling network 
TNF-α is a principal mediator of acute inflammatory responses to infectious 
microbes and can cause notable systemic inflammation. The major source of TNF-α 
is activated mononuclear phagocytes. However, various kinds of cells are also found 
to secrete TNF-α, including antigen-stimulated T cells, NK cells, fibroblasts and 
mast cells (Wajant et al., 2003). It is primarily produced as a type II transmembrane 
protein in a stable homotrimer form with an intracellular amino terminus and an 
extracellular carboxyl terminus (Kriegler et al., 1988). This membrane-integrated 
form can be futher proteolytically cleavaged by the metalloprotease, TNF alpha 
converting enzyme (TACE), and is secreted as a soluble homotrimeric cytokine that 
tends to dissociate at concentrations below the nanomolar range (Black et al., 1997). 
Both the membrane-integrated and soluble TNF-α exert their functions via 
interaction with their membrane receptor, TNF receptor (TNF-R). 
 
Two receptors have been identified, TNF-R1 (CD120a, 55kD) and TNF-R2 
(CD120b, 75kD) (Locksley et al., 2001). TNF-R1 mediates the inflammatory 
response in the majority of cells, whereas the effect of TNF-R2 is more focused to 
the lymphoid system. The main physiologic function of TNF-α is to promote the 
recruitment of inflammatory cells to sites of infection or injury (Locksley et al., 
2001), by inducing adhesion molecule expression on endothelial cells and 
stimulating production of chemokines. In addition, large amounts of TNF-α can be 
produced and enter into circulation during chronic inflammation, causing systemic 
clinical and pathologic abnormalities (e. g, fever, cachexia, and sepsis) (Locksley et 
al., 2001). Furthermore, TNF-α is also engaged in tissue regeneration. For example, 
studies have shown an impaired hepatocyte DNA synthesis in TNF-R1-defecient 
animals after partial hepatectomy, indicating an essential role of TNF-α signalling 
involved in liver regeneration (Yamada et al., 1997). In contrast, TNF signalling is 
also a potent factor causing liver destruction in TNF-α-induced acute hepatotoxicity 
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(Bradham et al., 1998). Therefore, insight into the signalling pathways induced by 
TNF-α is critical in understanding of the role of TNF in body systems. TNF-α is first 
recognized as a potent cytotoxic factor due to its capacity to induce cell death 
(Schulze-Osthoff et al., 1992; Hsu et al., 1995). However, TNF-induced cell death 
seems to have only a minor role compared to its function in the regulation of 
inflammatory processes through NF-κB, AP-1, and p38-MAPK pathway. 
 
In vivo, the NF-κB pathway is found to be activated in preference to the 
death-inducing pathway by TNF-α (Wajant et al., 2000; Tanaka et al., 1999). The 
activation of TNF-receptor results in the recruitment of the TNF-receptor type 1 
associated death domain-containing adaptor protein (TRADD) which in turn interacts 
with TRAF-2 and receptor-interacting protein-1 (RIP-1), leading the activation of the 
NF-κB pathway. A summary of the TNF-induced NF-κB pathway is showed in 
Figure 1.9A. Alternatively, TRAF-2 and RIP-1 are also shown to activate AP-1 
(Reinhard et al., 1997) and p38-MAPK pathways (Yuasa et al., 1998), respectively. 
The AP-1 proteins are well known in the prevention of apoptosis by signalling in 
cellular proliferation, differentiation and induction (Shaulian and Karin, 2002). In 
addition, it has been shown that TNF-α can induce cytokine expression in murine 
embryonic fibroblasts, including IL-1 and IL-6, by activating the p38-MAPK 
pathway. The study also demonstrated that depletion of Mitogen-activated protein 
kinase kinase 3 (MKK3) can significantly reduce cytokine production (Wysk et al., 
1999). A summary of TNF-induced AP-1 and p38-MAPK pathway is presented in 







                 A                                B 
 
Figure 1.9. TNF-α signalling network. A: TNF-α induced NF-κB activation. B: 
TNF-α induced activation of p38–MAPK and JNK. The poorly defined connection 
between RIP and MKK3, TRAF2 and ASK1, TRAF2 and MEKK1 are indicated by a 
dotted line. Figure adapted from (Wajant et al., 2003). 
 
In summary, the function of TNF is not limited to actions as a pro-apoptotic and 
inflammatory cytokine. It also acts in tissue repair through its anti-apoptotic 
signalling pathway. Therefore, the tissue type, cellular context, timing and duration 
of TNF action are important to define in determining the role of TNF in diseases.   
 
1.4.3.3 TGF-β function and signalling network 
TGF-β is another multi-functional cytokine known to be involved in tissue repair. In 
the immune system, TGF-β can act as an anti-inflammatory factor by inhibiting the 
proliferation and activation of lymphocytes and other leukocytes (Moustakas et al., 
2002). However, abnormal TGF-β expression is found to be associated with many 
fibrotic diseases including scar and post-operative adhesion. The TGF-β superfamily 
contains a range of proteins which also include inhibins, activin, and bone 
morphogenetic protein (Massague, 1998). TGF-β is part of this large family and 
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exists as three isoforms: TGF-β1, TGF-β2, and TGF-β3 (Massague, 1998). These 
three isoforms share 60-80% homology but are encoded by different genes. They are 
synthesized as latent precursors which contain latent TGF-β binding proteins (LTBP). 
The activation of these precursors requires the removal of the LTBP extracellularly 
via proteolytic cleavage. Many factors are shown to mediate this process, including 
plasmin, thrombin, MMP-2, MMP-9, that are also important mediators induced in 
tissue repair (Annes et al., 2003). Thus, increased TGF-β activation can be expected 
during any healing process, indicating an important role of TGF-β in tissue repair. 
TGF-β induces the cellular response by binding to a transmembrane receptor 
composed of a heteromeric complex of serine/threonine kinases. These receptors are 
named TGF-β type receptors (TGF-βR) consisting of TGF-βR-I, -II, and III (Roberts, 
1999). TGF-β1 is the major effective member in many situations, since it is the 
predominant one expressed by a number of cells. TGF-β1 is a homodimeric protein 
that can be produced by antigen-stimulated T cells, LPS-activated monouclear 
phagocytes, platelets, and many other cell types. The main signalling pathway 
induced by TGF-β1 is the Smad pathway (Attisano and Wrana, 2002). It has been 
shown that TGF-β1 can bind to TGF-βR-II, which in turn forms a complex with 
TGF-βR-I. The external signal from TGF-β1 is transferred through the Smad family. 
In the presence of TGF-β ligand, the TGF-βR-I can phosphorylate the Smad 2 and 3, 
which in turn bind a common mediator Smad 4. The complex of Smad 2/3 and Smad 
4 translocates into the nucleus and induces suppression and activation of various 
genes (Klass et al., 2009) (Figure 1.10). 
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Figure 1.10. TGF-β1–Smad pathway. The ligand (black) binds to the receptors. 
Active receptors phosphorylate Smad 2/3 (white with black spots), which can be 
presented to the receptor by accessory proteins such as Smad anchor for receptor 
activation (SARA) (grey). Phosphorylated Smad 2/3 can form complexes with 
Smad4 (black with white spots). This complex can translocate into the nucleus and 
regulate gene transcription. A phosphatase (grey square) can remove the 
phosphorylation of Smad 2/3. Smad 2/3 and Smad 4 can translocate back into the 
cytoplasm. A complex of Smad7–Smurf can terminate signalling by preventing the 
phosphorylation of Smad 2/3 or causing the degradation of the active receptors. 
Adapted from (Klass et al., 2009). 
 
In addition, TGF-β1 can also signal through non-Smad pathways (Derynck and 
Zhang, 2003). The activation of these non-Smad pathways is also elicited by the 
binding of TGF-βR-I and TGF-βR-II receptors. Recent data have shown that the 
MAPK pathway is activated by TGF-β1 and mediated by Ras (Derynck and Zhang, 
2003; Lee et al., 2007) (Figure 1.11). The TGF-β ligand can assemble a 
Shc/Grb2/Sos complex associated with TGF-βR-I, and then initiate Ras activation. 
Ras activation can lead to the activation of Erk 1/2 MAP kinase mediated by MEK 
1/2. In addition, TGF-β can also induce activation of p38 and JNK MAP kinases 
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(Figure 1.11) (Bakin et al., 2002; Yu et al., 2002). It has been shown that TGF-β can 
activate TAK1 by TRAF6 associated with the receptor complex. TAK1 is required 
for TGF-β-induced p38 and JNK MAPK activation by activating MKK 3/6 or MKK4 
respectively (Santibanez, 2006; Alcorn et al., 2008). Other non-Smad signalling 
pathways induced by TGF-β1 include the activation of Rho-like GTPase (Cho and 
Yoo, 2007) and PI3 kinase/Akt signaling pathways (Bakin et al., 2000; Yeh et al., 
2008). As the involvement of these two signalling pathways in tissue fibrosis is 
limited, the detail of their activation by TGF-β1 will not be discussed further in this 
thesis.  
 
Figure 1.11. TGF-β activates p38-MAPK and JNK-MAPK signalling.  through 
the activation of TAK1 by ubiquitin ligase TRAF6 associated with TGF-β receptor, 
and Erk MAP kinase signalling through recruitment and phosphorylation of Shc by 
the TβRI receptor. Figure adapted from (Xu et al., 2009). 
 
As discussed above, TGF-β is a key mediator in tissue fibrosis. It has been shown 
that Smad signalling contributes to the induction of profibrotic genes such as type I 
collagen and CTGF in fibroblasts (Verrecchia et al., 2001; Holmes et al., 2001). 
Smad3 activation is generally required for TGF-β-induced gene expression in 
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fibroblasts. In contrast, TGF-β is shown to inhibit the activity of MMPs in certain 
situations (Varga and Jimenez, 1986; Overall et al., 1989). Additionally, TGF-β- 
induced p38 MAPK and ras/MEK/ERK pathways also contribute to the production 
of profibrotic genes in various cell types (Chen et al., 2002; Stratton et al., 2002; Sato 
et al., 2002). As described earlier (section 1.3.2), TGF-β1 plays an important role in 
the EMT process, mediated by the Smad signalling pathway (Xu et al., 2009). 
Ectopic adenoviral overexpression of Smad 2/3 with Smad 4 in NMuMG cells is 
found to induce EMT independently without TGF-β binding (Piek et al., 1999; 
Valcourt et al., 2005). Overexpression of negative forms of Smad 2/3 significantly 
blocks TGF-β induced EMT in cell systems (Valcourt et al., 2005). The downstream 
signal transducers, including the Snail family, the ZEB family, and the basic 
helix-loop-helix (bHLH) family, are shown to mediate the Smad-dependent EMT 
process, down-regulating epithelial markers and upregulating mesenchymal ones (Xu 
et al., 2009). In summary, TGF-β is a key cytokine involved in tissue repair. 
However, aberrant TGF-β expression is also implicated in scarring and other fibrotic 
diseases. A deeper understanding of TGF-β effects in post-operative adhesion may 
lead to the development of novel treatments for fibrotic disease.  
 
1.4.4 Anti-inflammatory effect of glucocorticoid on tissue fibrosis 
As previously discussed, tissue fibrosis is mainly caused by chronic inflammation. 
Anti-inflammatory steroids have long been used as a treatment for inflammatory 
diseases and disorders. In this context the most important and widely used steroids 
are glucocorticoids (GC), which are proven to counteract many inflammatory 
responses (Liberman et al., 2009). GCs are synthesized within the adrenal cortex 
from cholesterol through a series of reactions (Balsalobre et al., 2000). The major 
active GC steroid in humans is cortisol. After its synthesis and secretion by the 
adrenal gland, it travels to sites of action via the circulation. However, local 
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modulation of cortisol can also be found during inflammatory events. It has been 
shown that proinflammatory cytokines can regulate the level of 11β-hydroxysteroid 
dehydrogenase (11β-HSD) expression, involved in local interconversion of cortisol 
and cortisone (Davani et al., 2000; Quinkler et al., 2001; Rae et al., 2004a). 11β-HSD 
consists of two isoforms, 11β-HSD1 and 11β-HSD2, encoded by two separate genes 
sharing only 14% homology (Draper and Stewart, 2005). 11β-HSD1 is the key 
enzyme converting local cortisone (inactive) into cortisol, whereas 11β-HSD2 
catalyzes the opposite reaction (Figure 1.12) (Seckl and Walker, 2001). It has been 
shown that pro-inflammatory cytokines, such as IL-1α (Rae et al., 2004a; Fegan et al., 
2008), can stimulate 11β-HSD1 mRNA expression as well as its enzyme activity, 
with little if any, change in 11β-HSD2 levels. Therefore, local re-synthesis of cortisol 
arising from inactive cortisone is tightly regulated by 11β-HSD and inflammatory 
cytokines. Cortisol is a lipophilic molecule which can cross the cellular lipid bilayer 
and enters into the cytoplasm by free diffusion (De Bosscher et al., 2003). It then 
binds to the specific glucocorticoid receptor (GR), a transcription factor that 
translocates on binding of its ligand into the nucleus and thereafter regulates gene 
transcription. GR is present in the cytoplasm in an inactive form combined with 
co-chaperone molecules, such as heat shock protein (hsp) (Pratt and Toft, 1997). The 
binding of GC allows the GR complex to translocate into the nucleus and bind to 
specific DNA sequences (De Bosscher et al., 2003). These sequences, called 
GC-response elements (GRE) are encoded in genes positively regulated by GC, 
whereas negative GRE (nGRE) are found in genes negatively regulated by GC. GR 
can also modulate gene transcription by interacting with other transcription factors, 
including NF-κB, AP-1, signal transduction activator of transcription (STAT) etc. 
Therefore, GCs can modulate inflammatory response by both dynamic 
transactivation and transrepression effects.   
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Figure 1.12. Reactions catalysed by 11βHSD-1 and -2. 
 
As discussed above, negative modulation of the inflammatory response can be 
achieved by GC-induced transrepression. Binding of GRs to specific nGREs on the 
DNA can caused direct transcriptional repression of target genes. The function of the 
nGRE is to guide GR to bind as a monomer (Heck et al., 1994; Radoja et al., 2000). 
However, the majority of inflammatory genes do not contain nGRE. Therefore, the 
anti-inflammatory effect of GCs is mainly dependent on the interplay with the other 
two main transcriptional pathways, NF-κB and AP-1 (Herrlich and Gottlicher, 2002). 
Evidence indicates that GR suppresses NF-κB through physical association with 
NF-κB proteins, including RelA and p65 in vitro (Ray and Prefontaine, 1994; 
Caldenhoven et al., 1995; Scheinman et al., 1995b). In vitro studies have successfully 
shown an interaction between endogenous p65 and GR, by using IL-1β and 
dexamethasone (DEX) co-treatment of A549 cells (Adcock et al., 1999). It has been 
shown that similar mechanisms are involved in AP-1 transrepression (Cippitelli et al., 
1995; Schule et al., 1990; Jonat et al., 1990). However, these mechanisms are strictly 
dependent on cell type, promoter, and receptor. Alternatively, GC-dependent 
repression of the NF-κB pathway has been proposed to be triggered by upregulation 
of IκBα, the cytoplasmic inhibitor of NF-κB (Scheinman et al., 1995a; Auphan et al., 
1995). Although the mechanism is not totally understood, transcriptional regulation 
of the IκBα promoter by GCs has been demonstrated in several studies (Auphan et al., 
1995; Heck et al., 1997). Additionally, GR is found to bind certain coactivator 
molecules which are also required by other transcriptional factors. These coactivators 
 58
are characterized by an intrinsic histone acetyltransferase activity (Wolffe et al., 1997) 
which can promote gene activation by providing a more relaxed chromatin 
environment. These coactivators are also implicated in bridging p65, AP-1 to the 
factors of their respective transcription pathways (Kamei et al., 1996; Gerritsen et al., 
1997; Sheppard et al., 1999; Vanden Berghe et al., 1999). Hence, GR-induced 
repression can be due to a territorial subdivision of GR from other transcriptional 
factors for a limited amount of coactivators (e.g. CBP, p300, and steroid receptor 
coactivator-1) (Doucas et al., 1999; Lin et al., 2003). Lastly, it has been shown that 
chromatin modification and remodelling can also contribute to GR-induced 
repression, since GR can bind to these related coactivators (Yoshinaga et al., 1992; 
Ostlund Farrants et al., 1997; Fletcher et al., 2000; Belikov et al., 2000).  
 
Although the molecular mechanisms underlying GC-mediated anti-inflammatory 
response are far from understood, it is accepted that GC activity is based on 
interference with other transcription factor actions. GC is shown to regulate cytokine 
receptor expression in inflammatory response. For example, GC can inhibit IL-2 and 
IL-12 receptor expression. On the other hand, induced IL-6, GM-CSF and IL-7 
receptor expression are found after GC treatment of various cell types (Liberman et 
al., 2007). GC is also capable of regulating cytokine induced transcription by 
interfering with intra-cellular signalling pathways. Furthermore, GC can regulate 
inflammatory cell development and maturation. For example, GC can promote a Th2 
cellular inflammatory response by inhibition of Th1 cytokines (IL-2 and IFN-γ) and 
stimulation of Th2 cytokines (IL-4 and IL-10) (Ramirez et al., 1996; Visser et al., 
1998b). In addition, GC treatment during the process of monocyte differentiation, 
results in a marked augmentation of macrophage capacity for phagocytosis of 
apoptotic cells (Giles et al., 2001). Therefore, the anti-inflammatory effect of GC can 
contribute to the resolution of tissue fibrosis, through an orchestration of effects.   
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1.5 ECM remodelling and tissue fibrosis 
 
The previous section discussed the mechanism of normal tissue repair and the 
pathology of tissue fibrosis. In both processes, the deposition of ECM is critical. The 
ECM can be secreted locally, assembling into a network in the spaces around cells 
(Frantz et al., 2010). The ECM serves several functions. For example, it helps 
maintain water and minerals content of soft tissues. It can also function as a reservoir 
for growth factors controlling cell proliferation and is also involved in cell-cell 
interactions (Frantz et al., 2010).  
 
The ECM is made up of three main groups of macromolecules (Jarvelainen et al., 
2009; Schaefer and Schaefer, 2010), namely, (1) fibrous structural proteins, 
including collagens, elastins and fibronectin; (2) adhesive glycoproteins, such as 
cadherins and integrins; (3) proteoglycans and hyaluronic acid. These factors 
contribute to the formation of two main general types of ECM structures i.e., 
interstitial matrix (Jarvelainen et al., 2009) and basement membrance (BM) (Sanes, 
2003). The former is present in spaces between epithelial, endothelial, and smooth 
muscle cells and in connective tissue; whereas the BMs are normally associated with 
the cell surface. Although these two structures occur at different sites, their 
components are quite similar. These ECM components are introduced in the 
following section.  
 
1.5.1 Collagen 
Collagens are the most important component providing the ECM framework in the 
human body. They are composed of a triple helix of three polypeptide alpha chains, 
each chain having a gly-x-y repeating sequence. The structure of the triple helix is 
stabilized by numerous hydrogen bonds. Currently, 27 different types of collagen are 
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found, encoded by 41 genes dispersed on at least 14 chromosomes (Myllyharju and 
Kivirikko, 2001). The most abundant collagens are the interstitial or fibrillar 
collagens including types I, II, III, V and XI. In contrast, type IV collagen is 
non-fibrillar forming sheets instead of fibrils (PH, 2001). Therefore, together with 
laminin, type IV collagen is the main component of the BM (Sanes, 2003). Besides 
these, other collagens are found as meshworks and function as anchors in 
epidermal-dermal junctions, cartilage, and blood vessel walls.  
 
Collagens can be produced by a variety of cells, including fibroblasts, epithelium, 
mesothelium, hepatocytes and macrophages. Fibrillar collagen is synthesized from 
procollagen. Procollagen is a precursor molecule derived from preprocollagen which 
is transcribed from collagen genes. The three procollagen chains are hydroxylated 
between their proline and lysine residues or lysine glycosylation to form the triple 
helix. The procollagen is then secreted from the cells and processed by proteases 
which cleave the propeptides. The mature collagen is the basic unit of the fibrils. 
They are further oxidised at the specific lysine and hydroxylysine residues. This 
results in cross-linking between the chains of adjacent collagen molecules, thus 
changing the soluble collagen macromolecules into insoluble collagen fibrils (Figure 
1.13) (Chen and Raghunath, 2009). The main enzyme involved in the cross-linking 
procedure is called lysyl oxidase (LOX), which we will discuss more in detail in 




Figure 1.13. Collagen biosynthesis pathways. (1) Epigenetic level: chromatin 
remodelling and unfolding. (2) Post-transcriptional level: mRNA translation. (3) 
Post-translational level: Formation of the procollagen triple helix. (4) Post-secretion 
level: Procollagen proteinases (scissors symbol) cleave propeptides of procollagen 
molecules at the cell surface (5) Collagen crosslinking: lysyl oxidase (LOX) 







1.5.2 Elastin, Fibrillin, Laminin and Fibronectin 
Although ECM mainly consists of collagens, other ECM components include elastin, 
fibrillin, fibronectin and laminin. Tissues such as blood vessels and skin, which 
require elasticity for their function, contain elastin fibres. Fibrillin is a 250-kDa 
secreted glycoprotein forming a peripheral microfibrillar network. Elastic fibres 
consist of a central core made of elastin, with the microfibrillar network surrounding 
it (Milewicz et al., 2000).  
 
Fibronectin is another ECM component which can bind to many molecules, 
including collagen, fibrin, proteoglycans, and cell-surface receptors. It is formed by 
two glycoprotein chains held together by disulphide bonds. The two forms of 
fibronectin, tissue fibronectin and plasma fibronectin are translated from two spliced 
mRNA variants. The tissue fibronectin accounts for the fibrillar aggregates at wound 
healing sites. The plasma fibronectin binds to fibrin, contributing to the provisional 
blood clot formation filling the space at the wound sites and serving as a substratum 
for ECM deposition (Smith et al., 2007).  
 
Laminin is the most abundant glycoprotein in the basement membrane. It is a 
trimeric protein that contains α-chain, β-chain, and γ-chains; with five, three, and 
three genetic variants respectively. In the basement membrane, polymers of laminin 
and collagen type IV form tightly bound networks. It can also provide binding 
domains for ECM and cell-surface receptors. In addition, it has been shown that 
laminin can mediate the attachment of cells to connective tissue substrates 





1.5.3 Cell adhesion molecules 
The CAMs (cell adhesion molecules) are classified into four main families: 
immunoglobulin family CAMs, cadherins, integrins, and selectins (Kumar et al., 
2005a). Most are cell membrane-associated receptors, but some can be also found in 
the cytoplasm. It has been shown that these receptors can bind to various molecules 
providing interactions between similar cells (homotypic interaction) or different cell 
types (heterotypic interaction). Immunoglobulin family CAMs can participate in both 
homotypic and heterotypic cell-to-cell interactions. Selectins are a family of 
heterotypic CAMs that bind fucosylated carbohydrates, such as mucins. Such 
binding mediates the attachment of leukocytes to endothelial cells during the 
inflammatory response. The best studied of the CAMs are the cadherins (Zeisberg 
and Kalluri, 2004) and integrins (Hynes, 2002; Stupack and Cheresh, 2002), 
indicating the important roles of these two families in tissue fibrosis. Cadherins are a 
class of type-1 transmembrane proteins containing almost 90 members (Hazan et al., 
2004). They participate in interactions between similar cell types, for example, 
connecting the plasma membrane of adjacent cells. The cell-to-cell interactions 
provided by cadherins play a major role in regulating cell proliferation, motility and 
differentiation. In contrast, integrins (Hynes, 2002; Stupack and Cheresh, 2002) 
mostly bind to matrix proteins including fibronectin and laminin, mediating adhesion 
between cells and ECM. All integrins are heterodimeric cell surface proteins 
composed of two noncovalently linked polypeptide chains, α and β. The family 
consists of about 30 structurally homologous proteins. The extracellular domains of 
the heterodimeric chains bind to various ligands, such as ECM glycoproteins, 
activated complement components, and proteins on the surfaces of other cells. The 
extracellular ligand signals transfer into the cells through the cytoplasmic domains of 
the integrins, interacting with cytoskeletal components, including vinculin, talin, 
actin, α-actinin and tropomyosin. Therefore, integrins play a critical role not only in 
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cell migration and adhesion formation, but also to regulate cell signalling and cell 
cycling.   
 
1.5.4 ECM degradation 
As discussed above, the inter-relationship between ECM and fibrosis is a complex 
process regulated by ECM components. Thus, the balance of ECM synthesis and 
degradation, and the regulation of factors controlling these processes, is critical in 
regulating tissue repair. Although the ECM components can be degraded by several 
proteolytic enzymes including neutrophil elastase (Belaaouaj et al., 2000), cathepsin 
G (Korkmaz et al., 2008), kinins (Cohen et al., 2007) and plasmin (Silverstein et al., 
1984), the degradation of collagen and other ECM proteins is mainly mediated by a 
family of MMPs, which are dependent on zinc ions for their activity (Visse and 
Nagase, 2003). The MMP family currently has 23 identified members, which share a 
common 180-residue zinc-protease domain. Various cell types have been shown to 
secrete MMPs, including macrophages, epithelial and mesothelial cells, and 
fibroblasts. Their secretion is induced by stimuli including growth factors (PDGF, 
FGF), cytokines (IL-1, TNF-α), phagocytosis, and physical stress (Werb et al., 1980; 
Circolo et al., 1991; Goetzl et al., 1996); and is inhibited by TGF-β (Sporn and 
Roberts, 1992) and steroids (Green and Friedland, 2007). The whole family can be 
divided into 6 main groups based on their respective substrates: collagenases, 
gelatinases, stromelysins, matrilysins, membrane-type MMPs, and other MMPs 
(further detail listed in Table 1.6). Collagenases (including MMP-1,-8,-13) can 
cleave collagen at a specific site three-quarters of the way from the N-terminus, 
cutting the triple helix into two unequal fragments to be further digested by other 
proteinases (Aimes and Quigley, 1995). In contrast, gelatinases (MMP-2,-9) account 
for the digestion of gelatins, although MMP-2 but not MMP-9 is also shown to digest 
type I, II, and III collagens (Allan et al., 1995). Stromelysins (MMP-3,-10) have 
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similar substrates, but the proteolytic efficiency of MMP-3 is higher than that of 
MMP-10. In addition, MMP-3 also activates a number of proMMPs to generate fully 
active MMPs (Suzuki et al., 1990). For example, it helps process proMMP-1 to 
generate the mature MMP-1 enzyme by activating procollagenase. Other important 
MMPs, such as MMP-7, can process cell surface molecules including pro-TNF-α 
(Uria and Lopez-Otin, 2000); while MMP-14 is a type I membrane-type MMP 
playing important role in angiogenesis and cell invasion (Pepper, 2001; Hotary et al., 
2002).  
 
Table 1.6. Groups of human MMPs and their respective substrates. Table 
adapted from (Visse and Nagase, 2003). 






Collagens (type I, II, III, VII, VIII, X, and XI), gelatin, 
fibronectin, vitronectin, laminin, entactin, tenascin, 
aggrecan, link protein, myelin basic protein, versican 
(Visse and 
Nagase, 2003; 






Collagens (type I, II, and III), aggrecan, fibrinogen (Visse and 
Nagase, 2003; 




Collagens (type I, II, III, IV, VI, IX, X, and XIV), 
collagen telopeptides, gelatin, fibronectin, osteonectin, 
aggrecan, perlecan , large tenascin-C, fibrinogen 
(Hiller et al., 
2000; Knauper 




Collagens (type I, II, III, IV, V, VII, X, and XI), 
gelatin, elastin, fibronectin, vitronectin, laminin, 
entactin, tenascin, osteonectin, aggrecan, link protein, 
galectin-3, versican, decorin, myelin basic protein 
(Patterson et al., 
2001; Ochieng 
et al., 1994; 




Collagens (type IV, V, XI, and XIV), gelatin, elastin, 
vitronectin, laminin, osteonectin, aggrecan, link 
protein, galectin-3, versican, decorin, myelin basic 
protein 
(Ochieng et al., 





Collagens (type III, IV, V, VII, IX, X, and XI), 
collagen telopeptides, gelatin, elastin, Fibronectin, 
vitronectin, laminin, entactin, tenascin, osteonectin, 
(Perides et al., 
1995; Bini et 
al., 1996) 
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aggrecan, link protein, decorin, myelin basic protein, 
perlecan, versican15, fibulin, fibrinogen 
MMP-10 
(Stromelysin 2) 
Collagens (type III, IV, and V), gelatin, elastin, 











Collagens (type I, and IV), gelatin, elastin, fibronectin, 
vitronectin, laminin, entactin, tenascin, osteonectin, 






Collagen type IV, gelatin, fibronectin, vitronectin  (Marchenko et 







Collagens (type I, II, and III), gelatin, fibronectin, 
tenascin, vitronectin, laminin, entactin, aggrecan, 
perlecan, fibrinogen 
(Hiller et al., 




fibronectin, tenascin, entactin, laminin, aggrecan, 
perlecan, 




Collagen type III, gelatin, fibronectin, vitronectin, 
laminin 




Fibronectin, Gelatin, chondroitin sulphate 
proteoglycan, dermatan sulphate proteoglycan 
(Wang et al., 
1999a) 
B) Glycosylphosphatidylinositol (GPI)- anchored 
MMP-17 
(MT4-MMP) 




Collagen type IV, gelatin, fibronectin, chondroitin 
sulphate proteoglycan, dermatan sulphate proteoglycan 
(English et al., 






Collagens (type I, V, and IV), gelatin, elastin, 
fibronectin, vitronectin, laminin, entactin, osteonectin, 
aggrecan, myelin basic protein 
(Shapiro et al., 
1993; Shipley et 
al., 1996) 
MMP-19 Collagen type IV, gelatin, laminin, entactin, large 
tenascin-C, fibronectin, aggrecan, COMP,fibrinogen, 
fibrin 
(Stracke et al., 
2000b; Stracke 
et al., 2000a) 
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The main regulation of MMP activities involves another enzyme family, namely the 
tissue inhibitors of metalloproteinases (TIMPs). TIMPs are specific endogenous 
inhibitors that bind MMPs in a 1:1 stoichiometric fashion. The family comprises four 
protease inhibitors: TIMP-1, TIMP-2, TIMP-3, and TIMP-4 (Brew et al., 2000). 
They have N- and C-terminal domains of 125 and 65 amino acids respectively, with 
each containing three conserved disulphide bonds. The N-terminal domain serves as 
a separate domain and is capable itself of inhibiting MMPs (Murphy et al., 1991). So 
far, TIMPs are shown to inhibit all MMPs, except that TIMP-1 fails to inhibit 
MT1-MMPS (MMP-14) (Will et al., 1996). Although some other proteins have been 
reported as MMP inhibitors, including tissue factor pathway inhibitor-2 (Herman et 
al., 2001) and chlorotoxin (Deshane et al., 2003), the mechanisms underlying their 
MMP inhibition are not known.  
 
In summary, the ECM is a complex structure consisting of several components. It is 
well recognized that the ECM is not only a scaffold for cells, but that it can also have 
biologic activity to regulate cell function and structure. The degradation of the ECM, 
regulated by MMPs and TIMPs, is critical during tissue repair and tissue fibrosis. 
However, the importance of ECM synthesis should be also emphasized, because it is 
the actual balance between ECM synthesis and ECM degradation that leads to tissue 
repair or tissue fibrosis. Hereby, in this thesis, we focus our studies of ECM synthesis 
principally on collagen which is the most important ECM component involved in 
tissue repair. The role of lysyl oxidase, a specific enzyme accounting for collagen 
cross-linking, will be the subject of further investigation in this thesis. 
 
1.5.5 The role of lysyl oxidase (LOX) 
LOX is a secreted, copper-dependent amine oxidase first demonstrated in 1968 
(Pinnell and Martin, 1968). To date, a further four different LOX-like (LOXL) 
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proteins have been described including LOXL1, LOXL2, LOXL3, and LOXL4 
(Csiszar, 2001). These proteins contain a consensus N-terminal signal peptide 
domain followed by a variable sequence region, and share a similar catalytic 
C-domain region to that of LOX. LOX is first translated as an N-glycosylated, 
50-kDa pro-protein (proLOX), which has two consensus sites for posttranslational 
N-glycosylation (Trackman et al., 1992). The proLOX is then secreted into the 
extracellular space in a catalytically quiescent form. The proLOX is activated after 
proteolytic cleavage between Gly 162 and Asp 163 (rat LOX sequence) by 
extracellular proteases, mainly procollagen C-proteinase, to form a 30-kDa mature 
LOX protein (Panchenko et al., 1996). The same procollagen N- and C-proteinase is 
needed to process the procollagen species into the mature collagens, by removing the 
N- and C-terminal propeptide domains on each of their three α chain polypeptides 
(Siegel, 1974). Combined with the findings that purified LOX can only act on mature 
collagen substrates rather than procollagen precursors, it is noteworthy that the 
formation of crosslinked collagen is based on a highly integrated mechanism. 
Additionally, it has been shown that the proteolytic process is reduced in the absent 
of cellular fibronectin (Fogelgren et al., 2005). Furthermore, several proteolytic 
activators of proLOX have been found, including tolloid proteinases, mTLD, 
mTLL-1, AND mTLL-2, in the absence of other proteins. Thus, the proteolytic 
activation of proLOX is also mediated by these simple factors (Uzel et al., 2001).         
 
The LOX-catalyzed reaction belongs to the oxidation-reduction category. It requires 
two essential cofactors for its catalytic function: one being a tightly bound copper ion 
and the other a unique, covalently integrated organic cofactor identified as lysine 
tyrosylquinone (LTQ) (Wang et al., 1996). LTQ is formed between specific tyrosine 
and specific lysine residues (Figure 1.14). It plays a critical cofactor role as a 
transient electron sink in the catalytic mechanism of LOX action.  
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Figure 1.14. The lysyl tyrosine quinone (LTQ) cofactor of LOX. Figure adapted 
from (Lucero and Kagan, 2006) 
 
Figure 1.15. Stoichiometry of the LOX-catalyzed reaction. Figure adapted from 
(Lucero and Kagan, 2006) 
 
Figure 1.16. Spontaneous formation of the dehydrolysinonorleucine (deLNL) 
and aldol condensation product (ACP) crosslinkages from peptidyl AAS and 
lysine residues. Figure adapted from (Lucero and Kagan, 2006) 
 
The main function of LOX is to convert the δ-amino group of peptidyl lysine to the 
aldehyde residue (Lucero and Kagan, 2006) (Figure 1.15). The generation of the 
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aldehyde dramatically changes the microenviroment at the site of oxidation, 
introducing a potentially electrophilic carbonyl in place of the original unreactive 
methylene carbon of the lysine residue. Thus, the aldehyde can bind to a 
neighbouring δ-amino group of an unmodified lysine to form the 
dehydrolysinonorleucine (deLNL). Similarly, two aldehydes of different lysine 
residues can react to form the aldol condensation product (ACP) (Lucero and Kagan, 
2006) (Figure1.16). Both the deLNL and ACP can lead to the crosslinking of 
collagens and elastins, converting these soluble ECM proteins into insoluble fibres. 
The substrates of LOX are thought to be limited to the soluble precursors and 
immature fibrillar forms of elastins and collagens. However, it has been shown that 
purified LOX can readily oxidize many other basic globular proteins with PI ≥ 8.0 
including H1 histone, as well as some non-peptidyl amine substrates including 
n-butylamine and 1,5-diaminopentane (Kagan et al., 1984). Thus, the catalytic ability 
of LOX is mainly but not exclusively on collagens and elastin. Mature LOX is found 
in the extracellular compartments of many tissues including skin, aorta, heart, lung, 
liver, and cartilage (Trackman et al., 1990; Kagan et al., 1986; Hayashi et al., 2004). 
Furthermore, the presence of the mature active LOX has been demonstrated within 
the nuclei of vascular smooth muscle cells (VSMCs) and fibroblasts by confocal 
immunomicroscopy and by western immunoblot analyses of nuclear extracts 
(Nellaiappan et al., 2000). The mechanism might well involve specific cellular 
uptake, since nuclear entry was not inhibited by beta-aminoproprionitrile (BAPN, a 
chemical inhibitor for LOX) nor competed against by adding 29-kDa carbonic 
anhydrase. It has been shown that LOX can oxidize histone H1 which has abundant 
lysine residues (Kagan et al., 1983), as well as histone H2 (Giampuzzi et al., 2003). 
Since histone H1 plays an important role in electrostatically interacting both with the 
DNA bridge linking consecutive nucleosomes and with DNA wound around the 
nucleosome core (Fan et al., 2005; Hizume et al., 2005), oxidation by LOX of 
histone could disrupt these electrostatic bonds. Therefore, the presence of LOX in the 
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nucleus might play a role in changing cellular phenotypes by re-organizing the 
nuclear chromatin.    
 
In addition to its catalytic role in ECM formation, other important functions of LOX 
have recently been identified. It has been shown that LOX can act as a potent 
chemoattractant for many cell types. For example, purified 32-kDa LOX was found 
to increase the migration ability of human peripheral blood mononuclear cells over 
the control group by 240% (Lazarus et al., 1995). Another study revealed that 
VSMCs were also chemotactically responsive to a LOX-dependent chemotaxis (Li et 
al., 2000). Further investigation discovered that the chemotactic response was not 
due to the reaction of LOX with secreted proteins but to the H2O2 product of the 
LOX-catalyzed reaction. It has been shown that intracellular H2O2 can enhance stress 
fibre formation and focal adhesion assembly, thereby causing the induction of the 
chemotactic response; since the response was not found if the LOX enzyme was 
inactivated or catalase was added into the culture system (Li et al., 2000). These 
studies have been extended to others involving tumour metastasis, since LOX mRNA 
was found to be upregulated in invasive breast cancer cells (Kirschmann et al., 2002). 
Reports from the same group found that a LOX-dependent chemotactic response can 
facilitate the invasion of the breast cancer cells, which is also elicited by the H2O2 
product of LOX acting on unidentified substrates (Payne et al., 2005). Similar studies 
have found that an elevated level of LOX under hypoxic conditions is essential for 
the hypoxia-induced metastatic response of several cancers including head and neck 
tumours (Erler et al., 2006). A further report noted that hypoxia-induced LOX is 
critical for pre-metastatic niche formation (Erler et al., 2009). More importantly, 
Studies (Higgins et al., 2007) found that LOX was involved in hypoxia-promoted 
fibrogenesis associated with chronic renal disease. The inhibition of LOX and 
LOXL2 was shown to reduce the hypoxia-induced cell migration in vitro and 
decrease renal fibrogenesis in vivo. Similarly, the inhibition of LOX by BANP 
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appeared to minimize liver fibrosis following bile duct ligation in an experimental 
animal model (Andrew et al., 2007). These observations point towards a general role 
that LOX might have in tissue fibrotic diseases, by promoting cell motility and ECM 
deposition. 
 
1.6 Project background 
 
Post-operative adhesion in the abdominal cavity is a common complication after 
abdominal surgery. Despite huge progress in surgical techniques in recent decades, 
the incidence rate of post-operative adhesion has improved very little. Currently, the 
common strategies used to prevent adhesion are the application of anti-inflammatory 
agents such as colloids (dextran) and crystalloid solutions (Ringer lactate or saline), 
or physical barrier including carboxymethyl cellulose and polyethyleneoxide. 
Although there have been developments in adhesion prevention, none have been 
demonstrated to produce significant benefit. Since peritoneal fibrosis and its 
associated ECM remodelling process are critical in the development of 
post-operative adhesion, further investigation of the pathophysiology of peritoneal 
fibrosis is undoubtedly required to improve patient outcome.  
 
Homeostasis of the abdominal cavity is maintained by the mesothelium. Many 
studies have shown a critical role of mesothelium in the development of adhesion 
following by surgery. Most of these studies are focused on its role in fibrinolysis and 
re-epithelialization. This thesis examines the role of mesothelium in ECM 
remodeling, and especially in collagen deposition. A hypothesis is proposed that 
mesothelial cells can produce lysyl oxidase (LOX), a key mediator in promotion of 
collagen deposition during the healing process. Thus, inhibition of LOX activity of 
mesothelial cells could pave the way to minimize post-operative adhesion. The 
inflammatory response is also involved as a key process in wound healing. A further 
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hypothesis is that the function of mesothelial cells is regulated by the inflammatory 
response; particularly inflammatory cytokines. Thus, experiments will be designed to 
investigate the effect of these inflammatory cytokines on the mesothelial cells. Cell 
phenotype change, LOX expression, as well as other ECM-adhesion related genes 
will be used as potential investigable targets.  
 
In addition, ovarian repair presents a scar-free healing model existing alreadt in the 
adult body. In humans, the ovary is regularly subjected to ovulation-associated injury 
that heals without fibrosis. The human ovary is covered by a thin layer of ovarian 
surface epithelial (OSE) cells, which arises in the embryo from the same lateral plate 
mesoderm as the peritoneal mesothelial cells (PMC). They share many common 
characteristics and equivalent homeostatic functions (Ross et al., 1998). During 
ovulation, a local induction of high levels of ovarian steroids occurs (Andersen, 1991; 
Andersen and Hornnes, 1994; Rae et al., 2004a). Steroids involved in 
anti-inflammatory processes, such as progesterone and cortisol, are synthesised and 
secreted into the follicular fluid and peritoneal fluid during ovulation. Therefore, the 
unique scar-free healing of ovary is hypothesised to be a consequence of the 
production of the elevated local anti-inflammatory steroids. We propose that the 
application of anti-inflammatory steroids, such as cortisol or progesterone, might 
help to minimize the occurrence of post-operative adhesion.  
This thesis aims to answer the overarching hypothesis: 
‘Regulation of extracellular matrix remodeling helps prevent peritoneal fibrosis’ by 
addressing the following sub-questions: 
1. What is the role of LOX in peritoneal fibrosis?  
2. What is the role of mesothelial cells in peritoneal fibrosis in response to 
inflammatory cytokines? 


















Chapter 2  













2.1 Primary cell culture 
 
2.1.1 Primary Peritoneal Mesothelial Cells (PMC) and Ovarian Surface 
Epithelial (OSE) cell culture 
Normal PMC and OSE cells were collected from patients undergoing surgery for 
benign gynaecological conditions; such as fibroids, heavy menstruation and pelvic 
pain; with local ethics committee approval (under Local Regulatory Ethics 
Committee approval LREC 04-51103-36) and informed consent. Exclusion criteria 
included current malignancy, gynaecological inflammatory states (such as current 
pelvic inflammatory disease or endometriosis) and use of gonadotrophin-releasing 
hormone agonists or antagonists. Following recruitment, PMC and OSE were 
collected by gently brushing the respective organs (Table 2.1) early in the surgical 
procedure using a Tao cytobrush (Cook Medical, Limerick, Ireland) at laparoscopy. 
The early stage collection reduced contamination with blood and stromal cells. In 
addition, handling of the ovaries was minimized by the surgeon to prevent loss of the 
OSE layer during surgery. The collecting instrument was rinsed in 15ml pre-warmed 
HOSE1 (Table 2.2) medium to dislodge the cells that were then transported to the 
laboratory at room temperature.  
 






PA Peritoneal abdominal wall PMC 
PB Peritoneal side of body of 
uterus 
HR Right ovarian cortex OSE 
HL Left ovarian cortex 
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Table 2.2. Components of HOSE1 Medium. *: MCDB 105 (Sigma-Aldrich Inc, 
Poole, UK) was established at pH 7.3 by titrating with 5 M sodium hydroxide. 
Medium199 (GIBCO, Invitrogen Ltd, Paisley, UK), Pen/Strep (Sigma), L-glutamine 
(GIBCO). 
Additive Quantity Supplier 
Medium 199:MCDB 105* 1:1 (v/v) Gibco 
Fetal Bovine Serum (FBS) 15% (v/v) Sigma-Aldrich 
L-glutamine 2mmol/l Sigma-Aldrich 
Penicillin 50IU/ml Sigma-Aldrich 
Streptomycin 50μg/ml Sigma-Aldrich 
 
The primary cells were cultured in HOSEI medium as previously described (Hillier 
et al., 1998). Briefly, the medium was aspirated and transferred to a 75cm2 tissue 
culture flasks (Corning, Sigma). Flasks were inspected using phase-contrast 
microscopy to confirm presence of cell “flakes”, and then incubated for up to two 
months in a humidified atmosphere of 5% CO2, 95% air at 37°C. The flasks were 
inspected a week later and HOSE1 medium was changed weekly until confluency 
reached. Normally, cells reached confluency after 4 to 6 weeks of culture. Cell purity 
was confirmed by phase-contrast microscopy. Confirmation of the purity of 
mesothelial cultures were checked by staining with several mesothelial markers 
including cytokeratins 5, 6, 7, 8 and 17 (Fegan et al., 2008). After reaching 
confluency, the culture medium was removed and cells were washed twice with 
Dulbecco’s phosphate-buffered saline (DPBS, Sigma) and enzymatically isolated by 
incubating in 5ml 0.05% trypsin/EDTA solution (GIBCO) at 37oC for 5min. Then 
the same amount of HOSE1 medium was added to neutralize the trypsin solution. 
The whole cell solution was transferred into a 15ml centrifuge tube (Corning). After 
centrifugation at 800 g for 5min, cells were pelleted and the supernatant was 
discarded. Cells were re-suspended in HOSE1 medium and the cell number was 
counted using a haemocytometer. Cell viability was assessed with trypan blue 
(Sigma) staining exclusion. Cell suspensions were then taken forward for 
experimentation or a further passage. The passage number for primary cells was 
limited to no more than 3. The outcome of primary cell culture is that 60% of the 
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total PMC cultures were discarded due to lack of cell growth or fibroblast 
contamination (Fegan, 2009). Therefore, the experimental repeats conducted in this 
thesis are limited by the number of viable samples.   
2.1.2 Separation of peripheral blood mononuclear cells (PBMC) from Buffy Coat 
(BC) and PBMC culture 
 
The protocol used in this thesis was adopted from a previous publication (Repnik et 
al., 2003). Combined Ficoll-Percoll density gradients were used for the separation. 
The buffy coat samples were generously provided by the Scottish National Blood 
Transfusion Service. The samples were normally generated from 240ml whole blood 
taken from healthy people within the previous 24 h. All the materials used 
throughout the procedure were sterile and endotoxin-free. The detailed procedures 
included: 
 
(1). PBMC Isolation 
The concentrated BC (around 60ml) was diluted with calcium- and magnesium-free 
PBS (Sigma) up to 200ml (normally twice volume of PBS added to the BC). 12ml 
Ficoll (GE Healthcare Bio-Sciences AB UK Ltd, Buckinghamshire, UK) into 50ml 
Falcon centrifuge tubes (BD Biosciences, Oxford, UK). The number of tubes 
depended on the final volume of the diluted BC. The diluted BC solution was 
carefully transferred into the tube (25ml per tube), overlaying the Ficoll on the top. 
The gradients were then centrifuged at 950 g for 15 min with the brake off (Sigma 
6K15 centrifuge). The PBMC were collected at the interface between the Ficoll and 
the plasma-medium layers with a pasteur pipette. Cells were transferred from two 
tubes into one new tube and resuspended with addition of PBS to a final volume of 
45 ml. Then this tube was centrifuged at 350 g for 7 min. The supernatant was 
discarded carefully and cells were resuspended in PBS. Cells from two tubes were 
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combined into another new tube with adding PBS to a final volume of 45 ml. Tubes 
were centrifuged again at 350 g for 7 min. Supernatant was again discarded and the 
cells from two tubes combined by adding pre-warmed Iscove's Modified Dulbecco's 
medium (IMDM, GIBCO) to a final volume of 25ml. Cells were counted in a 
standard haemocytometer and resuspended at a concentration of 40–60 x106 cells/ml 
in IMDM medium to give a final volume which is a multiple of 3 (i.e. 3/6/9/12/. . . 
ml). 
 
(2). Separation of monocytes from lymphocytes 
PBMC suspension (3ml, containing 120–180 x 106 cells) was carefully laid onto 10 
ml of hyper-osmotic Percoll (GE Healthcare) solution (48% Percoll, 41.5% 
deionized water, 10% 1.6M NaCl) in each centrifuge tube so that the interface 
between the layers was preserved. The tubes were centrifuged at 580 g for 15 min 
(brake off). Cells at the interface were collected with a Pasteur pipette, excluding the 
last 4 ml. Cells from up to three tubes were combined with adding IMDM medium to 
a final volume of 45ml. Tubes were centrifuged at 350 g for 7 min. Supernatant was 
discarded and resuspended the cells in 3ml IMDM medium. This suspension is later 
referred to as a monocyte-enriched suspension. 
 
(3). Separation of monocytes from platelets and dead cells 
In each centrifuge tube, 10ml iso-osmotic Percoll solution (41.5%Percoll, 48.5% 
deionized water, 10% 1.5M NaCl) was overlaid with 3ml of the monocyte-enriched 
suspension (up to 200 X106 cells). Tubes were centrifuged at 350 g for 15 min (brake 
off). The supernatant was discarded using a Pasteur pipette, or alternatively, saved 
for analysis of its composition. The sediment was resuspended in <1ml of IMDM 
medium (avoiding tube wall ‘wash-off’) and transferred into a new centrifuge tube. 
IMDM medium was added to a final volume of 45ml. Tubes were centrifuged at 
350g for 7 min. After the supernatant was discarded, cells were resuspended in 5ml 
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of culture medium. A cell count was conducted, mixing 20μl of the cell suspension 
with 180μl trypan blue solution.  
 
 
(4). Culture of monocytes 
Separated PBMC were resuspended at a concentration of 1x106 cells/ml and seeded 
into 12 well-plates (1x106cells/well) with pre-warmed IMDM medium. Plates were 
incubated for 1 hour at 37°C to allow monocytes to adhere to the plate. Swirling the 
plates gently the supernatant was removed into waste. Fresh IMDM medium (1 ml) 
was added to each well to remove any unattached cells. The adherent PBMC were 
cultured in IMDM medium including 10% FBS and 20ng/ml Macrophage 
colony-stimulating factor (M-CSF) (R&D Systems Inc, Abingdon, UK) for 6-7 days, 
allowing the PBMC to mature into macrophages. Medium was changed at day 3 and 
replenished appropriately.  
 
2.1.3 Culture of mesothelial cell line 
 
The mesothelial cell line MeT-5A (ATCC-CRL-9444) was purchased from 
American Type Culture Collection (ATCC). It is derived from mesothelial cells 
isolated from pleural fluids obtained from non-cancerous individuals. The cells were 
transfected with the pRSV-T plasmid (an SV40 ori-construct containing the SV40 
early region and the Rous sarcoma virus long terminal repeat) and cloned. Cells 
originating from ATCC were cultured in the recommended complete medium of 
Medium 199 containing 10% FBS, 3.3nM epidermal growth factor (EGF) (R&D), 
400nM hydrocortisone (Sigma), 20mM HEPES (Sigma), 1% 100X 
Insulin-Transferrin-Selenium A (GIBCO), and 0.1% trace elements B (Media Tech 
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Inc, Manassas, USA). Cells were passaged and cultured in adapted medium with 




2.2 Experimental treatment on cells 
 
2.2.1 Treatment on PMC and MeT-5A cells 
For cytokines treatment, primary cells suspensions were adjusted to 3x105 viable 
cells per well of 6-well culture plates (Corning) for mRNA studies or 1.5 x105 viable 
cells per well of a 12-well plate (Corning) for ELISA. After establishment of a cell 
monolayer (24 h), the culture medium was replaced with HOSE2 medium, 
serum-free HOSE1 containing 0.01% bovine albumin serum (BSA, Sigma) instead 
of FBS, for 24 h. Cells were then exposed to the treatments of interest (cytokines, 
cytokine antagonists, steroids, etc) in HOSE2 medium. Incubation times and 
concentrations applied are denoted in the relevant Chapters. In all experimental sets, 
untreated cells were used as the control. 
 
For treatments with multi-wall carbon nanotubes (NT, provided by Matthew Boyles, 
University of Cambridge) PMC cell suspensions were adjusted to 1.5 x105 viable 
cells per well of 12-well plates. Prior to experimental treatment, NT were dispersed 
by suspending in 0.5% BSA and placed in an ultra-sonic water bath as previously 
described (Poland et al., 2008). NT solutions were further diluted in HOSE1 medium 
to achieve the required concentration. PMC were treated with different doses of NT 
solutions for 48h after the establishment of the cell monolayer.  
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2.2.2 Treatment on MeT-5A cells 
MeT-5A cells suspensions were adjusted to 5x105 viable cells per well of 6-well 
culture plates for mRNA studies. After establishment of a cell monolayer (24 h), the 
culture medium was replaced with serum-free IMDM medium containing 0.01% 
BSA for 24 h. Cells were then exposed to the agents of interest. Incubation times and 
treatment conditions applied are denoted in the relevant Chapters. In all experimental 
sets, untreated cells were used as the control. 
 
2.2.3 Treatment on macrophages 
Separated PBMC were plated at 1x106 per well of 12-well culture plates as described 
above (Chapter 2.1.2). After 7 days, the culture medium were replaced with fresh 
IMDM medium containing 10% FBS for 24 h. NT were diluted to appropriate 
concentrations as shown above (section 2.2.1). Macrophages were exposed to the NT 
solution for 48 h.  
 
2.2.4 Sample harvest 
For mRNA studies, the cell monolayers of 6-well plates were washed twice with 1ml 
DPBS after experimental treatments. Homogenization of cells was achieved by cell 
lysis using 0.35ml guanidine thiocyanate-containing buffer (RLT lysis buffer, Qiagen, 
UK) supplemented with 0.01% β-mercaptoethanol (Sigma). The resultant cell lysate 
was transferred to autoclaved eppendorf tubes (Eppendorf UK Limited, Cambridge, 
UK) and stored at -80°C for further experiments.  
 
For ELISA, PMC culture-conditioned medium from each well were collected in 
eppendorf tubes and stored at -20°C, while cells were lysed by repeated freezing and 
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thawing in 1ml serum-free medium. The cell lysates were kept in -20°C for further 
use. For macrophages, only culture-conditioned media were collected and stored at 




2.3 mRNA studies 
 
2.3.1 RNA extraction 
RNA was extracted from cultured cells using the RNEasy Mini-kit (Qiagen). This kit 
allows the purification of RNA longer than 200nt and is based on the selective 
binding properties of a silica-gel membrane. Cell lysates were removed from storage 
and thawed in a waterbath at 37°C. 70% ethanol (350µl) was added to the lysate and 
mixed by pipetting. The sample was applied to a RNEasy mini column, placed inside 
a centrifuge tube then centrifuged at 10,000rpm for 15 seconds (MIKRO 200, 
Hettick Zentritugen, DJB Labcare Ltd, Buckinghamshire, UK). The flow-through 
was discarded. 350µl RW1 buffer (Qiagen) was added to the column followed by 
centrifuging the tube for 15 seconds at 10000rpm. After the flow-through was 
discarded, on-column DNase digestion was performed. 10µl DNase I stock solution 
(Qiagen) was added to 70µl DNase buffer (Qiagen) per sample and mixed by gently 
flicking the tube. The DNase mix was pipetted directly onto the membrane of the 
RNEasy column and left at room temperature for 15 minutes. A further 350µl RW1 
wash buffer was added and the tube was centrifuged for 15 seconds at 10000 rpm. 
The flow-through was discarded. 500µl RPE elution buffer (Qiagen) was added to 
the column, centrifuged for 15 seconds at 10000 rpm and flow-through discarded. A 
further 500µl RPE elution buffer was added to the column, centrifuged for 2 minutes 
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at 10000 rpm, and the flow-through discarded. The column was transferred to a new 
tube and centrifuged for 1 min at full speed to dry the column. The column was once 
again transferred to a new tube and 20-30µl RNase-free water pipetted directly on to 
the membrane. The tube was centrifuged for 1 min at 10000 rpm. The eluate was 
removed from the tube and passed through the column once more as described to 
obtain a higher RNA concentration. RNA was stored at -80°C. 
 
2.3.2 RNA quantification and quality assay  
Purified RNA was quantified using a Nanodrop spectrophotometer (ND-1000, 
Thermo Scientific, Essex, UK). RNA (1.5μl) was loaded onto an optical fibre to 
measure the ultraviolet (UV) absorbance from the light passing through the sample. 
The RNA concentration was measured at 260 nm. To ascertain the purity of RNA, 
two absorbance ratios were also assessed: the 260/280 and 260/230 ratios to evaluate 
protein and genomic contamination respectively. Purified RNA samples were used 
further only when ratios of 260/280 were above 2.0, which indicated minimal protein 
contamination. 
 
2.3.3 Reverse-Transcriptase PCR 
RNA was reverse-transcribed by using the high capacity cDNA Reverse 
Transcriptase kit (Applied Biosystems, Warrington, UK). RNA was reverse 
transcribed to cDNA in a 10μl reaction mixture consisted of: 1μl 10X RT buffer, 1μl 
10X RT Random Primer, 0.5μl (1U/μl) RNase Inhibitors, 0.4μl (4 mM) 25X dNTP 
mix, 0.5μl (2.5U/μl) MultiScribeTM Reverse Transcriptase, 200ng RNA sample, and 
adding RNase-free H2O up to 10μl. Reaction mixes were thoroughly vortexed and 
briefly centrifuged in a microcentrifuge to ensure all contents were in the bottom of 
the tube. Tubes were then put in a thermal cycler (G-Storm, Surrey, UK) and samples 
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incubated at 25°C for 10 min, 37°C for 120 min, then 85°C for 5 min. Two negative 
controls were also included, an “RT-negative” containing no multiscribe RTase and a 
“RT-water” containing nuclease-free water in place of RNA. The resulting cDNA 




2.3.4 Quantitative Real-Time PCR (Taqman) 
Quantitative Real-Time PCR (QRT-PCR) measures the level of a gene-specific 
sequence of cDNA generated in a reverse-transcriptase PCR reaction, and thus 
provides a measure of RNA expression in a tissue. It was carried out using the 
Taqman system and ABI Prism 7900HT sequence detection system (Applied 
Biosystems). The underlying mechanism is based on the production of a fluorescent 
signal during the amplification of the PCR product. Forward and reverse primers are 
designed for the target DNA sequence and the probe is annealing to this target 
sequence between the primers. Two labels are contained in the probe, a reporter label 
at the 5’ end (FAM; 6-carboxyfluoroscein) and a quencher at the 3’ end (TAMRA; 
6-carboxytetramethylrhodamine). A higher melting point is designed for the probe 
compared to the primers. When intact, the quencher suppresses the fluorescence of 
the reporter. The probe anneals to the cDNA during the polymerisation step while 
amplification occurs. The probe is cleaved during the amplification step by 
AmpliTaq Gold (contained within Taqman Universal PCR Master Mix, Applied 
Biosystems) and the reporter and quencher are separated. Fluorescence can now be 
detected. The amount of fluorescence is directly proportional to the amount of PCR 
product, as non-specific amplification does not cause fluorescence. The whole 
process is represented diagrammatically in Figure 2.1. 18S ribosomal RNA detection 
is used as an internal control in this system. The 18S probe also has a reporter (VIC) 
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which emits fluorescence at a different wavelength to the FAM reporter on the gene 
of interest probe. Quantification is relative to 18S as its levels remain relatively 
constant in cells. Data are acquired when PCR amplification is in the exponential 
phase. The data are in the form of the cycle number where the fluorescence of the 
reporter dye rises above a threshold, this value is the threshold cycle, CT. 
 
 
Figure 2.1. Diagrammatic representation of Taqman QRT-PCR. Adapted from 
Taqman PCR Reagent Kit Protocol (Applied Biosystems). 
 
2.3.4.1 QRT-PCR procedure 
Taqman primers and probes were either designed in-house using ProberFinder 
software (Universal Probe Library), or purchased from Assay on Demand (Applied 
Biosystems). Details of primers and probes used are given in the Table 2.3. Primers 




































and diluted to 100μM in nuclease-free water (Sigma). The designed primers had 
previously been validated in the lab before use. Assay on Demand primer/probe sets 
were used directly as they are provided pre-optimized at a final concentration of 
900nM primer and 250µM probe. Pro-collagen-I primers were gifted by Dr. Moira 
Nicol (University of Edinburgh). Integrin alpha 5 and TGF-β1 primers were gifted by 
Dr. Sarah McDonald (University of Edinburgh). 
Table 2.3. Gene list for QRT-PCR primers and probes. 
Gene Primers Probe 
Lysyl oxidase Assay on Demand Assay on Demand 
MMP 9 Assay on Demand Assay on Demand 
ACTB Assay on Demand Assay on Demand 
Left: 5’ ctggccgaaaatacattgtaaa 3’ Fibronectin 
Right: 5’ ccacagtcgggtcaggag 3’ 
probe #32 (Universal 
Probe Library , cat. 
no. 04687680001) 
Left: 5’ ggaagaacatgtcctccttatacaat 3’ Integrin  
alpha 5 
Right: 5’ gcagctacagaaaatccgaaa 3’ 
probe #46 (Universal 
Probe Library , cat. 
no. 04687680001) 
Left: 5’cccgggacaacgtttattac 3’ E-cadherin 
Right: 5’gctggctcaagtcaaagtcc 3’ 
probe #35 (Universal 





















For Assay on Demand primer/probe sets, reaction mixtures containing TaqMan 
Universal PCR Master Mix (Applied Biosystems) and specific Assay on Demand 
were made in a final volume of 34µl per sample consisting of: 17μl 2X Universal 
Taqman mastermix (1X), 0.51μl ribosomal 18S primers and probe (50nM), 1.7μl 
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20X of the Assay-on-Demand primers and probe mixture of the target genes (1X), 
2.72μl cDNA sample, and 12.07μl nuclease-free H2O.  
 
For in-house designed primers, reaction mixtures containing TaqMan Universal PCR 
Master Mix and specific forward and reverse primers and probe were also made in a 
final volume of 34µl per sample consisting of: 17μl 2X universal Taqman mastermix 
(1X), 0.51μl ribosomal 18S primers and probe (50nM), 0.07μl 100μM primer 
forward (200nM), 0.07μl 100μM primer reverse (200nM), 0.34μl 10μM probe 
(100nM), 2.72μl cDNA sample, and 13.29μl nuclease-free H2O.  
 
All samples were run in triplicate on a 384-well ABI Prism 7900 sequence detection 
system (Applied Biosystems). For each 34µl sample mixture, 10µl aliquots were 
pipetted into three separate wells of a 384-well plate. The RT-negative and RT-water 
controls were included, alongside a “no template” control (NTC, 2.72μl 
nuclease-free H2O instead of cDNA) were used as negative controls in each run, 
while a placental cDNA sample was used as a positive control. Taqman reactions 
were carried out in the ABI Prism 7900 Sequence Detector following the default 
protocol (Table 2.4):  
 
Table 2.4. Taqman amplification default protocol. 
Cycles Description 
1 Cycle  50oC for 2min for the activation of UNG 
[UNG prevents re-amplification of 
carry-over PCR products by removing 
any uracil incorporated into amplicons 
1 Cycle  95oC for 10 min (Taq Polymerase 
activation) 
40 Cycles -Denaturation at 95oC for 15 sec 




2.3.4.2 Data analysis 
Data output was in the form of a “CT” value; the number of PCR cycles required 
before there is sufficient cDNA amplification to be detected. A CT value was given 
for both the gene of interest and 18S. These data were transferred to a Microsoft 
Excel spreadsheet for analysis. The CT values were used to calculate the abundance 
of the mRNA of each sample. Firstly, the difference between the CT of the target and 
the internal control was calculated (dCT). As each sample was run in triplicate, the 
mean dCT was ascertained. Then, the mean dCT of the control was subtracted from 
the mean dCT of each sample (ddCT) to relate all the samples to control, while the 
mean dCT of the placenta was used instead of the control when all the samples were 
expressed relative to placenta. Finally, the relative copy number was determined by 
the formula 2-(ddCT). The results of 2-(ddCT) are referred to the fold change of je 
particular target gene group compared to the control group or placenta. An example 
spreadsheet is shown in Figure 2.2. 
 
Sample CT(18S) CT(sampleDCT AVERAGE DDCT 2 -̂DDCT
1 11.3966 29.13059 17.73399 17.74 -0.03 1.02346
1 11.10005 29.08031 17.98026
1 11.83673 29.33213 17.4954
2 11.28214 28.79379 17.51166 17.61 -0.16 1.1204
2 11.42452 28.96353 17.53901
2 11.00313 28.77044 17.7673
3 11.63524 27.03788 15.40265 14.92 -2.85 7.20317
3 11.88735 26.58823 14.70089
3 11.71255 26.37313 14.66058
4 11.30327 25.67604 14.37276 14.21 -3.56 11.7859
4 11.31162 25.58229 14.27068
4 11.16155 25.15116 13.98961
CT(sample)-CT(18S)
average of the 3 
triplicates for each 
sample. average-comparator average
=2^(-DDCT)
Figure 2.2. Example Microsoft Excel Spreadsheet showing Taqman data 
analysis 
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2.3.5 RT2 ProfilerTM PCR Array 
2.3.5.1 Sample preparation 
For the PCR array, RNA samples were collected and quantified as detailed earlier 
(Chapter 2.3.1, 2.3.2). To obtain the best results from the PCR array, all RNA 
samples were selected by the following criteria: i) A260:A230 ratio should be greater 
than 1.7, ii) A260:A280 ratio should be 1.8 to 2.0, iii) concentration determination by 
A260 should be greater than 40μg/ml total RNA; iv) No RNA degradation (checked 
by ribosomal RNA band integrity). RNA 1.5 μg from each sample was used to make 
cDNA using a RT2 First Strand Kit (SABiosciences, Qiagen, Crawley, Sussex, UK). 
RNA samples were first mixed with 2μl GE (5 x gDNA Elimination Buffer) and 
nuclease-free H2O added up to 10μl. The mix was incubated at 42oC for 5 min and 
chilled on ice immediately for at least 1 min. Then, 10μl RT cocktail that included 
4μl BC3 (5 X RT Buffer3), 1μl P2 (Primer & External Control Mix), 2μl RE3 (RT 
Enzyme Mix 3), and 3μl Nuclease free water; was added to each 10μl RNA mixture. 
The synthetic reaction mixture was incubated at 42oC for exactly 15 min, and the 
reaction was immediately stopped by heating at 95oC for 5 min. Finally, 91μl of 
nuclease-free H2O was added to each 20μl of reaction mixture. The cDNA was 
stored at -20oC for later use. An optional RT2 RNA Quality Control PCR Array 
(SABiosciences) was used to test the quality of the cDNA samples.  
 
2.3.5.2 Performing Real-Time PCR 
i) For RT2 RNA Quality Control PCR Array 
The content of the RT2 RNA Quality Control PCR Array (SABiosciences) is showed 
in Table 2.5. Three cocktails for each sample were prepared for respective rows on 
the plate. 25μl of each cocktail was added to each well (Table 2.6). 
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Table 2.5. Content of RT2 RNA Quality Control PCR Array 
ROW Symbol UniGene GeneBank Description 
A ATCB Hs.520640 NM_001101 Actin, beta 
B HPRT1 Hs.412707 NM_000194 Hypoxanthine phosphoribosyltransferase 1
C RTC N/A N/A Reverse Transcription Control 
D PPC N/A N/A Positive PCR Control (with template) 
E GDC N/A N/A Genomic DNA Contamination control 
F NRT N/A N/A No Reverse Transcription Control 
G PPC N/A N/A Positive PCR Control (without template) 
H NTC N/A N/A No Template Control 
Table 2.6. Reagent mixtures to add to RT2 RNA Quality Control PCR Array 
Cocktail NO Rows on the 96-well plate Reagent mixture 
Cocktail 1 Rows A through E - 75μl 2 X SuperArray PCR master mix 
- 6μl Diluted first strand cDNA synthesis 
reaction 
- 69μl nuclease-free water 
Cocktail 2 Rows G and H - 45μl 2 X SuperArray PCR master mix 
- 45μl nuclease-free water 
Cocktail 3 Rows F - 1μl of a 1:100 dilution of original input total 
RNA 
- 24μl 1 X SuperArray PCR master mix 
 
ii) For RT2 ProfilerTM PCR Array (PAHS-013A: Human Extracellular Matrix and 
Adhesion Molecules) 
The PCR array was conducted using the RT2 ECM-Adhesion PCR Array (Gene list 
will be shown in Chapter 4.6). The experimental cocktail was prepared as follows: 
1350μl 2X SABiosciences RT2 qPCR master mix, 102μl diluted first strand cDNA 
synthesis reaction, and 1248μl nuclease-free water. This experimental cocktail (25μl) 
was added to each well. 
 
iii) For both PCR arrays, a two-step cycling program was used on the ABI Prism 
7900HT sequence detection system by detecting the fluorescent signal released from 
SYBR-green (Table 2.7) 
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Table 2.7. Amplification protocol for super array. 
Cycles Description 
1 Cycle 95oC for 10 min  
40 Cycles - Denaturation at 95oC for 15 sec 
- Annealing and extension at 60oC for 1 min 
1 Cycle for 
disassociation 
- 95oC for 15 sec 
- 60oC for 15 sec 
- 95oC for 15 sec 
 
2.3.5.3 Data analysis 
Data from each PCR array were input into the respective Excel-based RT2 RNA QC 
PCR Array Data Analysis template or RT² Profiler PCR Array Data Analysis 




IL-1α and TNF-α contents of conditioned-culture media and cell lysates from 
primary PMC and primary macrophages were determined using the DuoSet® ELISA 
Development System (R&D). Firstly, a capture antibody was diluted into respective 
working concentration in PBS (Sigma) without carrier protein. Diluted capture 
antibody (100µl) was added to each well to coat a 96-well Costar EIA plate (R&D) 
and left overnight at room temperature. The plate was sealed with a ELISA plate 
sealer (R&D). The plate was then washed three times with wash buffer (0.05% 
Tween® 20 in PBS, Sigma) and dried by blotting on clean paper towels. The plate 
was blocked by adding 300µl of reagent diluent (1% BSA in PBS, pH 7.2-7.4) to 
each well for a minimum of 1 h at room temperature. When the block reagent was 
washed off as noted above, sample (100µl) or standard were added to each well in 
duplicate. The plate was sealed and incubated for 2 h at room temperature. After 2 h, 
samples and standards were washed off as detailed above. Detection antibody (100µl) 
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diluted in reagent diluent was added to each well. The plate was incubated for 
another 2h at room temperature. Repeated washes were carried as noted above. A 
working dilution of streptavidin-HRP (100µl) was added to each well and incubated 
for 20 minutes at room temperature. The plate was placed in a dark area to avoid 
direct light and washed after 20 minutes incubation. Substrate solution (100µl, a 1:1 
mixture of H2O2 and tetramethylbenzidine, R&D) was added to each well and 
incubated for a further 20 min at room temperature in the dark. Then, stop solution 
(50µl, 2N H2SO4, R&D) was added to each well. The optical density of each well 
was immediately determined using a microplate reader (Max microplate reader, 
Thermo) with the wavelength set at 450 nm.  
 
For data analysis, the average of duplicate readings for each standard and sample 
were subtracted from the average zero standard optical density. A standard curve was 
generated for each set of samples assayed by using software (Softmax Pro V5) 
capable of generating a four-parameter logistic curve-fit. Sample concentrations were 




Immunohistochemistry, an experimental method to allow investigation of the 
presence or absence of a protein in situ in tissue, is based on the antigen-antibody 
complex that naturally occurs in living organisms. Primary antibodies, specifically 
raised to recognize the target protein (antigen), are reacted with the tissue in situ. 
Then, a secondary antibody, raised against the immunoglobulin of the species in 
which the primary antibody was produced, is added to bind the primary antibody. 
The secondary antibody is usually labelled with biotin that allows the recognition 
and amplification of the signal with avidin-biotin complex (ABC) conjugated to 
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horseradish peroxidise (HRP). Finally, a substrate that specifically interacts with 
HRP is added allowing visualisation (colourimetric reaction) of the signal.   
 
For colourimetric inmmunohistochemistry, sections were dewaxed in xylene, 
following by rehydration in serial dilutions of ethanol (100%, 95%, and 70%) and 
double deionised water (dH2O). Then, sections were boiled in pressure cooker (20 
minutes) with pre-heated 0.1M Na citrate buffer pH 6.0 (42.02g citric acid, made up 
to 2l) for antigen retrieval. The sections were then cooled for a further 20 min under 
running tap H2O. Sequential steps of blocking endogenous peroxidase (3% H2O2 in 
dH2O (v/v); Sigma), avidin and biotin additions (Vector; Peterborough, UK) were 
then carried out for 30 min, 15 min, and 15 min respectively. Each step was followed 
by two washes with tris-buffered saline (TBS: 100ml 0.5M Tris-HCl, 8.5g NaCl, 
made up to 1L). Afterwards, sections were submitted to blocking with non-immune 
normal goat serum (NGS; Sigma) diluted in PBS (1:5 v/v) containing 5% (w/v) BSA 
(Sigma) for 20 min. Then the sections were incubated overnight with a rabbit 
polyclonal antibody raised against a synthetic peptide of human LOX 
(EDTSCDYGYHRRFA; a kind gift from Dr. Janine T. Erler, Institute of Cancer 
Research, London, UK). The antibody had been proved to work for both human and 
mouse tissue (Erler et al., 2006). A one in fifty dilution of this LOX antibody was 
used for the staining. Negative antibody staining controls incubated with matched 
concentratons of unconjugated normal rabbit IgG fraction (Dako, Birmingham, UK) 
were routinely included. Sequential incubations with goat-anti-rabbit biotinylated 
secondary antibody (Dako) and RTU-ABC elite kit (avidin-biotin complex; HRP 
conjugated; Vector) were conducted for 30 min each. Between steps sections were 
washed three times with TBS supplemented with 0.05% Tween 20 (v/v) (TBST). 
Sections were subsequently incubated with HRP-conjugated diaminobenzidine (DAB; 
Vector) chromagen for 5 min followed by haematoxylin counterstaining. Finally, 
slides were dehydrated in serial ethanol dilutions (70-100%) and xylene and mounted 
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with a cover glass (VWR, UK) in an aqueous medium. The immunostained sections 
were visualized with an Olympus Provis microscope. 
 
2.6 LOX enzyme activity assay 
 
To test the LOX enzyme activity of the conditioned cell culture medium, a 
fluorometric-based assay was adapted in our lab from the published work of Prof. 
Philip Trackman (Palamakumbura and Trackman, 2002). The assay to detect LOX 
activity in medium is based on measuring released H2O2 from the oxidation process 
using the Amplex red (N-Acety1-3,7-dihydroxyphenoxazine) fluorometric reaction. 
Generally LOX present in the medium can effectively oxidise a simple amine 
substrate, 1,5-diaminopentane. The reaction generates H2O2, which in turn oxidises 
Amplex red. The oxidation of Amplex red is facilitated by the addition of 
horseradish peroxidase. It produces resorufin with a fluorescent excitation maximum 
at 563 nm and an emission maximum at 587 nm. Meanwhile, parallel assays were 
prepared with 500μM BAPN to completely inhibit the activity of LOX. The 
differences in emission between the raw samples and the BAPN-treated ones are 
used as a fluorescence increase recorded either in a discontinuous end-point reading 
or as a continuous reading. The enzyme activity therefore is presented by the relative 
fluorescence increase. It has been demonstrated that this assay allows the detection 
the activity of LOX as low as 20ng/ml (Palamakumbura and Trackman, 2002).  
 
To evaluate LOX production, PMC cell suspensions were adjusted to 1x105 viable 
cells per well of 24-well culture plates (Corning). After 24 h, the cells were washed 
with phenol red/serum-free medium consisted of phenol-red free medium 199 
(GIBCO), 0.01% BSA, 2mmol/l L-glutamine, 50IU/ml penicillin and 50μg/ml 
streptomycin. Cells were serum-starved for a further 24 h in the phenol 
red/serum-free medium. Phenol red was excluded as it interfered with the emission 
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intensity, due to fluorescence quenching. The cells were then treated in the following 
groups for 96 h with phenol red-free medium: (1) Control, (2) cortisol (F, 10-6 M, 
Sigma), (3) IL-1α (0.5ng/ml, R&D), (4) IL-1α + F. After 96 hours, whole media 
were collected for the assay. For the activity assay, reaction solutions were prepared 
in a final volume of 1ml at pH 8.2 containing 1.2M urea (Sigma), 0.05M sodium 
borate (Sigma), 1unit/ml horseradish peroxides (Sigma), 10μM Amplex red 
(Invitrogen), 10mM 1,5-diaminopentane dihydrochloride (Sigma), and 200μl of 
sample. A parallel set of negative controls was set up by adding 500μM BAPN in the 
solutions. Solutions were mixed by vortexing, and aliquoted into a 96-well 
FluoronuncTM black solid plate (nunc, Thermo) at 200μl per well. One set of 
triplicates for each sample and another set of triplicates with BAPN were set up in 
the plate. Fluorescence readings were obtained at 0 h using a BMG FLUO star plate 
reader (BMG LABTECH, Aylesbury, Germany) at a specified range of excitation 
(570 nm) and emission (590 nm). The plate was then incubated at 37oC with 
protection from light. Fluorescence readings were taken again at 1 h and 2 h time 
points.  
 
For the fluorescence increase calculation, subtractions were taken by both 1 h and 2 h 
record from the 0 h record. The average of the triplicates was taken to present each 
sample and negative control. The difference of the fluorescence increase between the 
sample and the negative controls gave the enzyme activity for each sample. This 
calculation gave a relative activity determination for LOX. 
 
2.7 In vitro wound healing assay 
 
For an in vitro scratch assay, 1.5 x 105 PMC were seeded into 12-well plates 
(Corning) and incubated at 37 oC. Cells were allowed to grow to form a confluent 
monolayer, when culture medium was removed and replaced with serum-free 
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HOSE2 medium for 24h. To investigate the effect of cytokines on cell motility, cells 
were pre-treated in following groups for 48h: (1) Control, (2) BAPN (500µM), (3) 
IL-1α (0.5ng/ml)+TGFβ-1 (2ng/ml, R&D), (4) IL-1α +TGF-β1+BAPN. Before 
scratching, 500µM fresh BAPN solution was added to groups 2 and 4 again to 
completely suppress LOX enzyme activity. A wound in the centre of the well was 
made by scratching the monolayer gently using a 1 ml pipette tip. Wound widths 
were recorded at 0 h and 16 h by measuring the width across the wound area between 
the wound edges on a pixel scale. The cell migration distance was calculated by 
subtracting the wound width at 16 h from the width in the corresponding wound area 
at the 0 h time point. Usually quadruplicate replicates were employed for each 
treatment group due to the limited number of cells available from any individual 
patient. 
 
2.8 In vitro cell-ECM adhesion assay 
 
The in vitro adhesion assay carried out in this thesis was based on a previous 
description (Odero-Marah et al., 2003). The ability of cells to adhere to the ECM was 
achieved using fibronectin-coated plates. 12-well plates were pre-coated with 
fibronectin (Sigma) at a final concentration of 10μg/ml, and 400μl per well of 
fibronectin solution was added to make a surface coverage at 1μg/cm2. Plates were 
incubated in a 37 oC incubator for 1 h to allow the completion of coating and solution 
then removed. The plates were air-dried in the fume hood, and then used for 
adhesion assays or kept at 4oC for later use. To investigate the effect of cytokines on 
cell-ECM adhesion, PMC were serum-starved in HOSE2 medium for 24 h, and then 
pre-treated in groups for 48 h as follows: (1) Control, (2) BAPN (500µM), (3) IL-1α 
(0.5ng/ml)+TGFβ-1 (2ng/ml), (4) IL-1α+TGF-β1+BAPN. Then, the condition 
medium from each treatment were collected, fresh BAPN (500µM) was added again 
to the condition medium from group (2) and (4). Cells were harvested by 
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trypinisation and counted using a haemocytometer. A final number of 2 x 105 cells 
were added into each fibronectin-coated well with 1ml of corresponding condition 
medium. Plates were incubated in 37 oC incubator for 1h to allow the cells adhere to 
fibronectin. Non-adherent cells were removed by washing three times with warm 
HOSE2 medium. Adhered cells were detached by trypsinisation (1ml/well) and cell 
counts were carried out with a haemocytometer. Duplicate wells were set up for each 
treatment group. 
 
2.9 In vivo animal work. 
 
All animal experiments were performed with Home Office Approval under a project 
license issued to Professor Ken Donaldson. The animal work was done with the kind 
assistance of Dr. Craig Poland. 
 
Initially a preliminary BAPN dose trial was carried out to determine the optimum 
dose of BAPN to use in further experiments. 8-week-old female C57/Bl6 mice 
(Harlan, UK) were randomly assigned to 6 treatment groups: Vehicle (saline), 0.1, 
0.2, 0.5, 1 and 2g/kg BAPN, experiment was done in triplicate for each treatment 
group. Mice were injected directly into the peritoneal cavity (I.P. injection) daily for 
a period of 2 weeks. From this trial it was concluded that 1g/kg would be the most 
appropriate dose to use in further experiments as analysis of the ovaries, diaphragms 
and peritoneal fluid from the different BAPN treatment groups showed no clear 
differences to the control group; however, the highest evaluated dose (2g/kg) 
appeared to make the mice lethargic.   
 
Following on from this, 24 mice were randomly assigned to 8 treatment groups as 
follows: Vehicle (Saline), BAPN (1g/kg), dexamethasone (DEX) (Sigma, 1mg/kg), 
multi-walls nanotubes (NT) (20µg/ml, which equated to 10µg/mouse, provided by 
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Matthew Boyles, University of Cambridge), NT+BAPN, NT+DEX, BAPN+DEX 
and NT+BAPN+DEX. Each treatment was done in triplicate. Prior to experimental 
treatment, NT were dispersed by suspending in 0.5% BSA (Sigma) and placed in an 
ultrasonic water bath, as previously described (Poland et al., 2008). On day 1 of the 
experiment, mice were injected intraperitoneally within their treatment groups. 
Injection volumes were as follows: 0.5ml NT, 0.5ml vehicle, 250µl BAPN and 250µl 
DEX. NT and vehicle injections were given only once, whereas BAPN and DEX 
injections were given daily for a period of 7 days. The diaphragms were carefully 
dissected from the mice and fixed overnight in methacarn (60% methanol, 30% 
chloroform, 10% glacial acetic acid) for histological analysis. 
 
Sections were stained with H&E, and collagen in the tissue was stained with 
picrosirius red. Pictures of each section were taken by Olympus BH-2 microscope. 
The whole fibrotic lesion area (granuloma) and collagens contained in these areas 
were quantified by Imagine Analysis (Image-Pro 4.0). Briefly, the whole fibrotic 
lesion was highlighted in the picture, the total pixels contain in the highlighted area 
were counted and recalculated into landmeasure (mm2). The area of collagen staining 
was calculated in the same way. Quantification data was presented by using the area 
of lesion and collagens over the length of respective diaphragm section.  
 
2.10 Statistical analysis 
All data from each experimental set were combined and presented as means and 
standard errors (±sem). Numbers of replicate experiments are denoted by the number 
(n) of independent replicates and are given in figure legends and text. Basic 
statistical analysis was performed using one-way analysis of variance with the 
GraphPad Prism 5.0 software (GraphPad Software Inc., San Diego, USA). 
Repeated-measures-one-way ANOVA and Turkey post test were run for multiple 
comparisons between parametric samples (cell line) , whereas repeated-measures- 
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nonparametric Friedman test and Dunn’s multiple comparison test were done for 
group comparisons between nonparametric samples (primary samples). Two-tailed 
paired Student t-tests were performed for single parametric test. Wilcoxon 
matched-paired tests were performed for single nonparametric test. A p value <0.05 




























































Several animal models have been developed to investigate the formation of 
peritoneal adhesions and fibrosis in the peritoneum. For example, Sulaiman and 
colleagues have successfully induced peritoneal adhesion by injuring the surface of 
the caecum and adjacent abdominal wall (Sulaiman et al., 2000). Hung and 
associates induced peritoneal fibrosis in a rat model by introducing Staphylococcus 
aureus into the peritoneal cavity using microcarriers (Hung et al., 2001). Other 
studies induced peritoneal adhesion as a consequence of direct injury by suturing or 
electrocoagulation (Kucukozkan et al., 2004; Reed et al., 2008; Wallwiener et al., 
2010).  
 
A recent study by Poland and colleagues proposed a new model to investigate 
peritoneal fibrosis in the peritoneal cavity (Poland et al., 2008). They induced tissue 
fibrosis on the peritoneal side of the diaphragm by direct intraperitoneal (i.p) 
injection of mice with long multi-walled nanotubes (NT). Carbon nanotubes (CNT) 
are a new type of nanomaterial that has been developed as a novel structural material. 
They are graphite cylinders that vary in size but are usually a few nanometers in 
diameter, with their length ranging from a few micrometers to millimeters. NTs are 
CNTs which are made up of more than one graphite cylinder whereas a single 
cylinder is referred to as a single-walled nanotube (SWNT) (Figure 3.1). Such 
structures give nanotubes properties that are highly desirable in many industrial 








Figure 3.1. Representative molecular images and transmission electron 
micrographs of SWNT (left) and NT (right). Figure adapted from (Donaldson et 
al., 2006).  
 
The pathology of the NT-induced fibrosis on the diaphragm is due to the chronic 
inflammation caused by the injection of long forms of NTs. It occurs most probably 
as a consequence of the failure of macrophages, the inflammatory cells usually 
responsible for clearing infection or infectious agents, to completely phagocytose the 
NT, as illustrated in Figure 3.2 (Poland et al., 2008; Kostarelos, 2008). It has been 
shown that such frustrated phagocytosis can induce significantly more TNF-α and 
reactive oxygen species production from macrophages (Brown, 2007). This initiates 
a chronic inflammation, as indicated by elevated levels of total protein, 
polymorphonuclear leukocytes (PMN) and foreign body giant cells (FBGCs) 
presenting in the lavage fluid from NT-treated mice. It results in the formation of 
granulomas on the mesothelial side of the diaphragm. The granulomas are formed by 
aggregates of cells containing NT fibres, most likely macrophages and FBGCs, with 




Figure 3.2. Response of Macrophages to Long NTs. Diagrammatic representation 
of the response of macrophages to NTs as demonstrated by Poland et al (Poland et al., 
2008), summarising the fact that macrophages are able to cope with short or tangled 
NT as these can be efficiently taken up by the macrophage cells and degraded, 
resulting in resolution of the inflammatory response and no fibrosis or granuloma 
formation. This should be compared to the reaction to long NT that cannot be 
effectively taken up and phagocytosed by the macrophages resulting in a chronic 
inflammatory response, which leads to granuloma formation and fibrosis. Figure 
adapted from (Kostarelos, 2008). 
 
This in vivo model was used to investigate the role of LOX and anti-inflammatory 
factors in pathologic peritoneal fibrosis caused by NT. Obviously there are a few 
differences between NT-induced fibrosis and postoperative adhesion; one causes 
hyperplasia whereas the other causes adhesion. Furthermore, surgery may sometimes 
cause much more serious damage to the peritoneal architecture than a NT injection. 
However, adhesions are widely regarded as a form of fibrosis, and they share 
common features. Both are caused by external irritation and undergo a chronic 
inflammation at particular sites. A previous study showed that suturing is a principal 
reason for peritoneal adhesion (Hubbard et al., 1967). The pathology is thought to be 
quite similar to the failed digestion of NT. In addition, both are formed on the 
peritoneal mesothelium. I therefore believe that the NT-induced adhesion model is 
















3.2 Material and Methods 
 
To investigate the effect of BAPN and DEX on NT-induced peritoneal fibrosis, 24 
mice were divided into 8 groups as shown in section 2.9: Vehicle (Saline), BAPN 
(1g/kg), dexamethasone (DEX) (Sigma, 1mg/kg), multi-walls nanotubes (NT) 
(20µg/ml, which equated to 10µg/mouse), NT+BAPN, NT+DEX, BAPN+DEX and 
NT+BAPN+DEX. Pathologic fibrosis was induced on the peritoneal side of the 
diaphragm by i.p injection of 0.5ml of carbon nanotubes. Daily injections with 250µl 
BAPN or 250µl DEX were given for 7 days, and diaphragm sections were sampled 
for further investigation. 
 
To investigate the effect of NT on macrophages, buffy coat samples were obtained 
from Scottish National Blood Transfusion Service. The profile of the individual 
donated samples used for these studies is presented in Table 3.1  
 
Table 3.1 Profile of buffy coat donator 
Donation No/ LOT ABO Volume (ml) Collection Data 
G101 610 897 847 1 A+ 62 14/07/10 
G101 610 771 680 H A+ 67 20/07/10 
G101 610 767 668 J O+ 60 22/07/10 











3.3.1 Carbon nanotubes induction of peritoneal fibrosis within mouse abdominal 
cavity 
Seven days after i.p injection of carbon nanotubes, diaphragms of experimental mice 
were sampled and sectioned as indicated in Figure 3.3A. The complete section 
comprised two main parts: the muscle-rich costal parts on both sides and the 
collagen-rich tendon parts in the middle, linking the muscle-rich parts. These were 
stained with picrosirius red to indicate the distribution of collagen deposition. In 
control diaphragm sections, both the pleural and peritoneal sides were covered by a 
thin layer of mesothelium with an underlying collagen-rich basement membrane 
(Figure 3.3B). In contrast, diaphragm sections of NT-treated mice showed extensive 
granuloma lesions on the peritoneal side with massive collagen deposition, whereas 
the mesothlium on the pleural side was normal in all cases (Figure 3.3C). The inset 
image also show NT contained within a granuloma.   
 
Immunohistochemistry was used to locate LOX protein in the control and fibrotic 
tissue (Figure 3.4). In the control group, a weak staining of LOX was distributed 
inside the muscle area, and also in the peritoneal mesothelial cells on the edge of the 
diaphragm (Figure 3.4 A, C, E). In the NT-treated group weak LOX staining was 
also found in the muscle. However, intensive staining was found along the edge of 
the fibrotic lesion, with gradual reduction from the edge to the inside areas (Figure 
3.4 B, D, F). Furthermore, in higher magnification images, larger cells and bigger 
nuclei were found in the NT-treated group, which are hallmarks of granuloma tissue 
(Figure 3.4 G, H). LOX staining was found to locate in both the cytoplasm and 
intercellular space. However, the granuloma tissue which contained the NT fibres 







Figure 3.3. In vivo peritoneal fibrosis model. A: Abdominal surface of a diaphragm 
and its attachment. The fleshy sternal, costal and lumbar origins of the diaphragm 
attach centrally to the trefoil-shaped central tendon, the aponeurotic insertion of the 
diaphragmatic muscle fibres. The red box indicates the sampling site. B: Histology 
section of control mouse diaphragm stained with picrosirius red. Insert pictures 
indicate the abdominal surface of the diaphragm. C: Histology section of NT-treated 
mouse diaphragm stained with picrosirius red. Insert pictures indicate the abdominal 
surface of diaphragm. *: Widespread collagen staining observed as the red staining. 




Figure 3.4. NT-treated mice exhibit upregulated LOX expression in diaphragm. 
Immunohistochemistry staining for LOX using rabbit anti-LOX (1:50 dilution) 
performed on diaphragm sections. (A, C, E) Control group X4, X20, X40. (B) NT 
group X4. (D, F) NT group X20. (G, H) NT group X40. Negative control for NT 





















     
     
     






3.3.2 Effects of β-aminoproprionitrile and dexamethasone on the inhibition of 
peritoneal fibrosis 
As shown above, NTs induced fibrosis on the peritoneal side of the diaphragm and 
this was associated with an elevated LOX expression. Daily injection of LOX 
activity inhibitor (β-aminoproprionitrile, BAPN) and dexamethasone (DEX) was 
conducted as attempts to resolve the pathologic fibrosis in vivo.  
 
Representative whole diaphragm sections from five groups of treatment are shown in 
Figure 3.5 (A: control, B: NT, C: NT+BAPN, D: NT+DEX, E: NT+BAPN+DEX), 
with inset images taken at a higher magnification to highlight the peritoneal 
mesothelium and the tendon link in the middle. No granulomas were seen on the 
diaphragms of the control group (Figure 3.5A), as well as those treated with BAPN, 
DEX and BAPN+DEX in the absence of NT (Appecdix 2). Sections of the 
NT-treated group showed dramatic granuloma formation on the peritoneal side, with 
widespread collagen staining (Figure 3.5B).   
 
Importantly there was a dramatic reduction of fibrotic tissue formation in the 
NT+BAPN, NT+DEX and NT+BAPN+DEX groups, as well as a visual reduction of 
collagen staining (Figure 3.5C, D and E). We used software to quantify the formation 
of such fibrotic granuloma tissue and the percentage of collagen (one section per 
group). The data indicated that granuloma formation was significantly reduced in the 
treatment groups compared to the NT group (p<0.05) (Figure 3.6A), with a 75% 
reduction in granuloma formation in the NT+BAPN+DEX group, The quantification 
of collagen staining also showed significant reductions of collagen deposition in 
these three groups compared to the NT group (p<0.01) (Figure 3.6B), with an 90% 
reduction in collagen staining found in the NT+BAPN group.  
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Figure 3.5. Histology sections of mouse diaphragm stained with picrosirius red. 
Diaphrams were recovered from mice following 7 days treatment of the following 
groups: A: Control, animal treated with 0.5ml saline on day 1 and daily 200μl i.p. 
injections of saline for 7 days. B: animal treated with 0.5ml NT (20μg/ml) on day 1 
and daily 200μl i.p. injections of saline for 7 days, or C: daily 200μl i.p. injections of 
BAPN (1g/kg) for 7 days, or D: daily 200μl i.p. injections of DEX (1mg/kg) for 7 
days, or E: daily 200μl i.p. injections of BAPN+DEX for 7 days. No granulomas 
seen in control group (A). Extensive granuloma formation on peritoneal side of 
diaphragms of the NT-treated group with widespread collagen staining (B). 
Granuloma formation, but much reduced, also seen in NT+BAPN, NT+DEX, 































































































































Figure 3.6. Quantification of the effect of NT and anti-fibrotic treatment on 
diaphragms after 7 days. A: Quantification of granuloma formation on the 
peritoneal side of diaphragm from NT, NT+BAPN, NT+DEX, NT+BANP+DEX 
groups. (n=3), *: p<0.05, **: p<0.01 compared to the NT group. B: Quantification of 
the amount of collagen staining within the granuloma lesions. (n=3). Statistical 
analysis was undertaken by one-way ANOVA. Bars represent mean±S.E.M. **: 




3.3.3 Effect of nanotubes on human peripheral blood mononuclear cell-derived 
macrophages  
To investigate the effect of NT on macrophages, peripheral blood mononuclear cells 
(PBMC) were separated from buffy coat samples obtained from healthy donors. As 
described in section 2.1.2, an adapted ficoll-percoll density gradient separation 
protocol was used. This method allowed PBMC separation from buffy coat with high 
purity and minimal lymphocyte contamination (Figure 3.7A, B). PBMC were further 
enriched by adhering cells to culture plates, followed by several washing steps. After 
6 days of culture with serum and M-CSF, PBMC matured into macrophages (Figure 
3.7C, D), indicated by the increased size of the cells, a rounded regular nucleus in the 
centre, and developing cytoplasm vacuolation.  
A                                B 
  
C                                D 
  
Figure 3.7. A, B: Population of PBMC separated from buffy coat stained with 
haematoxylin at X20 magnification (A) and X40 magnification (B) (Red arrow: 
monocyte; black arrow: lymphocyte). C,D: A population of matured macrophages 
after 6 days culture at X20 magnification (C) and X40 magnification (D) (Red arrow: 
monocyte; black arrow: lymphocyte; green arrow: cytoplasm vacuolation).
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LOX mRNA level was first measured in cultured macrophages (Figure 3.8). The 
result showed that LOX mRNA levels were extremely low in matured macrophages, 
















































Figure 3.8. Quantitative RT-PCR comparing LOX mRNA expression in 
matured macrophages and peritoneal mesothelial cells (PMC). Values are 
relative to placenta (n=2 donors).  
 
Macrophages were then exposed to NT across a range of doses (0, 5, 15, and 
30μg/ml) for 48h. TNF-α and IL-1α contents of the culture media were evaluated by 
ELISA. The data showed a dose-dependent increase of TNF-α released from 
NT-treated macrophages, with 30μg/ml NT significantly increasing TNF-α levels in 
the culture medium (Figure 3.9A, 810±405pg/ml compared to 7.8±4pg/ml in the 
control). In contrast, IL-1α levels remained low in all treatment groups and was not 









































































Figure 3.9. Cytokine production from NT-treated macrophages. A: TNF-α 
released by human macrophages after 48h treatment with carbon NTs at 0, 5, 15, and 
30μg/ml. Treatment with 1μg/ml LPS (48h) was used as a positive control for these 
experiments. Statistical analysis was done by repeated-measures-nonparametric 
Friedman test; group comparisons were done by Dunn’s multiple comparison test 
(n=3 donors). Data represent the mean±S.E.M. **: p<0.01. B: IL-1α release by 
human macrophages after 48h treatment with carbon NTs at 0, 5, 15, and 30μg/ml. 
Insufficient replicates (n=2 donors) did not allow statistical analysis.  
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Since the in vivo studies showed that DEX treatment could minimize the formation 
of granuloma tissue, we further tested whether DEX treatment could suppress TNF-α 
production from NT-treated macrophages. The results showed that the addition of 
DEX reduced the level of TNF-α released from NT-treated macrophages (Figure 







































Figure 3.10. TNF-α release by human macrophages after 48h treatment with 
DEX (1μM), carbon NTs (15μg/ml), and NT+DEX. Insufficient replicates 




By using the protocols previously published (Poland et al., 2008), we established an 
in vivo peritoneal fibrosis model using C57/BL6 mice. Injection of multi-wall 
nanotubes (NT) into the abdominal cavity notably induced fibrotic lesions on the 
peritoneal side of diaphragms. The lesions exhibited features of granulomatous tissue, 
comprised of aggregates of cells containing NT fibres, most likely foreign body giant 
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cells (FBGCs), and associated deposition of collagen. As noted in the Introduction, 
such pathologic changes induced by NT could arise from a frustrated phagocytosis 
when macrophages tried to eliminate the NT particles. This leads to increased 
numbers of FBGCs presenting in the peritoneal fluid, with significant PMN and 
protein exudation (Poland et al., 2008). Peritoneal fluid moves in response to 
pressures generated by the diaphragm (Yao et al., 2003). Such a mechanism aids 
peritoneal clearance by drainage into lymphatic lacunae that lie beneath gaps 
(stomata) in the mesothelium lining the undersurface of the diaphragm (Nakatani et 
al., 1996). Therefore, the peritoneal side of the diaphragm becomes a perfect bed to 
house either NT particles or the FBGCs presented in the fluid. The deposition of NTs 
or FBGC can further breakdown the normal construction of the diaphragm and 
replace the mesothelium with granulomas. In addition, milky spots in omentum can 
be another possible way of the self-clearance of NTs in peritoneal cavity. Therefore, 
omentum could be another important site to investigate such peritoneal fibrosis 
induced by NTs. Due to the extremely long half life for the NT particles (He et al., 
2010), it can be expected that more severe fibrotic damage can be seen over longer 
periods. The experiment shown in this chapter ended at day 7 after the injection of 
NT. Another experiment, which continued for 14 days after NT injection, revealed 
significant adhesions forming between the diaphragm and the liver (F Gardiner & C 
Harlow, unpublished results). It indicates a potential of these granuloma lesions to 
develop into fibrotic adhesion.  
 
LOX protein was localized to the edge of the granuloma lesions, and the staining was 
much more intense than on the normal mesothelium overlying the peritoneal side of 
the diaphragm. A gradation of LOX staining was found from the edge of granulomas 
to the inner part. This suggested a completed collagen deposition process had 
occurred in the older granuloma tissue, while an ongoing process was occurring at 
the newly forming edge of the granuloma lesions. Additionally, we showed that there 
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was no apparent LOX staining in the granuloma tissue (or FBGCs) wrapping the NT 
fibres. Thus, combined with the finding that LOX mRNA was highly expressed in 
PMC but not in macrophages, the data were suggestive that such collagen deposition 
might be mediated by PMC-derived LOX presented in the peritoneal fluid, while 
FBGCs were not essential for this process since they did not express LOX.      
 
The results also showed a potential method to minimize peritoneal fibrosis by 
inhibiting LOX activity. By daily injection of BAPN (an irreversible chemical 
inhibitor of LOX activity), significant reduction of collagen deposition was found 
which was associated with a reduction of the size of the granuloma lesion. DEX was 
also shown to suppress the formation of granulomas and collagen deposition. 
Unfortunately, there was no significant additive effect when using the combined 
treatment of BAPN plus DEX. DEX has long been used as a treatment for 
inflammatory diseases. The application of DEX to prevent post-operative adhesion 
has been shown in many studies (Binda and Koninckx, 2009; Kucukozkan et al., 
2004; Letowska-Andrzejewicz et al., 2011), which indicates an anti-adhesion effect 
of DEX. Interestingly, inhibition of LOX showed a similar pattern of reduction in 
fibrotic tissue as DEX. It suggests an alternative method to prevent post-operative 
adhesion by suppressing collagen crosslinking, which can further reduce collagen 
deposition. It may be of particular clinical relevance in situations where 
glucocorticoids are contra-indicated. Inhibition of LOX by BAPN has been used in 
many studies related to cancer metastasis (Erler et al., 2009; Erler et al., 2006). There 
has been no obvious side-effect seen in any of these studies. We also demonstrated 
that i.p injections of BAPN can be used at doses up to 1 g/kg. However, 2 g/kg 
injection of BAPN appeared to make the mice lethargic. Thus, BAPN may be an 




Because macrophages are essential components in our in vivo fibrosis model, our 
studies also focused on macrophage responses to NT particles. The results firstly 
showed that LOX was principally expressed by PMC, and not by macrophages. 
Therefore, we hypothesized that macrophages could induce LOX expression by 
producing inflammatory cytokines in response to NT. It has been shown that carbon 
NTs can induce TNF-α release from macrophages, as well as production of reactive 
oxygen species (ROS) (Brown, 2007). The underlying mechanism might involve the 
activation of the proinflammatory transcription factor NF-κB by ROS, a second 
messenger regulating such transcription processes. Our studies confirmed this by 
demonstrating a dose-dependent increase in TNF-α released by macrophages in 
response to NT. The impact of NT on macrophages varies considerably, as shown 
previously (Brown, 2007), suggesting that variable effects of NT could occur in 
individuals. In contrast, another important cytokine, IL-1α, was not secreted by 
macrophages in response to NT treatment. However, the most commonly secreted 
form of IL-1 is IL-1β, while IL-1α is largely retained in the cytoplasm in a precursor 
form. Thus, the level of IL-1β in the medium remains to be tested. Furthermore, 
addition of DEX into the medium suppressed the production of TNF-α from 
NT-treated macrophages, possibly due to suppression of the NF-κB pathway caused 
by DEX binding to glucocorticoids receptors (van der Laan and Meijer, 2008). 
Therefore, DEX may help to minimize granuloma lesions by reducing TNF-α release 
from macrophages.  
 
In summary, our in vivo model had been shown to be a simple and suitable model to 
study peritoneal fibrosis. Quantification can be made on a section of the diaphragm 
allowing the study to be more objective and reliable. However, since measurements 
were only conducted on one section from each group, a series of sections cut from 
the same sample would have been preferable so that the mean value of all sections 
can be used to minimize variation between sections. We confirmed a key role of 
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LOX in peritoneal fibrosis. Inhibition of LOX could reduce collagen deposition, 
further minimizing the formation of granuloma lesions. In addition, application of 
DEX was also shown to prevent fibrosis in this model, possibly through the 
suppression of TNF-α production from macrophages exposed to NT. However, LOX 
was mainly found expressed in PMC and not macrophages. Therefore, the interplay 











































Chapter 4  


























As shown in Chapter 3, LOX was highly expressed in peritoneal mesothelial cells 
(PMC) whereas macrophages had reduced expression of LOX compared to PMC. 
The research focus of this thesis was therefore shifted from macrophages to PMC. 
Although a large body of work has looked at the role of PMC in peritoneal repair, the 
interaction between PMC and inflammation and their roles in extracellular matrix 
(ECM) remodeling require further investigation. From previous studies, we knew 
that an elevated accumulation of several cytokines was found in the peritoneal fluid 
after surgery, particularly TNF-α, IL-1 and TGF-β (see section 1.4.3). The 
concentrations of these three cytokines were found to vary in the peritoneal fluid 
after surgery. For example, after 48h, the concentration of IL-1 increased 
significantly to around 20pg/ml in patients who had adhesion reformation; whereas, 
in those who had no adhesion reformation, the concentrations of IL-1 remained 
relatively low (around 4pg/ml) (Cheong et al., 2002). Similarly TNF-α was 700pg/ml 
in the adhesion reformation group compared to 200pg/ml in the no adhesion 
reformation group (Cheong et al., 2002). In addition, the concentration of TGF-β1 in 
the peritoneal fluid after surgery (2861±347pg/ml) was significantly higher 
compared to that before the surgery (1229±157pg/ml) (Cheong et al., 2003). 
Therefore, the interaction between PMC and these three cytokines may be critical to 
an understanding of the pathology of post-operative adhesion formation. In Chapter 3, 
we showed that macrophages could produce TNF-α but not IL-1α when exposed to 
nanotubes. However, TNF-α has also been shown to induce IL-1 production from 
other cells, such as murine embryo fibroblasts (Wysk et al., 1999). It suggested that 
TNF-α could be the initial inflammatory cytokine at the site of nanotube deposits in 
our in vivo model, followed by the production of either IL-1 or TGF-β. Therefore, in 
this Chapter, interactions between PMC and these three cytokines were tested in vitro, 
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to better understand the role of PMC and the inflammatory response in 
post-operative adhesion.   
 
4.2 Materials and methods 
 
Investigation of the role of PMC in peritoneal fibrosis was assessed using primary 
PMC monolayers as described in Chapter 2. Treatments of several inflammatory 
cytokines were conducted on PMC monolayers for 48h in serum-free medium. RNA 
was extracted from the experimental groups, and quantitative real-time PCR was 
used to evaluate gene expression in the groups. ELISA was performed on cell 
lyasates and conditioned medium as described in section 2.4. In vitro wound healing 
assay and cell-ECM adhesion assay were performed as described in section 2.7 and 
2.8 respectively. The basic clinical profile of patients involved with the respective 
assays performed on each are presented in Table 4.1.  
 





Surgery Reason for surgery Study 
6848 54 NA TAH & BSO Fibroids & HMB mRNA 
7672 47 19 TAH HMB mRNA 
7638 23 25 Diag Lapscpy HMB mRNA 
6832 51 19 STAH & 
BSO 
HMB mRNA 
7641 38 11 TAH HMB mRNA 
7548 31 5 Lap Ster NA mRNA 
3028 29 19 Diag Lapscpy RIF Pain  mRNA 
7539 40 27 TAH HMB & Pain mRNA 
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Surgery Reason for surgery Study 
7538 21 NA Diag Lapscpy Pelvic pain mRNA 
7607 45 17 Diag Lapscpy RIF pain & IMB mRNA 
5621 44 8 TAH HMB & Fibroids mRNA, healing assay 
7531 37 27 Diag Lapscpy HMB & Pain mRNA, healing assay 
7613 48 26 STAH Erratic Menstrual Cycle mRNA,  
Adhesion assay 
6316 43 24 TAH & RSO HMB & Pain Healing assay 
7541 33 7 Lap Ster Unwanted Fertility Healing assay 
Adhesion assay 
5636 34 NA TAH morbid fear of pregnancy Adhesion assay 
7638 23 25 Diag Lapscpy HMB & Endometriosis  Adhesion assay 
6832 51 19 STAH & 
BSO 
HMB ELISA 
7672 47 19 TAH HMB ELISA 
7686 43 16 Laparoscopy HMB ELISA 
7715 46 45 TAH & BSO HMB ELISA 
5678 38 4 Diag Lapscpy
Hysteroscopy
HMB ELISA 
7741 37 NA TAH No cycle constant bleeding ELISA 
Abbreviation: TAH = total abdominal hysterectomy, BSO = bilateral 
salpingo-oophorectomy, HMB= heavy menstrual bleeding, Diag Lapscpy = 
diagnostic laparoscopy, Lap Ster = laparoscopic sterilisation, NA = not applicable, 
RIF = right Iliac Fossa, LIF = left Iliac Fossa, STAH = subtotal abdominal 








4.3.1 Regulation of LOX mRNA expression in peritoneal mesothelial cells by 
inflammatory cytokines. 
In order to mimic the inflammatory response caused by frustrated phagocytosis of 
macrophages, PMC were treated with TNF-α (10ng/ml) for 48h. LOX was 
up-regulated nearly 3-fold in the TNF-α-treated group compared to control, although 
































Figure 4.1. Quantitative RT-PCR for LOX mRNA expression in PMC. PMC 
cells were treated with 10ng/ml TNF-α for 48h. Statistical analysis was conducted by 
paired t-test (n=3 donors). Bars represent mean (±S.E.M.) values relative to untreated 
control.  
 
In addition to TNF-α, other cytokines were also tested in our cell culture system, 
including IL-1α, IL-4, IL-6, IL-8, IL-10, and TGF-β1. Treatments of PMC were 
conducted for 48h at a concentration of 0.5ng/ml for all the interleukin factors and 
2ng/ml for TGF-β1. IL-1α, IL-4 and TGF-β1 were found to significantly increase 
LOX expression in PMC (Figure 4.2, 2.9±0.18-fold, 2.1±0.08-fold and 2.6±0.05-fold 
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respectively), whereas the other cytokines had no significantly effect on LOX mRNA. 
Combined with the outcome from TNF-α treatment, these results indicated that IL-1α 
was likely the most effective cytokine inducing LOX expression during peritoneal 
fibrosis, since it induced a 3-fold increase of LOX at 0.5ng/ml, whereas the fold 
changes induced by TNF-α and TGF-β1, even at a much higher concentration, are 













































Figure 4.2. Quantitative RT-PCR for LOX mRNA expression in PMC. PMC 
were treated with IL-1α, IL-4, IL-6, IL-8, IL-10 (0.5ng/ml), and TGF-β1 (2ng/ml) for 
48h. Statistical analysis was conducted by repeated-measures-paired-one-way 
ANOVA (n=3 donors). Bars represent mean (±S.E.M.) values relative to untreated 
control, ***: p<0.001. 
 
TNF-α and IL-1α are believed to induce common signalling networks, whereas 
TGF-β1 has been shown to signal through a separate pathway. Therefore, we asked 
whether there was any synergistic effect between TNF-α and TGF-β1, or IL-1α and 
TGF-β1. To investigate this, PMC were treated with TNF-α and TGF-β1 alone, or in 
the combination, at the same concentration used above. The result showed that LOX 
was significantly upregulated by TNF-α alone or the combination of TNF-α and 
TGF-β1 (Figure 4.3, 2.6±0.52-fold and 3.0±0.20-fold respectively), whereas TGF-β1 
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Figure 4.3. Quantitative RT-PCR for LOX mRNA expression in PMC. PMC 
were treated with TNF-α (10ng/ml) and TGF-β1 (2ng/ml) alone, or in combination: 
TNF-α+TGF-β1 for 48h. Statistical analysis was conducted by 
repeated-measures-paired-one-way ANOVA (n=3 donors). Bars represent mean 
(±S.E.M.) values relative to untreated control, *: p<0.05, **: p<0.01. 
 
A similar study was carried out by treating PMC with IL-1α and TGF-β1 alone, or in 
combination. We found that LOX was up-regulated significantly in the IL-1α-treated 
group compared to control (Figure 4.4, 3.9±0.63-fold). TGF-β1 induced LOX 
expression in PMC by 2.5±0.67-fold, but this was not significant. There was an 
additive effect of IL-1α plus TGF-β1 in the up-regulation of LOX (6.4±1.3-fold); this 
was significant compared to control or TGF-β1 treatments, but not that of IL-1α. 
Interesting, the combined effect of IL-1α and TGF-β1 was dramatically stronger than 












































Figure 4.4. Quantitative RT-PCR for LOX mRNA expression in PMC. PMC 
were treated with IL-1α (0.5ng/ml) and TGF-β1 (2ng/ml) alone, or in combination 
for 48h. Statistical analysis was conducted by repeated-measures-paired-one-way 
ANOVA (n=4 donors). Bars represent mean (±S.E.M.) values relative to untreated 
control, *: p<0.05, ***: p<0.001. 
 
To test the effect of inflammatory cytokines on gene transcription in more detail, we 
asked whether IL-1α and/or TGF-β1 would affect procollagen I expression in PMC. 
Procollagen I mRNA was up-regulated by TGF-β1 in PMC compared to control 
(Figure 4.5, 3.6±0.95-fold), while IL-1α treatment had only a modest effect 
(1.7±0.14-fold increase). There appeared an additive effect of combined IL-1α and 
TGF-β1 treatments of PMC (4.8±1.03-fold), but this was not significant compared to 














































Figure 4.5. Quantitative RT-PCR for COL1A1 mRNA expression in PMC. PMC 
were treated with IL-1α (0.5ng/ml) and TGF-β1 (2ng/ml) alone, or in combination 
for 48h. Statistical analysis was conducted by repeated-measures-paired-one-way 
ANOVA (n=5 donors). Bars represent mean (±S.E.M.) values relative to untreated 
control, **: p<0.01. 
 
These results showed that LOX and procollagen-I expression were regulated by 
IL-1α and TGF-β1 separately. This suggests that both IL-1α and TGF-β1 are 
required for promoting collagen deposition during tissue fibrosis. Given that IL-1 
shares common signalling pathways with TNF-α, we believe that the combination of 
IL-1α and TGF-β1 treatments provided a suitable model to mimic the inflammatory 









4.3.2 Inflammation-induced epithelial-mesenchymal transition of peritoneal 
mesothelial cells 
4.3.2.1 IL-1α and TGF-β1 treatment induces cell morphology change 
As we showed above, in order to mimic the inflammatory environment in wound 
healing, we treated the cells with IL-1α and TGF-β1 for 48h. Under control 
conditions confluent PMC formed a monolayer of flat polygonal, polarized cells 
exhibiting typical cobblestone morphology. The cells were connected to each other 
by tight cell junctions and covered the whole submatrix without any visible 
intercellular clefts (Figure 4.6A). Treatment of the PMC with IL-1α for 48h resulted 
in a cell morphologic change, which included loss of cell-cell contacts and an 
exposure of submatrix. The cells were less rounded in shape and showed a complete 
disorganization with a loss of cellular polarization (Figure 4.6B). A similar loss of 
intercellular junctions was found in the TGF-β1-treated PMC. In addition, cells were 
scattered and adopted a spindle-shaped fibroblastic phenotype (Figure 4.6C), 
characteristic of an epithelial-mesenchymal transition (EMT). The synergistic effect 
of IL-1α and TGF-β1 on morphology was even more exaggerated compared with that 
of each cytokine alone. It was characterized by a more intensive exposure of the 











A                                B 
  
C                                D 
  
Figure 4.6. Pro-inflammatory factors promote phenotype changes in PMC 
monolayer. Cells were treated in 6-well plates for 48h in the following groups: A. 
Control, B. IL-1α (0.5ng/ml), C. TGF-β1 (2ng/ml), D. IL-1α + TGF-β1. 
 
To further confirm the EMT process, E-cadherin and fibronectin mRNA expression 
in the treated PMC was measured by qRT-PCR. Downregulation of E-cadherin and 
upregulation of fibronectin are considered as key hallmarks of the EMT process. In 
the treated PMC (Figure 4.7A), both IL-1α (5-fold) and TGF-β1 (6-fold) were shown 
to downregulate E-cadherin expression significantly compared to control. A further 
reduction was found in response to IL-1α and TGF-β1 treatment combined (30-fold 
compared to control). On the other hand, expression of fibronectin was upregulated 
by both IL-1α (7-fold) and TGF-β1 (11-fold) in PMC (Figure 4.7B). A further 
upregulation was found in response to IL-1α and TGF-β1 treatment combined 































































































Figure 4.7. EMT process changes E-cadherin and Fibronectin expression in 
PMC. A: Quantitative RT-PCR for CDH1 (E-cadherin) mRNA expression in PMC. 
B: Quantitative RT-PCR for FN1 (Fibronectin) mRNA expression in PMC. PMC 
were treated with IL-1α (0.5ng/ml) and TGF-β1 (2ng/ml) alone, or in combination 
for 48h. Statistical analysis was conducted by repeated-measures-nonparametric 
Friedman test and Dunn’s multiple comparison test (n=4 donors). Bars represent 
mean (±S.E.M.) values relative to placenta, *: p<0.05, **: p<0.01, ***: p<0.001 
compared to control. 
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4.3.2.2 EMT-promoted cell migration  
We questioned whether the EMT process would promote cell migration. Cell 
motility is considered to have an important role in wound healing, as it could affect 
cell infiltration and cell aggregation at the wound site. In our study, we performed an 
in vitro wound healing assay to investigate the effect of IL-1α and TGF-β1 on PMC 
migration. We observed an almost complete closure of the wound after 16 h in the 
IL-1α+TGF-β1 treated group, while the control group still had a large gap in the 
central area (Figure 4.8A). Because LOX has been shown to be essential for 
hypoxia-induced cancer metastasis, indicating a role of LOX in promoting cancer 
cell migration, we hypothesized that the up-regulation of LOX by pro-inflammatory 
factors on PMC could also contribute to such enhanced cell motility. In order to 
confirm this, PMC were pretreated with BAPN alone or in combination with 
IL-1α+TGF-β1 to completely inhibit LOX activity. BAPN-treated PMC showed a 
similar rate of wound closure to the control group, while the rate of wound closure in 
the IL-1α+TGF-β1+BAPN group was also no different compared to the 
IL-1α+TGF-β1 group. We quantified the cell migration by measuring the distance 
between the edges of the wound (Figure 4.8B). The results indicated that cell 
migration was promoted by IL-1α and TGF-β1 treatment, whereas inhibition of LOX 




































































Figure 4.8: In vitro wound healing assay. PMC were treated with a combination of 
IL-1α (0.5ng/ml) and TGF-β1 (2ng/ml) in the presence or absence of BAPN 
(500μM). A: Photomicrograph of PMC 0 and 16 h after wounding. The top panel 
shows the initial wound in each group; the bottom panel is the wound after 16h. B: 
Quantification of the effect of IL-1α+TGF-β1 on PMC migration in wound healing 
assay. Broken line indicates the initial wound width. Statistical analysis was 
conducted by repeated-measures-paired-one-way ANOVA, values with no 
superscript letter in common are statistically different from each other (n=4 donors). 





4.3.2.3 EMT enhances Cell-ECM adhesion 
We then examined whether EMT also enhanced the adherence of PMC to ECM 
substances. We first demonstrated that expression of integrin α5, an important 
fibronectin receptor, was induced by IL-1α (2-fold) and TGF-β1 (2.4-fold) in PMC. 
Moreover, IL-1α+TGF-β1 treatment significantly upregulated the expression of 
integrin α5 in PMC (Figure 4.9, 3-fold). Later on, PMC were pre-treated with 
IL-1α+TGF-β1 for 48h, and then seeded on to fibronectin-coated 12-well plates. 
After 1 h incubation, unattached PMC were washed off, and photomicrographs of 
each treatment groups were taken. More PMC were found to attach to fibronectin in 
the IL-1α+TGF-β1-treated group compared to the control (Figure 4.10A). The effect 
of LOX on cell-ECM adhesion was also tested by adding BAPN during pretreatment. 
However, there was no effect of BAPN on cell-ECM adhesion in either the control 
group or the IL-1α+TGF-β1-treated group (Figure 4.10A). To quantify cell adhesion, 
cell counts were performed on the attached cells after trypsinisation. The results 
indicated that EMT-transformed PMC could more efficiently adhere to the ECM 
component than normal PMC, while inhibition of LOX activity had no effect on 











































Figure 4.9. Quantitative RT-PCR for ITGA5 (Integrin α5) mRNA expression in 
PMC. PMC were treated with IL-1α (0.5ng/ml) and TGF-β1 (2ng/ml) alone, or in 
combination for 48h. Statistical analysis was conducted by repeated-measures- 
nonparametric Friedman test (n=4 donors). Bars represent mean (±S.E.M.) values 
























































Figure 4.10. In vitro Cell-ECM adhesion assay. PMC were treated with a 
combination of IL-1α (0.5ng/ml) and TGF-β1 (2ng/ml) in the presence or absence of 
BAPN (500μM). A: Photomicrograph of in vitro cell-ECM adhesion assay on PMC. 
From left to right: control, BAPN, IL-1α+TGF-β1, IL-1α+TGF-β1+BAPN. B: 
Quantification of the effect of IL-1α+TGF-β1 on PMC-ECM adhesion in vitro. 
Broken line indicates the initial cell number added. Statistical analysis was 
conducted by repeated-measures-paired-one-way ANOVA, values with no 
superscript letter in common are statistically different from each other (n=4 donors). 
Bars represent mean (±S.E.M.) values of each group, p<0.05.  
 
 
Control BAPN  IL-1α+ TGF-β1 IL-1α+ TGF-β1+ BAPN
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4.3.3 Cytokine production from peritoneal mesothelial cells 
4.3.3.1 IL-1α production from nanotube (NT)-treated PMC 
As shown above, IL-1α is likely the most potent cytokine to induce LOX expression 
in PMC. However, previous results showed that it was TNF-α rather than IL-1α that 
was secreted by NT-treated macrophages. The origin of IL-1α required further 
investigation. As the main cell type to maintain homeostasis within the abdominal 
cavity, PMC can produce many cytokines in response to stress, inflammation or 
other stimuli. Therefore, we first investigated IL-1α production from PMC in 
response to NT. PMC were treated with increasing doses of NT (0, 5, 10, and 
20μg/ml). Levels of IL-1α were measured in the culture medium after 48h. IL-1α 
production was undetectable in untreated cells and the production of IL-1α in 
response to NT was not dose dependent (Figure 4.11). However, due to a limitation 







































Figure 4.11. Secreted IL-1α production of PMC in response to NT treatment for 
48h. Insufficient independent replicates (n=1 donor) did not allow statistical analysis.  
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4.3.3.2 IL-1α production from cytokines-treated PMC   
Since TNF-α production was induced in vitro from NT-treated macrophages and 
TNF-α was shown to induce other cytokines expression in an autocrine fashion, we 
questioned whether such elevated TNF-α could contribute to a local IL-1α secretion 
from PMC. Therefore, PMC were treated with increasing doses of TNF-α (0, 5, 10, 
20, 50, and 100ng/ml). IL-1α secretion was evaluated in condition medium by 
ELISA after 24h of treatment. However, TNF-α did not induce IL-1α secretion to a 
biologically relevant level, as the highest concentration detected was 5pg/ml in the 
50ng/ml TNF-α-treated group (Figure 4.12). This suggested that TNF-α alone was 
not able to stimulate PMC to secrete IL-1α. Due to a limitation of sample, only one 















































Figure 4.12. Secreted IL-1α production of PMC in response to TNF-α treatment 
for 24h. Insufficient independent replicates (n=1 donor) did not allow statistical 
analysis.  
 
Cytokine orchestration is quite common in chronic inflammation due to the 
redundancy of these inflammatory factors. The combined effect of various cytokines 
can provide a much more effective stimulation of target cells. In the case of our in 
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vivo model, TGF-β1 could be another critical cytokine promoting peritoneal fibrosis, 
as dramatic tissue remodelling has been reported in the diaphragm. Therefore, IL-1α 
production was tested in PMC treated with TNF-α and TGF-β1 alone, or in 
combination. The results showed that neither TNF-α nor TGF-β1 alone caused a 
significant elevation of IL-1α secretion compared with control (Figure 4.13A, 
14.9±1.09pg/ml and 9.3±1.17pg/ml respectively). However, TNF-α and TGF-β1 had 
a significant synergistic effect increasing IL-1α secretion to 64.7±16.55pg/ml.  














































































Figure 4.13. ELISA of IL-1α production from PMC treated with TNF-α 
(10ng/ml), TGF-β1 (2ng/ml), and TNF-α+TGF-β1 for 24h. A: Secreted IL-1α 
concentration in the culture medium. Statistical analysis was conducted by 
repeated-measures-paired-one-way ANOVA (n=4). Bars represent mean (±S.E.M.) 
values of each group, *: p<0.05, **: p<0.01. B: cell-associated IL-1α (CA-IL-1α) 
concentration in the cell lysate. Statistical analysis was conducted by 
repeated-measures-noparametric Friedman test, group comparisons were done by 
Dunn’s multiple comparison test (n=4 donors). Bars represent mean (±S.E.M.) 
values of each group, *: p<0.05, **: p<0.01.  
 
As discussed in section 1.4.3.1, IL-1α can be active as both secreted protein and 
membrane-associated protein. Thus, we tested the cell-associated IL-1α (CA-IL-1α) 
production of PMC from the same TNF-α- and TGF-β1-treated cells. The same 
ELISA kit was used to measure the level of IL-1α in the cell lysate (CA-IL-1α). The 
data showed that both TNF-α and TNF-α+ TGF-β1 treatments significantly increased 
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CA-IL-1α protein within the PMC (Figure 4.13B). In addition, the level of CA-IL-1α 
found within the cell was much higher than the amount of secreted IL-1α. TNF-α 
induced CA-IL-1α up to 274.7±47.23pg/ml (Figure 4.13B) compared to the secreted 
level of IL-1α (14.9±1.09pg/ml). TGF-β1 also induced the production of CA-IL-1α 
(Figure 4.12B, 91.64±21.94pg/ml), while only 9.3±1.17 pg/ml was found for the 
secreted form. In the TNF-α+TGF-β1-treated group, a similar synergistic effect was 
found for the secreted form, but at a much higher level (848.1±176.3pg/ml compared 
to 64.7±16.55pg/ml). Overall, between 10- and 20-fold higher IL-1α levels were 
found to be as the cell-associated form compared to the secreted form. In summary, 
TNF-α and TGF-β1 can induce the production of CA-IL-1α within the PMC on their 
own, while neither of them was able to dramatically increase the level of secreted 
IL-α. However, the synergistic action of TNF-α+TGF-β1 was found not only to be a 
much more potent inducer of CA-IL-1α expression, but also of its secreted form 
recovered in the conditioned medium.  
 
4.3.4 Suppression of the TNF-α signalling pathway by inhibition of IL-1. 
As discussed in section 1.4.3.1, CA-IL-1α has equal biological activity, which can be 
transferred to the cell membrane and mediate local inflammatory responses. 
Therefore, we hypothesized that the elevated CA-IL-1α level observed above could 
also contribute to the inflammatory response. To confirm this hypothesis, MeT-5A 
cells (a PMC cell line) were treated with TNF-α (10ng/ml) and TGF-β1 (10ng/ml) in 
the presence or absence of the IL-1 receptor antagonist (IL-1ra, 100ng/ml). 
Treatments of IL-1α (2ng/ml) plus or minus IL-1ra (100ng/ml) on MeT-5A cells 
were used as a positive control in the experiment. MeT-5A cells were used due to a 
shortage of primary PMC cells from sample collections. The result is shown in 
Figure 4.14A. IL-1α, TNF-α and TGF-β1 all induced LOX expression significantly 
(6-fold, 4-fold and 12-fold respectively compared to the control group). The addition 
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of IL-1ra suppressed the effects of IL-1α and TNF-α significantly (70% and 56% 
respectively) whereas there was no suppression of TGF-β1-treatment. A similar 



















































































































Figure 4.14. Quantitative RT-PCR for LOX mRNA expression in MeT-5A cells 
and PMC. A. MeT-5A cells were treated with IL-1α (2ng/ml), TNF-α (10ng/ml) and 
TGF-β1 (10ng/ml) in the presence or absence of IL-1ra (100ng/ml) for 48h. 
Statistical analysis was conducted by one-way ANOVA (n=4), Bars represent mean 
(±S.E.M.) values relative to placenta, *: p<0.05, **: p<0.01, ***: p<0.001. B. PMC 
were treated with IL-1α (0.5ng/ml), TNF-α (10ng/ml) and TGF-β1 (2ng/ml) in the 
presence or absence of IL-1ra (25ng/ml) for 48h. Value relative to control. 




In Chapter 3, we demonstrated that LOX played an important role in the formation of 
peritoneal fibrosis by regulating collagen deposition. In addition, we further 
confirmed that PMC express high levels of LOX mRNA, while macrophages have 
little LOX expression. Therefore PMC, as an important cell type to maintain 
homeostasis of the abdominal cavity, can also be pro-fibrotic by producing LOX in 
response to inflammatory stimuli. In this Chapter, we have demonstrated that LOX 
mRNA can be induced by several cytokines, including IL-1α, IL-4, TNF-α and 
TGF-β1. However, only IL-1α (0.5ng/ml) was shown to be the most potent inducer 
of LOX expression. In contrast, the effects of TNF-α and TGF-β1 were weaker than 
that of IL-1α, even when used at much higher concentrations than IL-1α (TNF-α: 
10ng/ml, TGF-β1: 2ng/ml, compared to IL-1α: 0.5ng/ml). IL-4 is considered as a 
pro-fibrotic mediator in fibroblasts, being twice as effective as TGF-β (Fertin et al., 
1991). It also functions as an important mediator that can activate macrophages, 
differentiating them into wound-healing macrophages (Loke et al., 2007). However, 
IL-4 has also been considered as an anti-inflammatory cytokine. For example, IL-4 
was shown to increase 3β-HSD activity in ovarian surface epithelial (OSE) cells, 
resulting in an intracrine generation of progesterone (Papacleovoulou et al., 2009). 
Furthermore, IL-4 was shown to suppress IL-1α-induced cyclooxygenase-2 mRNA 
expression, an important inflammatory-related factor (Kurumbail et al., 1996), in 
OSE cells (Papacleovoulou, 2009). Given the similarity between PMC and OSE cells, 
IL-4 might also exert anti-inflammatory effects on PMC. Thus, the effect of IL-4 in 
peritoneal fibrosis could be conflicting. Since previous studies have not shown an 
association between IL-4 and postoperative adhesion, the effect of IL-4 was not 
investigated further in this thesis.  
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Cytokine orchestration is quite common during the inflammatory process due to their 
redundancy and pleiotropic function. Synergistic effects of different cytokines could 
co-regulate target genes expression. TNF-α and IL-1α have long been suggested to 
share common signalling pathways through NF-κB and AP-1 pathways (see section 
1.4.3.1 and 1.4.3.2), while TGF-β1 has been shown to regulate gene expression 
through Ras and Smad signaling (see section 1.4.3.3). Therefore, possible synergistic 
effects of TGF-β1 with TNF-α or IL-1α were tested on PMC. No combined effect of 
TNF-α+TGF-β1 was found on LOX expression, whereas an additive up regulation 
was found in response to IL-1α+TGF-β1. Therefore, in this case, cross-talk between 
different signalling pathways did not appear to cause significant changes in 
IL-1α-induced LOX expression in PMC. It further confirmed that IL-1 could be the 
most potent cytokine to induce LOX expression in PMC during inflammation. In 
contrast, expression of procollagen-I mRNA in PMC was mainly induced by TGF-β1, 
IL-1α being less effective. Again, no combined effect of IL-1α+TGF-β1 was found 
compared to the TGF-β1 alone group. Previous studies had shown that 
overexpression of procollagen-I was involved in many fibrotic diseases (Kaimori et 
al., 2007; Bergeron et al., 2003). These results suggest a crucial role of TGF-β1 in 
collagen production from PMC. Since procollagen-I is the precursor of mature 
collagen I, the main substrate for LOX enzyme, it indicated that IL-1α and TGF-β1 
were both needed for collagen deposition during peritoneal fibrosis.  
 
In contrast, TNF-α appeared less involved in this pathologic progression, since it did 
not exert a dramatic effect even at levels of 10ng/ml, which is far higher than 
physiological levels. However, the combination of TNF-α+TGF-β1 stimulated 
secreted IL-1α production from PMC. More interestingly, TNF-α alone and 
TNF-α+TGF-β1 can stimulate the production of the cell-associated form of IL-1α 
within PMC to a level dramatically higher than the secreted level. Due to the unique 
way that IL-1α is processed and secreted (section 1.4.3.1), the cell-associated IL-1α 
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could be the IL-1α precursor with biological activity. In contrast, the secreted form 
of IL-1α detected in the culture medium could be either the mature IL-1α or IL-1α 
precursors released from dead cells, since TNF-α and TGF-β1 can induce cell death 
through cell necrosis or cell apoptosis. It has been demonstrated in previous studies 
that TNF-α can induce IL-1 expression in fibroblasts, which requires the 
participation of mitogen-activated protein kinase kinase 3 (MKK3) (Wysk et al., 
1999). On the other hand, TGF-β1 has also been shown to activate MKK3/6 through 
TAK1 (Xu et al., 2009). Therefore, the synergistic effect of TNF-α and TGF-β1 on 
IL-1α production could be due to a co-activation of MKK3 in PMC.  
 
IL-1α precursors can exert their biological activity as a cell surface-bound protein 
(membrane-associated IL-1, MA-IL-1). Although there was no evidence that all the 
cell-associated IL-1α detected in cell lysate was membrane-associated, we assume 
that such elevation of IL-1α is a natural response of cells to create a local 
inflammatory environment rather than causing a systemic inflammation. In addition, 
we hypothesized that TNF-α signalling might be partially mediated by MA-IL-1. To 
confirm the concept, we showed that inhibition of IL-1 action with IL-1ra can 
suppress TNF-α induced LOX expression but that not of TGF-β1 in MeT-5A cells. 
Meanwhile, IL-1α was not detected in the medium from TNF-α-treated MeT-5A 
cells. However, since the IL-1β content of the culture medium has not been evaluated, 
TNF-α may exert its effect by increasing IL-1β production. However, MeT-5A cells 
do not represent primary cells in several aspects. For example, TGF-β1 induces EMT 
in PMC but not in Met-5A. Therefore, the same experiment needs to be carefully 
confirmed in PMC. In addition, the expression of MA-IL-1α needs to be confirmed 
by flow cytometric analysis and its bioactivity also requires further investigation.  
 
From the findings above, we assume that TNF-α could be an initial signal released at 
the first stage of peritoneal fibrosis in our in vivo model. Such inflammatory effect 
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may be kept locally to avoid the induction of persisted systemic inflammation. 
However, if such a response existed long term in combination with other cytokines 
such as TGF-β1, systemic inflammation can be induced by elevating other key 
secreted inflammatory mediators such as IL-1, leading to tissue fibrosis. Support for 
this mechanism is that overexpression of TNF-α in the rat peritoneum leads to a 
transient pathological change to the peritoneum, including dramatic angiogenesis 
together with collagen deposition, whereas overexpression of IL-1β induced a 
persisting vasculogenesis with submesothelial fibrosis (Margetts et al., 2002). In 
addition, overexpression of IL-1β has been demonstrated to lead to progressive 
fibrosis in the lung (Kolb et al., 2001), while overexpression of TNF-α leads only to 
a mild fibrosis (Sime et al., 1998).     
 
In contrast, TGF-β1 signalling was shown to be an essential complement for IL-1 
with respect to fibrosis progression. Therefore, the combination of TGF-β1 and IL-1 
is an ideal model to reproduce the complex inflammatory environment and 
profibrotic stimuli present during peritoneal fibrosis. This model has also been used 
in other studies of peritoneal dialysis-induced peritonitis (Strippoli et al., 2008; 
Yanez-Mo et al., 2003). As discussed above, in addition to regulating PMC gene 
expression at the transcriptional level, IL-1α and TGF-β1 caused phenotypic changes 
of PMC both on their own and in combination. TGF-β1 is a well known inducer of 
epithelial-mesenchymal transition (EMT). In the current study, IL-1α also appeared 
to induce EMT-like changes in PMC. Both IL-1α and TGF-β1 caused 
downregulation of E-cadherin and upregulation of fibronectin mRNA levels in PMC, 
hallmarks of the EMT process. Furthermore, the combination of these two cytokines 
provoked a further change in cell morphology, which was more intensive than any of 
the effects on their own. An additive effect of IL-1α and TGF-β1 treatment on 
E-cadherin reduction and fibronectin upregulation was also found. The same 
treatment has also been used to induce EMT on PMC (Strippoli et al., 2008; 
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Yanez-Mo et al., 2003), confirming that EMT is an important process involved in 
peritoneal fibrosis. It can disrupt intercellular junctions and increase mesenchymal 
features in the PMC. Eventually PMC are transformed into fibroblast-like cells with 
increased motility, cell-ECM adhesion ability, and fibrogenic features. A series of 
interlinked activation processes of IL-1α and TGF-β1 might account for such 
dynamic cell behaviors. For example, TGF-β is shown to activate Rho-like GTPase 
including Rho, Rac and Cdc42 which are key regulators involved in cell migration 
(Vicente-Manzanares et al., 2005; Xu et al., 2009). During EMT, TGF-β induces 
RhoA expression, which directly increases cell contractility (Cho and Yoo, 2007; 
Pellegrin and Mellor, 2007). Activation of RhoA was also shown to regulate mDia1 
promoting actin polymerization, which controls protrusion of the cells during 
migration (Vicente-Manzanares et al., 2005). On the other hand, EMT is associated 
with an increased cell-ECM adherence, which might be associated with the 
upregulation of several integrins molecular. We showed that integrin-α5 was 
upregulated by both IL-1α and TGF-β1. Integrin-α5β1 is a well know receptor 
binding to fibronectin (Morgan et al., 2009). Therefore, the enhanced adherence we 
found in the cell-ECM adhesion assay could be due to the increased integrin-α5 level. 
In addition, expression of integrin-α5β1 was also associated with RhoA-mediated 
contractility and random cell migration (Danen et al., 2005; White et al., 2007). 
Furthermore, the upregulation and activation of integrins were shown to induce the 
autophosphorylation of focal adhesion kinase (FAK) (Mitra and Schlaepfer, 2006) 
which further regulated adhesion turnover and membrane protrusion during cell 
migration (Huveneers and Danen, 2009). 
 
In previous studies, LOX had also been shown to regulate cell motility and cell-ECM 
adhesion in cancer cells (Payne et al., 2005) and vascular smooth muscle cells (Li et 
al., 2000). The underlying mechanism involved the activation of FAK and Src kinase, 
two key proteins involved in cell adhesion formation and turnover. It has been shown 
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that the H2O2 product of amine oxidation by LOX is critical in promoting such a 
response. H2O2 has long been known to cause changes in cell adhesion and motility 
(Sellak et al., 1994; Mahabeleshwar and Kundu, 2003). Removal of H2O2 by catalase 
suppressed cell migration and cell-ECM adhesion in both invasive cancer cell lines 
and vascular smooth muscle cells (Payne et al., 2005; Li et al., 2000). Hence, the 
effect of LOX on cell motility and adhesion ability was also tested in our in vitro 
model. However, inhibition of LOX was not found to suppress the 
IL-1α+TGF-β1-induced rise of cell-ECM adhesion or cell motility. One explanation 
could be that the FAK and Src kinase were already activated by the upregulation of 
integrins. The signal induced by H2O2 is not the key mechanism to promote cell 
adhesion or migration in our model. 
 
In summary, this Chapter shows that the combination of IL-1α and TGF-β1 can be a 
suitable in vitro model to mimic the inflammatory response during peritoneal fibrosis. 
Treatment of PMC with IL-1α+TGF-β1 induced the expression of LOX and 
pro-collagen I which are involved in the progression of fibrosis. However, due to a 
limitation in numbers of viable samples, a single dose and time were chosen for the 
experiment. The lack of dose treatments and time-points may cause misleading 
conclusions when comparing effects of different cytokines. In addition, up-regulation 
of procollagen needs to be confirmed at the protein level when more viable samples 
are obtained; however, a longer period of treatment seems to be required to obtain a 
detectable level of procollagen protein in the medium (Clarke et al., 2010). 
IL-1α+TGF-β1 treatment caused EMT of PMC. These transformed cells have 
enhanced cell motility and are more adherent to fibronectin. These findings provide a 
likely explanation for the centripetal cell migration and incorporation of free-floating 
mesothelial cells that are widely accepted mechanisms for peritoneal repair. 
Moreover, results showed an IL-1-mediated autocrine signaling network of PMC in 
response to TNF-α, which could be a likely mechanism to regulate the switch 












Anti-inflammatory effects of glucocorticoids on peritoneal 













In humans, not all injured tissue is healed with associated scarring. One example is 
the repair of ovary after each ovulatory cycle. The human ovary is covered with a 
thin layer of ovarian surface epithelium that separates the ovary from other organs 
within the lower abdominal cavity. Ovarian surface epithelial (OSE) cells are 
regularly subjected to ovulation-associated injury which is comparable to an 
inflammatory reaction (Espey, 1994). Such an inflammatory reaction can cause 
serious proteolytic damage to the ovarian surface (Murdoch et al., 2001). However, 
despite the dramatic structural damage to the surface of the ovary and underlying 
connective tissue caused by ovulation, the ovary always heals without residual 
scarring. Such remarkable postovulatory repair helps maintain the function of ovary, 
ensuring adhesions do not form with associated structures such as the Fallopian tube, 
and prepares for the next ovulation. Therefore, it suggests that there might be a 
unique mechanism in the ovary to repair this natural damage without scarring. 
Understanding of this mechanism might inform treatments to avoid other fibrotic 
conditions, including post-operative adhesions. PMC and OSE cells share many 
common characteristics. Both form an inconspicuous monolayer of 
squamous-to-cuboidal mesothelium that lies on a basement matrix. They arise in the 
embryo from the lateral plate mesoderm (Michailova and Usunoff, 2006) and share 
equivalent homeostatic functions (Ross et al., 1998). However, despite these 
common origins, there are also some significant differences between them. PMC are 
dominated by microvilli on the surface to increase the mesothelial surface area 
(Dobbie, 1990). These may influence absorption or secretion across the cell surface 
and play a role in the trapping of secreted proteins or glycoproteins. In contrast, OSE 
does not have microvilli. Additionally, monthly ovulation causes the release of the 
oocyte from the ovarian cortex. This process is always accompanied by an elevated 
local production of ovarian steroids. For example, the preovulatory follicle and 
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corpus luteum, the major sites of ovarian hormone production, can produce estrogen 
(Hillier et al., 1994) and progesterone (Rekawiecki et al., 2008), respectively. Such 
natural processes associated with ovulation create a steroid-rich environment around 
the ovary that is different from the environment within the abdominal cavity. 
Although OSE cells are unlikely to be a site of de novo steroid biosythesis (Rae and 
Hillier, 2005; Rae et al., 2004b), they can be involved in further steroid metabolism 
through expression of steroid dehydrogenases/reductases (SDR) which convert 
circulating bioinert steroids into bioactive forms (Okamura et al., 2003; Rae and 
Hillier, 2005). Many steroids circulate as bioinert precursor forms. They differ with 
respect to the redox state of important hydroxyl moieties, which determine the ability 
of these steroids to bind and activate their cognate receptors. For example, it has 
been shown that OSE cells can convert bioinert cortisone into bioactive cortisol by 
expressing 11βHSD-1 as discussed in section 1.4.4. Moreover, IL-1α was shown to 
induce time- and dose-dependent enhancement of 11βHSD-1 enzymic activity in 
OSE cells, whereas no changes were found in 11βHSD-2 expression that converts 
cortisol back to cortisone (Rae et al., 2004b). Therefore, the inflammatory response 
enhances the ability of OSE cells to produce anti-inflammatory steroid. Although the 
PMC exhibit similar characteristics to OSE cells in their transcriptional level 
activities with respect to local cortisol conversion, the actual 11βHSD-1 enzyme 
activity of OSE cells is much higher than that of PMC in both its normal quiescent 
phenotype and in response to IL-1α (Fegan et al., 2008). Given the finding that there 
is commonly 3-10 times more cortisone than cortisol in the local ovarian 
environment (Kushnir et al., 2009), it suggests that OSE might be more effective 
than PMC to create a local elevated level of cortisol based on such abundant supply 
of inactive cortisone.  
 
It has been shown that both cortisol and progesterone can act as anti-inflammatory 
steroids. The anti-inflammatory mechanism underlying cortisol action was discussed 
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in section 1.4.4. Progesterone shares a similar mode of action with cortisol, which 
includes binding to its cognate receptor (progesterone receptor, PR) and 
ligand-activated suppression of inflammation; however, its effect is less potent than 
cortisol (van der Burg and van der Saag, 1996). Receptors for both progesterone and 
cortisol (PR and GR) are expressed by PMC (Fegan et al., 2008) and OSE cells (Li et 
al., 2003). In addition, IL-1 was shown to upregulate GR but not PR in OSE cells 
(Rae et al., 2004a), which could further enhance the action of cortisol. Therefore, the 
local production of these steroids provides an anti-inflammatory environment around 
the ovary after ovulation that could help to minimize the inflammatory response and 
maintain tissue homeostasis. In contrast, the peritoneum has no such protective 
mechanism to counteract the inflammatory response caused by surgery, hence 
exposing it to adhesion formation.      
 
We hypothesized that scar-free healing of the ovary is a consequence of the 
anti-inflammatory steroid environment created by ovulation. Cortisol is considered 
as an important anti-inflammatory factor, which can be elevated in the ovary 
compared with the circulation due to enhanced local 11βHSD-1 enzyme activity 
(Fegan et al., 2008). The understanding of such a mechanism may assist in finding 
ways to prevent post-operative adhesions.   
 
5.2 Materials and Methods 
 
Investigation of the effect of cortisol (F) on PMC and OSE cells was assessed using 
primary PMC and OSE monolayers as described in Chapter 2. Treatments of several 
inflammatory cytokines were conducted on cell monolayers for 24 h or 48 h in 
serum-free medium. RNA was extracted from the experimental groups, and 
quantitative real-time PCR was used to evaluate gene expression in the treatment 
groups. ELISA was performed on cell lyasates and conditional medium as described 
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in section 2.4. Extracellular LOX activity was tested in the conditional medium by 
fluorometric-based assay (section 2.6). The basic clinical profile of patients involved 
with the respective assays performed on each are presented in Table 5.1.  
 





Surgery Reason for surgery Study 
6848 54 NA TAH & BSO Fibroids & HMB mRNA 
7672 47 19 TAH HMB mRNA 
7539 40 27 TAH HMB & Pain mRNA 
7532 27 4 Diag Lapscpy LIF pain mRNA 
7538 21 NA Diag Lapscpy Pelvic pain mRNA 
7541 33 7 Lap Ster Unwanted Fertility mRNA 
6321 26 22 Diag Lapscpy RIF Pain mRNA 
7559 43 4 TAH HMB mRNA 
7613 48 26 STAH Erratic Menstrual Cycle mRNA,  
6814 44 4 TAH   HMB mRNA, LOX activity 
assay 
7607 45 17 Diag Lapscpy RIF pain & IMB mRNA, LOX activity 
assay 
7618 49 27 TAH & BSO Urinary Symptoms, 
Cycle & Bleeding Erratic 
since Zoladex 
LOX activity assay 
6392 42 NA Diag Lapscpy Dysmen & Pain LOX activity assay 
7593 51 13 TAH & BSO Fibroid Uterus & HMB LOX activity assay 
7686 43 16 Laparoscopy HMB ELISA 
7715 46 45 TAH & BSO HMB ELISA 
5678 38 4 DiagLapscpy 
Hysteroscopy
HMB ELISA 
7741 37 NA TAH   No cycle constant bleeding ELISA 
Abbreviation: TAH = total abdominal hysterectomy, BSO = bilateral 
salpingo-oophorectomy, HMB= heavy menstrual bleeding, Diag Lapscpy = 
diagnostic laparoscopy, Lap Ster = laparoscopic sterilisation, NA = not applicable, 
RIF = right Iliac Fossa, LIF = left Iliac Fossa, STAH = subtotal abdominal 







5.3.1 Effect of glucocorticoid on lysyl oxidase mRNA expression in peritoneal 
mesothelial cells and ovarian surface epithelial cells 
To investigate how cortisol may contribute to the scar-free healing, we treated OSE 
cells with IL-1α and TGF-β1 in the presence and absence of cortisol. Induction of 
LOX mRNA by IL-1α alone or the combination of IL-1α plus TGF-β1 was 
confirmed in OSE cells (Figure 5.1A, 3.2±0.31-fold and 4.7±0.5-fold respectively), 
but not by TGF-β1 (Figure 5.1A, 1.9±0.28-fold). Cortisol alone had no significant 
effect on LOX expression in OSE cells. However, in the presence of cortisol, the 
IL-1α induced-rise in LOX expression was significantly suppressed up to 50% 
compared to the IL-1α treatment group (Figure 5.1A, 1.7±0.08-fold compared to 
3.2±0.31-fold). There was no significant suppression when cortisol was added to the 
TGF-β1 group or the IL-1α+TGF-β1 group. In PMC, LOX mRNA expression was 
significantly increased by IL-1α alone or the combination of IL-1α plus TGF-β1 
(Figure 5.1B, 2.6±0.14-fold and 5.2±0.5-fold, respectively), but not by TGF-β1 alone 
(Figure 5.1B, 2.1±0.34-fold). Cortisol alone had no significant effect on LOX 
expression in PMC. A slight suppression of cortisol was seen in the IL-1α treatment 
group (1.7±0.34-fold compared to 2.6±0.14-fold); however, the addition of cortisol 































































































































Figure 5.1. Quantitative RT-PCR for LOX mRNA expression in OSE cells and 
PMC. A: OSE cells were treated for 48h by IL-1α (0.5ng/ml) and TGF-β1 (2ng/ml), 
or the combination of IL-1α+TGF-β1, in the presence or absence of cortisol (F, 1μM). 
B: PMC were treated for 48h by IL-1α (0.5ng/ml) and TGF-β1 (2ng/ml), or the 
combination of IL-1α+TGF-β1, in the presence or absence of cortisol (F, 1μM). 
Statistical analysis was conducted by repeated-measures-paired-one-way ANOVA; 
bars represent mean (±S.E.M.) values relative to untreated control. Values with no 
common superscript letter are statistically different from each other (P<0.05).  
 155
5.3.2 Effect of glucocorticoid on lysyl oxidase enzyme activity of peritoneal 
mesothelial cells and ovarian surface epithelial cells 
In the previous chapter, we showed that IL-1α increased LOX mRNA levels in both 
PMC and OSE cells, while cortisol only significantly suppressed its increase in OSE 
cells. Since the presence of mRNAs might not always signify the synthesis of 
functional proteins, we evaluated LOX activity secreted by PMC and OSE cells into 
their culture media, using our adaptation of a previously developed fluorimetric 
assay. LOX enzyme activity of PMC and OSE cells was tested in response to IL-1α 
plus or minus cortisol. The relative activity changes for secreted LOX of PMC and 
OSE cells are shown in Figure 5.2. The results showed significant fluorescence 
increases after IL-1α treatment for both PMC and OSE cells, indicating increased 
LOX activity in the culture media. Cortisol alone had no significant effect on LOX 
activity in either PMC or OSE cells. In the presence of cortisol, the IL-1α-induced 
rise of LOX activity was suppressed significantly in OSE cells. However, cortisol 
had only a slight suppressive effect in PMC that was not significant. These findings 




































































Figure 5.2. Effect of IL-1α and Cortisol (F) on LOX enzyme activity of OSE 
cells and PMC. A: OSE cells were treated by IL-1α (0.5ng/ml) in the presence or 
absence of cortisol (F, 1μM) for 96h. B: PMC were treated by IL-1α (0.5ng/ml) in 
the presence or absence of cortisol (F, 1μM) for 96h. Statistical analysis was 
conducted by repeated-measures-paired-one-way ANOVA; bars represent mean 
(±S.E.M.) values. *: p<0.05, **: p<0.01. 
 
5.3.3 Effect of glucocorticoid on IL-1α production of peritoneal mesothelial cells.  
In section 4.4.2, we showed that the synergistic effect of TNF-α plus TGF-β1 
induced IL-1α secretion from PMC, as well as a large amount of the cell-associated 
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form of IL-1α (CA-IL-1α). Thus, we were interested in whether the 
anti-inflammatory effect of cortisol treatment could prevent such a response. PMC 
were treated with TNF-α and TGF-β1 alone or in combination, in the presence or 
absence of cortisol. IL-1α production was assayed in the conditioned medium and 
cell lysates. As already shown previously (Figure 4.12), neither TNF-α nor TGF-β1 
alone caused a significant elevation of secreted IL-1α in the medium (Figure 4.13A, 
16.31±1.03pg/ml and 9.96±0.82pg/ml respectively compared to control: 
7.47±1.24pg/ml ), while the synergistic effect of TNF-α plus TGF-β1 significantly 
induced IL-1α secretion to a concentration of 50.57±14.06pg/ml. Addition of cortisol 
significantly suppressed the synergistic effect and reduced the level of secreted IL-1α 
down to 19.81±1.66pg/ml (Figure 5.3A). On the other hand, TNF-α alone and 
TNF-α+TGF-β1 also induced elevated levels of CA-IL-1α (Figure 5.3B, 
315.2±62.91pg/ml and 659.7±90.4pg/ml respectively compared to control: 
15.48±2.24pg/ml). Addition of cortisol significantly suppressed these elevations 
(Figure 5.3B, 97.28±30.8pg/ml in the TNF-α+cortisol group, and 395.4±59.12pg/ml 


























































































































Figure 5.3. A: Secreted IL-1α levels in the culture media of control and treated PMC. 
B: CA-IL-1α concentration in the cell lysates of PMC. PMC were treated with 
TNF-α (10ng/ml) and TGF-β1 (2ng/ml) alone or the combination, in the presence or 
absence of cortisol (F, 1μM) for 24h. Statistical analysis was by 
repeated-measures-nonparametric Friedman test; group comparisons were by Dunn’s 
multiple comparison test; bars represent mean (±S.E.M.) values. *: p<0.05, **: 
p<0.01. ***: p<0.001.  
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As shown earlier (Figure 4.13), TNF-α-induced LOX expression in PMC might be 
mediated by IL-1. Therefore, we hypothesized that cortisol might suppress 
TNF-α-induced LOX expression by its anti-inflammatory signalling and the 
suppression of IL-1α production. To investigate this, PMC were treated with TNF-α 
and TGF-β1 alone or in combination, in the presence or absence of cortisol. LOX 
mRNA levels were measured by Q-RTPCR. TNF-α and TNF-α+TGF-β1 treatments 
significantly stimulated LOX mRNA expression in PMC compared to the control 
group (Figure 5.4, 2.6±0.52-fold and 3.0±0.21-fold, respectively), but not by TGF-β1 
(2.1±0.39-fold). The addition of cortisol inhibited the effect of TNF-α and the 
synergistic effect of TNF-α plus TGF-β1; however, no significant differences were 
found between the respective treatment groups (Figure 5.4, TNF-α vs TNF-α+F: 
2.6±0.52-fold vs 1.5±0.30-fold, TNF-α+TGF-β1 vs TNF-α+TGF-β1+F: 




















































Figure 5.4. Quantitative RT-PCR for LOX mRNA expression in PMC. PMC 
were treated by TNF-α (10ng/ml) and TGF-β1 (2ng/ml), or in combination 
(TNF-α+TGF-β1), in the presence or absence of cortisol (F, 1μM) for 48h. Statistical 
analysis was conducted by repeated-measures-paired-one-way ANOVA; bars 





In this Chapter, a comparison between PMC and OSE cells was undertaken to 
address the mechanism of ovarian scar-free healing and whether OSE have an 
intrinsic mechanism that prevents scarring in response to inflammatory and fibrotic 
stimuli. First, we showed that cortisol can suppress the IL-1α-induced rise of LOX 
expression in OSE cells. In contrast, cortisol suppression of IL-1α levels was less in 
PMC compared to OSE cells (35% reduction in PMC compared to 50% in OSE 
cells), indicating that PMC might be less sensitive in responding to cortisol compared 
to OSE cells. Such a difference was confirmed by the LOX activity assay. It showed 
that extra-cellular LOX activity was increased in both PMC and OSE cells by IL-1α 
treatment. Addition of cortisol significantly reduced the elevation in LOX activity in 
OSE cells (43% reduction), but not in PMC (22% reduction). The difference between 
PMC and OSE responses might due to a different level of glucocorticoid receptor 
(GR) expression in the two cell types. Fegan (Fegan, 2009) showed a higher level of 
GR mRNA was expressed in OSE cells compared to PMC, and although this 
difference was not statistically significant, suggesting a greater OSE sensitivity to 
cortisol thereby increasing the anti-inflammatory effect. In the meantime, no 
quantification has been made for the expression of GR protein. Thus, it remains to be 
established whether OSE cells have a higher GR protein content than PMC. As 
discussed above, OSE cells have higher 11-oxoreductase activity compared to PMC, 
that can be enhanced by the inflammatory response (Fegan et al., 2008). This might 
help the ovary to convert circulating cortisone into cortisol locally during the 
ovulatory process, providing a local anti-inflammatory steroid environment that the 
peritoneum lacks. Such mechanisms would explain how the ovary could minimize 
ovulation-induced inflammation and prevent adhesion formation.   
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Cortisol was unable to significantly suppress IL-1α-induced LOX expression in PMC; 
however, the results indicate that cortisol could still aid peritoneal repair by 
suppressing the levels of secreted IL-1α and CA-IL-1α. We further showed that 
cortisol suppressed the TNF-α-induced rise of LOX expression. Although the effect 
was not statistically significant, it was likely more effective than that on the 
suppression with IL-1α (43% reduction with TNF-α compared to 35% reduction on 
IL-1α). The anti-inflammatory effect of cortisol is mainly dependent on the interplay 
with two main transcriptional pathways, NF-κB and AP-1 (Herrlich and Gottlicher, 
2002), which can be induced by many cytokines. Cortisol inhibits the activation of 
NF-κB by upregulation of IκBα (Scheinman et al., 1995a; Auphan et al., 1995). This 
mechanism can contribute to the suppressive effect of cortisol on IL-1 and TNF-α 
signalling. However, other mechanisms including protein-protein interaction or 
transrepression are plausible. In addition, TNF-α induces IL-1 expression via p38 
MAP kinase signalling by activating MKK3 (Wysk et al., 1999), which is also a 
downstream factor activated by TGF-β (Santibanez, 2006; Alcorn et al., 2008). The 
most likely mechanism for cortisol to interfere with the MAPK pathway involves the 
induction of MAPK phosphatase 1 (MKP-1) (Lasa et al., 2002; King et al., 2009). 
MKP-1 is a dual specificity phosphatase that targets p38 and thereby inhibits its 
kinase activity. This might explain the downregulation of CA-IL-1α by cortisol 
addition to both the TNF-α and TGF-β1 treatment groups. Through direct interplay 
with the TNF-α signalling network, cortisol might also suppress TNF-α effects by 
reducing the production of IL-1α within the cell. Thus, cortisol suppresses TNF-α 
mediated effects more effectively than the suppression of IL-1α. In contrast, no effect 
of cortisol has been reported on TGF-β1 signalling. TGF-β1 has been shown to 
regulate gene transcription mainly through Ras-ERK and Smad pathways (Derynck 
and Zhang, 2003; Lee et al., 2007). Therefore, cortisol seems unable to interact with 
the TGF-β1 signalling pathway, which suggests that other small molecules, including 
retinoids, might be involved in inhibiting the effect of TGF-β1 (Yang et al., 2008). 
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In summary, PMC and OSE cells have differences in their biological functions 
despite arising from the same lateral plate mesoderm and sharing many common 
features. The ovary is subjected to a regular cycle of injury and repair, whereas the 
peritoneum is present in a more stable environment which is less prone to natural 
injury. The monthly regeneration of OSE cells might also be associated with their 
capacity to maintain some features with higher regenerative potential. However, that 
hypothesis needs further exploration. In addition, the ovary appears to maintain a 
compensatory anti-inflammatory environment, which minimizes the formation of 
fibrosis. In contrast, the peritoneum lacks a similar mechanism to protect it from 
iatrogenic sporadic injury, such as surgery. Thus, the inflammatory response can be 
more persistent and severe which thus permits fibrosis and adhesion formation. 
Application of anti-inflammatory steroids on PMC only partly suppresses 
pro-inflammatory signalling and has no effect on TGF-β action. Therefore, the 
successful use of steroid treatments to routinely prevent post-operative adhesion 
























Chapter 6  
PCR-based microarray study of inflammation- and 
fibrosis-induced extracellular matrix and adhesion related 













As discussed in Chapter 1, peritoneal repair is a complex process including phases of 
coagulation, infiltration of inflammatory cells, cell proliferation, extracellular matrix 
(ECM) deposition and remodelling, commonly with overlap between the phases 
(Hubbard et al., 1967). The data in previous chapters indicate an important role of 
PMC in the development of fibrotic tissue, including collagen deposition. In addition, 
it also revealed that PMC undergo an epithelial-mesenchymal transition (EMT) in 
response to an inflammatory stimulus, the combination of IL-1α and TGF-β1. These 
transformed cells have enhanced cell motility and are more adherent to fibronectin. 
Although these findings provide a likely mechanism for the centripetal cell migration 
(Whitaker and Papadimitriou, 1985; Mutsaers et al., 2000) and incorporation of 
free-floating mesothelial cells (Watters and Buck, 1973; Whitaker and Papadimitriou, 
1985) that are important for peritoneal repair, the underlying mechanism at the 
molecular level remaining unknown. To date, the only well-established pathologic 
mechanism of post-operative adhesion involves the formation of the fibrin layer and 
the regulation of peritoneal fibrinolytic capacity (Holmdahl et al., 1996). However, 
the contributions of collagen deposition and ECM remodelling to peritoneal repair 
are not well understood. 
 
Herein, we employed a real-time PCR-based microarray that allowed genomic 
analysis of ECM-adhesion-related gene expression of PMC in response to two main 
inflammatory factors, IL-1 and TGF-β. As presented earlier, IL-1α and TGF-β1  
regulate gene expression in PMC using independent signalling pathways. Therefore, 
microarrays were conducted to compare untreated PMC to IL-1-treated or 
TGF-β1-treated PMC. These data provide insight into the molecular response of 
PMC during peritoneal repair, helping to identify other key pro-fibrotic factors 
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involved in the development of peritoneal fibrosis which may further cause 
post-operative adhesion. 
6.2 Materials and methods 
 
To address other potential targets in the development of post-operative adhesion, a 
PCR-based microarray set on ECM-adhesion related gene was selected. Patient 
samples treated by IL-1α and TGF-β1 from previous experiment were carefully 
chose. Preparation of cDNA was conducted by using the cDNA synthesis kit from 
the microarray set (section 2.3.5.1). The quality of synthesized cDNA samples was 
tested by the RT2 RNA Quality Control PCR Array (section 2.3.5.2). The eligible 
cDNA samples were used for the microarray (section 2.3.5.2). To validate the 
microarray, RT-PCR was performed to verify that the observed changes in gene 
expression level. Using the same samples used for microarray analysis or other 
samples with the same treatments, gene-specific PCR was performed on a selection 
(n=7) of the genes modulated by IL-1α or TGF-β1. The basic clinical profile of 
patients involved with the respective assays performed on each are presented in 
Table 6.1.  





Surgery Reason for surgery Study 
7607 45 17 Diag Lapscpy RIF pain & IMB Microarray, validation 
7613 48 26 STAH Erratic Menstrual Cycle Microarray, validation 
7641 38 11 TAH HMB Microarray, validation 
7548 31 5 Lap Ster NA Microarray, validation 
5621 44 8 TAH HMB & Fibroids validation 
3028 29 19 Diag Lapscpy RIF Pain  validation 
7531 37 27 Diag Lapscpy HMB & Pain validation 
6814 44 4 TAH   HMB validation 
Abbreviation: TAH = total abdominal hysterectomy, HMB= heavy menstrual 
bleeding, Diag Lapscpy = diagnostic laparoscopy, Lap Ster = laparoscopic 
sterilisation, NA = not applicable, RIF = right Iliac Fossa, STAH = subtotal 
abdominal hysterectomy.  
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6.3 Results 
6.3.1 A comparison of IL-1α and TGF-β1 effects on PMC by PCR Microarray 
Table 6.2. Gene expression of PMC in response to IL-1α (0.5ng/ml) and TGF-β1 
(2ng/ml) treatment for 48h. The values are fold up- (positive values) or down- 
(negative values) regulation of gene expression in response to treatment compared to 
untreated cells. Two-fold or greater differences are highlighted (up-regulated in red, 
down-regulated in blue). Differences that are statistically significant have P values 

















ADAM metallopeptidase with thrombospondin 
type 1 motif, 1 -1.12 0.6011 -4.12 0.0256
NM_139028 ADAMTS13 
ADAM metallopeptidase with thrombospondin 
type 1 motif, 13 -1.26 0.3715 1.68 0.1595
NM_007037 ADAMTS8 
ADAM metallopeptidase with thrombospondin 
type 1 motif, 8 1.28 0.5612 -1.21 0.6707
NM_000610 CD44 CD44 molecule (Indian blood group) 1.90 0.2690 1.87 0.3400
NM_004360 CDH1 Cadherin 1, type 1, E-cadherin (epithelial) -7.84 0.0020 -24.97 0.0030
NM_001843 CNTN1 Contactin 1 -1.53 0.5229 1.39 0.5852
NM_080629 COL11A1 Collagen, type XI, alpha 1 -1.56 0.7012 -1.24 0.8480
NM_004370 COL12A1 Collagen, type XII, alpha 1 -1.20 0.6134 -1.01 0.9757
NM_021110 COL14A1 Collagen, type XIV, alpha 1 (undulin) -4.25 0.0030 -1.92 0.3324
NM_001855 COL15A1 Collagen, type XV, alpha 1 -1.03 0.9599 -2.31 0.1258
NM_001856 COL16A1 Collagen, type XVI, alpha 1 4.31 0.0446 5.29 0.0454
NM_000088 COL1A1 Collagen, type I, alpha 1 1.96 0.0916 6.77 0.0010
NM_001846 COL4A2 Collagen, type IV, alpha 2 1.24 0.4717 3.96 0.0028
NM_000093 COL5A1 Collagen, type V, alpha 1 1.30 0.2851 2.19 0.0353
NM_001848 COL6A1 Collagen, type VI, alpha 1 1.07 0.8835 3.69 0.0295
NM_001849 COL6A2 Collagen, type VI, alpha 2 1.08 0.8237 1.29 0.5571
NM_000094 COL7A1 
Collagen, type VII, alpha 1 (epidermolysis 
bullosa, dystrophic, dominant and recessive) 7.48 0.0457 22.04 0.0139
NM_001850 COL8A1 Collagen, type VIII, alpha 1 -1.84 0.0858 5.12 0.0362
NM_004385 VCAN Versican 1.80 0.2063 13.57 0.0023
NM_001901 CTGF Connective tissue growth factor -2.06 0.0974 2.21 0.0267
NM_001903 CTNNA1 
Catenin (cadherin-associated protein), alpha 
1, 102kDa -1.16 0.3706 -1.31 0.0647
NM_001904 CTNNB1 
Catenin (cadherin-associated protein), beta 
















NM_001331 CTNND1 Catenin (cadherin-associated protein), delta 1 1.25 0.1221 1.36 0.1231
NM_001332 CTNND2 
Catenin (cadherin-associated protein), delta 2 
(neural plakophilin-related arm-repeat 
protein) -5.65 0.0317 1.33 0.7402
NM_004425 ECM1 Extracellular matrix protein 1 1.70 0.0500 2.13 0.0129
NM_002026 FN1 Fibronectin 1 5.10 0.0058 18.86 0.0004
NM_001523 HAS1 Hyaluronan synthase 1 1.23 0.6363 1.78 0.2734
NM_000201 ICAM1 
Intercellular adhesion molecule 1 (CD54), 
human rhinovirus receptor 1.31 0.1379 1.85 0.0053
NM_181501 ITGA1 Integrin, alpha 1 4.82 0.0154 1.44 0.4216
NM_002203 ITGA2 
Integrin, alpha 2 (CD49B, alpha 2 subunit of 
VLA-2 receptor) 2.03 0.0972 5.53 0.0093
NM_002204 ITGA3 
Integrin, alpha 3 (antigen CD49C, alpha 3 
subunit of VLA-3 receptor) -1.92 0.2602 1.25 0.5022
NM_000885 ITGA4 
Integrin, alpha 4 (antigen CD49D, alpha 4 
subunit of VLA-4 receptor) -1.47 0.5041 5.29 0.0966
NM_002205 ITGA5 
Integrin, alpha 5 (fibronectin receptor, alpha 
polypeptide) 2.29 0.0374 4.27 0.0048
NM_000210 ITGA6 Integrin, alpha 6 -2.31 0.0028 1.08 0.6795
NM_002206 ITGA7 Integrin, alpha 7 -1.32 0.4871 2.33 0.0222
NM_003638 ITGA8 Integrin, alpha 8 -1.21 0.3085 1.21 0.6208
NM_002209 ITGAL 
Integrin, alpha L (antigen CD11A (p180), 
lymphocyte function-associated antigen 1; 
alpha polypeptide) 1.54 0.5964 1.23 0.5997
NM_000632 ITGAM 
Integrin, alpha M (complement component 3 
receptor 3 subunit) 1.36 0.4506 1.35 0.3214
NM_002210 ITGAV 
Integrin, alpha V (vitronectin receptor, alpha 
polypeptide, antigen CD51) 1.32 0.3799 1.78 0.0673
NM_002211 ITGB1 
Integrin, beta 1 (fibronectin receptor, beta 
polypeptide, antigen CD29 includes MDF2, 
MSK12) 1.71 0.0022 1.64 0.0596
NM_000211 ITGB2 
Integrin, beta 2 (complement component 3 
receptor 3 and 4 subunit) 4.41 0.0445 -1.11 0.8287
NM_000212 ITGB3 
Integrin, beta 3 (platelet glycoprotein IIIa, 
antigen CD61) 2.50 0.0016 6.96 0.0006
NM_000213 ITGB4 Integrin, beta 4 -5.66 0.0404 -1.69 0.4185
NM_002213 ITGB5 Integrin, beta 5 -1.35 0.1418 1.68 0.0037
NM_000216 KAL1 Kallmann syndrome 1 sequence -1.16 0.2634 -1.04 0.7891
NM_005559 LAMA1 Laminin, alpha 1 -2.88 0.0111 -2.36 0.0417

















Laminin, alpha 2 (merosin, congenital 
muscular dystrophy) -1.07 0.8996 -3.17 0.1099
NM_000227 LAMA3 Laminin, alpha 3 -3.19 0.0014 -5.31 0.0092
NM_002291 LAMB1 Laminin, beta 1 -1.05 0.8314 1.12 0.5147
NM_000228 LAMB3 Laminin, beta 3 4.15 0.0203 1.22 0.7551
NM_002293 LAMC1 Laminin, gamma 1 (formerly LAMB2) -1.07 0.8099 1.15 0.4630
NM_002421 MMP1 
Matrix metallopeptidase 1 (interstitial 
collagenase) 4.64 0.0092 1.33 0.5187
NM_002425 MMP10 Matrix metallopeptidase 10 (stromelysin 2) 1.88 0.3267 2.78 0.2674
NM_005940 MMP11 Matrix metallopeptidase 11 (stromelysin 3) -1.49 0.0187 1.14 0.1675
NM_002426 MMP12 
Matrix metallopeptidase 12 (macrophage 
elastase) 13.91 0.0291 2.00 0.4401
NM_002427 MMP13 Matrix metallopeptidase 13 (collagenase 3) 35.73 0.0217 4.94 0.2466
NM_004995 MMP14 
Matrix metallopeptidase 14 
(membrane-inserted) 1.28 0.2139 3.09 0.0141
NM_002428 MMP15 
Matrix metallopeptidase 15 
(membrane-inserted) -1.91 0.0576 -1.39 0.3123
NM_005941 MMP16 
Matrix metallopeptidase 16 
(membrane-inserted) -1.11 0.8321 3.79 0.0200
NM_004530 MMP2 
Matrix metallopeptidase 2 (gelatinase A, 
72kDa gelatinase, 72kDa type IV 
collagenase) 1.25 0.4174 1.87 0.0977
NM_002422 MMP3 
Matrix metallopeptidase 3 (stromelysin 1, 
progelatinase) 4.21 0.0062 3.69 0.1004
NM_002423 MMP7 Matrix metallopeptidase 7 (matrilysin, uterine) 1.14 0.8929 -2.42 0.3231
NM_002424 MMP8 
Matrix metallopeptidase 8 (neutrophil 
collagenase) 20.95 0.0002 1.42 0.6494
NM_004994 MMP9 
Matrix metallopeptidase 9 (gelatinase B, 
92kDa gelatinase, 92kDa type IV 
collagenase) 17.82 0.0124 11.74 0.0163
NM_000615 NCAM1 Neural cell adhesion molecule 1 -2.00 0.0077 1.11 0.6969
NM_000442 PECAM1 
Platelet/endothelial cell adhesion molecule 
(CD31 antigen) 1.77 0.1250 -1.13 0.7728
NM_000450 SELE Selectin E (endothelial adhesion molecule 1) 1.15 0.7367 1.27 0.5401
NM_000655 SELL Selectin L (lymphocyte adhesion molecule 1) 1.50 0.3829 -1.48 0.4084
NM_003005 SELP 
Selectin P (granule membrane protein 
140kDa, antigen CD62) -1.13 0.7645 -1.90 0.1507
NM_003919 SGCE Sarcoglycan, epsilon -1.10 0.5713 -1.20 0.5489
NM_003118 SPARC 
Secreted protein, acidic, cysteine-rich 

















Spastic paraplegia 7, paraplegin (pure and 
complicated autosomal recessive) -1.13 0.4013 1.12 0.5336
NM_000582 SPP1 
Secreted phosphoprotein 1 (osteopontin, 
bone sialoprotein I, early T-lymphocyte 
activation 1) -2.31 0.1333 2.38 0.2076
NM_000358 TGFBI 
Transforming growth factor, beta-induced, 
68kDa 2.88 0.0025 12.04 0.0020
NM_003246 THBS1 Thrombospondin 1 2.54 0.2395 35.14 0.0045
NM_003247 THBS2 Thrombospondin 2 -1.06 0.8511 2.85 0.0109
NM_007112 THBS3 Thrombospondin 3 -1.59 0.1120 2.07 0.0229
NM_003254 TIMP1 TIMP metallopeptidase inhibitor 1 1.31 0.0497 1.15 0.6037
NM_003255 TIMP2 TIMP metallopeptidase inhibitor 2 -1.22 0.2837 1.66 0.0416
NM_000362 TIMP3 
TIMP metallopeptidase inhibitor 3 (Sorsby 
fundus dystrophy, pseudoinflammatory) 1.79 0.0428 1.54 0.1604
NM_003278 CLEC3B C-type lectin domain family 3, member B -1.14 0.7771 -1.03 0.9466
NM_002160 TNC Tenascin C (hexabrachion) 4.82 0.0416 5.39 0.0408
NM_001078 VCAM1 Vascular cell adhesion molecule 1 -1.51 0.2700 -6.90 0.0342
NM_000638 VTN Vitronectin -1.36 0.5494 -5.09 0.0252
NM_004048 B2M Beta-2-microglobulin -1.20 0.1240 -2.30 0.0126
NM_000194 HPRT1 
Hypoxanthine phosphoribosyltransferase 1 
(Lesch-Nyhan syndrome) 1.04 0.8691 -1.19 0.7160
NM_012423 RPL13A Ribosomal protein L13a -1.30 0.0133 -1.58 0.0920
NM_002046 GAPDH Glyceraldehyde-3-phosphate dehydrogenase 1.75 0.0008 1.06 0.7344
NM_001101 ACTB Actin, beta -1.16 0.4649 1.32 0.1824
 
The arrays revealed that some genes were regulated by both IL-1α and TGF-β1, 
whereas others were independently regulated by IL-1α or TGF-β1. Genes that were 
upregulated by both IL-1α and TGF-β1 were COL16A1, COL7A1, FN1, ITGA5, 
ITGB3, MMP9, TGFB1, and TNC. Genes that were downregulated by both IL-1α 
and TGF-β1 were CDH1, LAMA1 and LAMA3. IL-1α upregulated several genes on 
its own, including ITGA1, ITGB2, LAMB3, MMP1, MMP3, MMP8, MMP12 and 
MMP13; while COL14A1, CTNND2, ITGA6, ITGB4 and NCAM1 were 
downregulated by IL-1α alone. TGF-β1 upregulated several genes on its own, 
including COL1A1, COL4A2, COL5A1, COL6A1, COL8A1, VCAN, CTGF, ECM1, 
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ITGA2, ITGA7, MMP14, MMP16, THBS1, THBS2 and THBS3; while ADAMTS1, 
VCAM1, VTN, and B2M were downregulated by TGF-β1 treatment.  
To validate the microarray, RT-PCR was performed to confirm the observed changes 
in gene expression level. Using the same samples used for microarray analysis, 
together with other samples, gene-specific PCR was performed on a selection (n=7) 
of the genes modulated by IL-1α or TGF-β1. This analysis confirmed the reliability 
of the microarray data: all the genes tested showed the same significant predicted 
shifts in expression (Table 6.3). 
 
Table 6.3. Subset of genes randomly selected and validated by quantitative 
real-time PCR on PMC samples subjected to microarray analysis. Statistical 
analysis was by paired t-test or nonparametric Wilcoxon-matched-pairs test, mean 
fold change ±S.E.M. ns, not significant, *p<0.05, **p<0.01 compared to untreated 
cells. 





(n) Array qRT-PCR Array qRT-PCR 
NM_004360 CDH1 n=4 -7.84 -5.03±1.60* -24.97 -5.60±3.02*
NM_000088 COL1A1 n=5 1.96 1.67±0.46* 6.77 2.83±0.45**
NM_002026 FN1 n=6 5.10 6.30±2.29* 18.86 11.56±3.89*
NM_002205 ITGA5 n=6 2.29 1.77±0.32* 4.27 2.54±0.48* 
NM_004994 MMP9 n=6 17.82 23.82±9.87* 11.74 14.90±6.45*
NM_000358 TGFBI n=6 2.88 1.64±0.15** 12.04 2.63±0.38**




The microarray results confirm the involvement of IL-1α and TGF-β1 in the 
activation or inhibition of a wide range of different genes, involved in tissue repair 
and fibrosis. This may help us to better understand the underlying mechanism of 
tissue repair that is unique to PMC. To interpret these findings more clearly, the 
genes regulated by IL-1α and TGF-β1 will be discussed by organizing them into five 
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groups namely a collagen group, a laminin group, an integrin group, a MMP group 
and others.  
 
The collagen family is the most important component in the progression of adhesion 
or fibrosis. They are formed by the triple helical three α chains that are composed of 
repeating peptide triplets of glycine-X-Y (X,Y can be any amino acid). However, 
different members of the collagen family may also include non-collagenous 
(non-gly-X-Y) regions flanked in each α chain. These regions contain recognizable 
spots found in other matrix molecules, which can direct collagen incorporation into 
the matrix (Gordon and Hahn, 2010). Therefore, the functions of collagens can be 
variable. It depends on the proper assembly of the supramolecular structure that 
directs incorporation into the matrix. The current data showed that TGF-β1 but not 
IL-1α induced the expression of most of the collagen family members, including 
collagens I, IV, V, VI and VIII. Collagens I and V are fibrillar collagens that contain 
a perfect gly-X-Y triplet structure. They can be assembled into heterotrimers with 
type V collagen molecules buried within the fibril and type I collagen molecules 
presented along the fibril surface (Birk, 2001). Type V collagen is also shown to 
nucleate fibrils of type I collagen and regulate the fibril diameter (Wenstrup et al., 
2006; Birk et al., 1990). Collagens IV, VI and VIII are shown to be network-forming 
collagens. Type IV is a basement membrane collagen which forms a 
three-dimensional structure from a chicken wire-like two-dimensional structure 
(Khoshnoodi et al., 2008). Collagen VI is a ubiquitous extracellular matrix protein 
that is present in the stroma. It also forms a microfibrillar network in close 
association with the basement membrane of most tissues (Lampe and Bushby, 2005). 
Collagen VIII can make a hexagonal lattice. It is expressed by many cells, 
particularly endothelial cells. Therefore, collagen VIII is an important component of 
vascular wall (Plenz et al., 2003). In summary, our data showed that TGF-β1 can 
induce collagen deposition by promoting fibril assembly and network collagen 
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formation. In the array, both IL-1α and TGF-β1 were shown to induce collagen VII 
and XVI expression in PMC. Both of these are non-fibrillar types of collagen which 
associate with other fibrils. The role of collagen VII is crucial to the attachment 
complex that rivets the epidermis to the dermis (Aumailley et al., 2006; 
Bruckner-Tuderman, 2009). As the major component of anchoring fibrils, collagen 
VII has been shown to be localized to the lamina densa of the epithelial basement 
membrane by binding to anchoring filaments at one end, while the other end can 
interact with derma by merging into the banded collagen fibrils of the dermis. 
Therefore, the production of collagen VII may contribute to adhesion formation by 
anchoring into the peritoneal tissue on opposite sides of the adhesion. Collagen XVI 
is primarily localized to basement membrane or junctions between tissues (Ratzinger 
et al., 2010). Evidence has shown that collagen XVI is a preferred substrate for the 
formation and maturation of focal contacts of myofibroblasts, promoting more stable 
and longer adhesion of myofibroblasts to the matrix (Ratzinger et al., 2010). Thus, 
the induction of collagen VII by IL-1α and TGF-β1 observed in the present study 
may promote tissue adhesion, while the upregulation of collagen XVI may enhance 
the adherence of myofibroblasts in the inflammatory areas. Interesting, the results 
also showed that IL-1α downregulated collagen XIV expression in PMC. Collagen 
XIV is also a non-fibrillar type of collagen binding to the surface of other fibrillar 
collagens. It functions as a fibril diameter regulator by preventing the fusion of fibrils 
into larger complexes (Ansorge et al., 2009). Therefore, IL-1α might also contribute 
to the formation of larger fibril bundles by suppressing collagen XIV expression in 
PMC.        
 
Laminins are also important components of the basement membrane together with 
collagens. The production of laminins by PMC will contribute to the reconstruction 
of basement membrane while they are also critical for the adherence of PMC to the 
newly forming basement membrane matrix (Tzu and Marinkovich, 2008). In the 
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array, both IL-1α and TGF-β1 downregulated laminin α1 and α3 expression in PMC. 
These comprise the two main alpha chains that combine with other β and γ chains to 
form the trimeric assembled laminin proteins. In contrast, laminin β3 was 
upregulated in PMC by IL-1α. To date, the only known role of laminin β3 is its 
involvement in the formation of laminin-332 that functions as a component of the 
hemidesmosome-anchoring filament complex (Tzu and Marinkovich, 2008). It helps 
to bridge the cell surface with the dermis. However, such function is based on the 
ability of C-terminal G domains of the α3 chain to bind to the cell surface integrins 
(α6β4, α3β1), while the N-terminal can connect to collagen VII to provide anchorage 
to the dermis (Tzu and Marinkovich, 2008; Suzuki et al., 2005). Therefore, the 
upregulation of laminin β3 is difficult to interpret in light of the downregulation of 
laminin α3. In summary, the effects of IL-1α and TGF-β1 may delay the repair of the 
basement at the injured sites by impeding the production of laminin protein. In 
addition, it may also prevent the cell-basement matrix attachment by preventing the 
hemidesmosome-anchoring filament complex formation. 
 
As discussed above, integrins are important for the adherence of cells to the ECM 
and cell motility. In this study, integrin α1 and α2 were upregulated by IL-1α and 
TGF-β1, respectively. Both integrin α1 and α2 can form heterodimers with integrin 
β1 (integrin α1β1 and α2β1) to function as collagen receptors which mediate cell 
binding to collagen (Humphries et al., 2006). Meanwhile, integrin α5 was 
upregulated by both IL-1α and TGF-β1 in the array. It can form heterodimers with 
integrin β1 (integrin α5β1) to function as the main fibronectin receptor mediating cell 
binding to fibronectin (Humphries et al., 2006). In addition, we showed that integrin 
β3 was upregulated by both IL-1α and TGF-β1. It also forms heterodimers with 
integrin αV and αIIb (integrin αVβ3 and αIIbβ3) to function as another fibronectin 
receptor mediating cell binding to fibronectin (Xiong et al., 2002). Integrin α5β1 and 
αVβ3 are also involved in the activation of RhoA and Rac1, respectively. They can 
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regulate the balance between RhoA and Rac1, and thus promote cell migration and 
control the direction of cell movement (Danen et al., 2005; White et al., 2007). These 
findings were partially confirmed in the wound-healing and cell-ECM adhesion 
assays. Integrin α7 was upregulated in PMC by TGF-β1. It can form heterodimers 
with integrin β1 (integrin α7β1) to function as a laminin receptor mediating cell 
binding to laminin-111 and to a mixture of laminin-211 and -221 but not to 
laminin-332 (Yao et al., 1996). In contrast, IL-1α was shown to suppress integrin α6 
and β4 expression in the array. Both integrin α6β1 and α6β4 play a role in the 
adherence of cells to laminin (Lee et al., 1992; Sonnenberg et al., 1990), including 
laminin-332. Integrin α6β4 is widely expressed in most epithelial tissues and 
contributes to the formation of hemidesmomes with laminin-332 (Soung et al., 2011; 
Borradori and Sonnenberg, 1999). A defect in integrin α6β4 leads to a skin blistering 
condition (Ashton et al., 2001). Integrin α7β1 is mainly expressed on the surface of 
skeletal myoblasts and myofibres. A lack of integrin α7β1 is associated with 
congenital muscular dystrophies. Therefore, integrin α7β1 is not as essential as 
integrin α6β1 and α6β4 with respect to the role of PMC during peritoneal repair. 
Lastly, IL-1α upregulated integrin β2 expression in PMC. Integrin β2 can form 
heterodimers with integrins αL, αM, αX and αD to function as leukocyte-specific 
receptors mediating leukocyte binding to cells by recognizing ICAM-1 on the target 
cells (Wang and Springer, 1998; Shimaoka et al., 2003). It is mainly expressed on 
leukocytes. Therefore, integrin β2 expression in PMC may be low, but its function is 
not clear. In general, IL-1α and TGF-β1 induced the expression of several integrin 
family members, which facilitate the adherence of PMC to ECM substrates including 
collagen and fibronectin. This enhanced cell adhesion could also promote cell 
motility by activating Rho-GTPases. Interesting, IL-1α was shown to impede cell 
attachment to the basement membrane by suppressing the expression of integrin α6 
and β4. Meanwhile, IL-1α reduced production of laminin from PMC that further 
inhibits the repair of basement membrane. This might explain the origin of 
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free-floating mesothelial cells in the peritoneal cavity found in other studies, due to 
lower adherence to the basement membrane and its delayed repair.  
 
The MMPs were regulated independently by IL-1α and TGF-β1 in PMC. IL-1α 
upregulated MMP1, MMP3, MMP8, MMP12 and MMP13. As discussed above 
(section 1.5.4), MMP1, MMP8 and MMP13 belong to a collagenase subgroup which 
preferentially cleave collagen. MMP3 is a stromelysin able to digest a wide range of 
substrates including collagens, laminins, fibronectin, etc. It also activates other 
MMPs including MMP-1, MMP-7, and MMP-9. MMP12 is mainly produced by 
macrophages as a macrophage elastase. It has also been shown that MMP12 is a 
potent proinflammatory molecule associated with lung fibrosis (Qu et al., 2009; 
Madala et al., 2010; Garbacki et al., 2009). The role of MMP12 produced by PMC in 
peritoneal fibrosis, however, requires further investigation. Both IL-1α and TGF-β1 
upregulated MMP9 expression in PMC. MMP9 is mainly a gelatinase, but it can also 
degrade collagens IV and V. It is a secreted product of activated monocytes 
(Opdenakker et al., 2001) and a major component of the tertiary granules of human 
neutrophils (Cowland and Borregaard, 1999). Elevated MMP9 is found during the 
wound-healing process in a variety of tissues. Its role may be in promoting cell 
locomotion in the wound matrix, remodelling of the granulation tissue matrix and 
angiogenesis in ischemic tissue (Muhs et al., 2003; Heissig et al., 2010). In addition 
to MMP9, TGF-β1 also upregulated MMP14 and MMP16 expression in PMC. Both 
are membrane-inserted MMPs. It has been shown that MMP14 and MMP16 can 
operate in an autonomous fashion to drive fibrin-invasive activity of fibroblasts 
(Hotary et al., 2002). In addition, MMP14 also exerts pericellualr collagenolytic 
activity supporting the tissue-invasive phenotype of fibroblast on collagen substrate, 
whereas MMP16 is not necessary for such cell behaviour (Sabeh et al., 2009). 
Therefore, the upregulation of MMP14 and 16 by TGF-β1 can facilitate the invasion 
of EMT-transformed PMC into fibrin-rich clots covering injury sites or other 
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pro-fibrotic tissue further promoting the progression of fibrosis. In general, IL-1α 
induced variant expression of MMPs in PMC, a response for the degradation and 
remodelling of the ECM. In contrast, TGF-β1 had little effect on the expression of 
secreted MMPs except for MMP9. However, membrane-inserted MMPs (MMP14, 
16) were upregulated only by TGF-β1, which might contribute to the invasion of 
PMC into the repairing tissue.  
 
Fibronectin 1 (FN1), another important component of ECM, was upregulated by both 
IL-1α and TGF-β1. In addition, both IL-1α and TGF-β1 were likely to induce an 
autocrine production of TGF-β1 from PMC by upregulating TGFBI transcription. 
Such a self-induced autocrine mechanism might account for a persistent and 
excessive tissue remodelling. In contrast, both IL-1α and TGF-β1 induced tenascin C 
expression in PMC, a well known anti-adhesive ECM component. Tenascin C is an 
extracellular matrix glycoprotein. It provides weak substrate adhesion with the 
formation of focal adhesion and loss of actin-containing stress fibres, which is also 
called an intermediate state of adhesiveness (Murphy-Ullrich, 2001). This state 
allows cell shape changes and motility but prevents apoptosis and differentiation. In 
addition, tenascin C also antagonizes the pro-adhesive effects of collagens, 
fibronectin and laminins (Hsia and Schwarzbauer, 2005). However, our in vitro 
adhesion assay confirmed an enhanced adherence of PMC to fibronectin. Thus, in 
this case, the elevation of tenascin C might be insufficient to prevent adherence of 
PMC to other ECM substrates.  
 
As a hallmark of the EMT process, E-cadherin had been shown to be downregulated 
by both IL-1α and TGF-β1 previously. IL-1α was also shown to suppress CTNND2 
expression in the array. CTNND2 can directly bind to the unique juxtamembrane 
domain in E-cadherin to support the stability of E-cadherin-based adherent junctions, 
that help to maintain epithelial tissue integrity (Lu, 2010). The role of CTNND2 in 
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cancer pathogenesis has been widely studied (Zhang et al., 2010; Wang et al., 2009), 
but its role in peritoneal fibrosis is still unclear. IL-1α also suppressed neural cell 
adhesion molecule 1 (NCAM1) expression in PMC. NCAM1 is a homophilic 
binding glycoprotein that has been studied in neurons (Stoenica et al., 2006) and 
renal interstitial cells (Markovic-Lipkovski et al., 2007). NCAM has been implicated 
as having a role in cell–cell adhesion, neurite outgrowth and learning and memory.  
   
TGF-β1 treatment alone upregulated some other important genes in PMC, including 
versican, CTGF, EMC1 and thrombospondins (TSP) 1,2 & 3. Versican is a large 
extracellular matrix proteoglycan present in many tissues. It is a basic structural 
molecule to create loose and hydrated matrices during events including tissue repair 
(Wight, 2002). It also regulates ECM assembly and expansion, cell adhesion and 
survival, cell proliferation and cell migration (Wight, 2002). Due to these varied 
functions, the induction of versican in PMC by TGF-β1 may apparently contribute to 
peritoneal repair. CTGF is a well-known downstream factor in TGF-β1-induced 
tissue remodelling. A recent paper has demonstrated a cooperative interaction 
between CTGF and TGF-β signalling to induce fibrosis and adhesion between organs 
in the abdominal cavity (Wang et al., 2011). ECM1 has a key interaction with 
perlecan, a major heparin sulphate proteoglycan of basement membrane, that allows 
ECM1 to function as a biological glue to help regulate basement membrane and 
collagen fibril assembly, and growth factor binding in dermis (Chan, 2004). However, 
the role of ECM1 in peritoneal fibrosis remains unclear. TSP 1, 2 and 3 are 
multifunctional secreted glycoproteins with anti-angiogenic properties. As the most 
common type, TSP 1 is secreted by a variety of cell types including endothelial and 
epithelial cells, fibroblasts and smooth muscle cells (Kazerounian et al., 2008). 
TSP-1 has been shown to inhibit angiogenesis and activate the latent form of 
platelet-derived TGF-β1 (Fitchev et al., 2010; Ahamed et al., 2009; Simantov and 
Silverstein, 2003). Therefore, the upregulation of TSP 1, 2 and 3 by TGF-β1 may 
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have an anti-angiogenic role and augment the autocrine circuit of TGF-β1 
production.  
 
In the array, TGF-β1 also suppressed the expression of ADAMTS1, VCAM1 and 
VTN. ADAMTS1 encodes the ADAMTS 1 (a disintegrin and metalloproteinase with 
thrombospondin motifs 1) protein, which is a secreted zinc metalloprotease with an 
ancillary domain containing one or more thrombospondin type 1 repeats. It has been 
shown that ADAMTS-1 plays a role in anti-angiogenesis (Vazquez et al., 1999) and 
degradation of aggrecan including the cleaving of versican (Rodriguez-Manzaneque 
et al., 2002; Kuno et al., 2000). Knockdown of ADAMTS1 in mice can induce 
growth retardation, malformation of adipose tissue, decreased fertility with changes 
in histology of uterus and ovaries, and renal lesions mimicking obstructive 
nephropathy (Shindo et al., 2000; Thai and Iruela-Arispe, 2002; Yokoyama et al., 
2002), indicating a possible role of ADAMTS1 in ECM remodelling. VCAM1 
encodes the key adhesion molecule expressed by endothelial cells to mediate 
leucocyte attachment to blood vessels during inflammation (Barreiro et al., 2002). 
Therefore, the downregulation of VCAM1 by TGF-β1 in PMC could prevent the 
adherence of leucocytes to the transformed PMC. VTN encodes vitronectin that is an 
abundant plasma protein regulating coagulation, fibrinolysis, complement activation, 
as well as cell adhesion (Hess et al., 1995). It has been shown that vitronectin can 
bind to type 1 plasminogen activator inhibitor (PAI-1) and stabilize PAI-1 in its 
active form (Mayasundari et al., 2004; Lawrence et al., 1997). In addition, 
vitronectin is also shown to bind fibrin during coagulation (Podor et al., 2002). 
Furthermore, vitronectin can contribute to the fusion of macrophages into foreign 
body giant cells (McNally and Anderson, 2011; McNally et al., 2008). Therefore, 
vitronectin may play an essential role in modulation of hemostasis and fibrinolysis 
during tissue repair. The suppression of vitronectin by TGF-β1 in PMC may 
facilitate fibrinolysis in the area of cell invasion.  
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A summary of the possible underlying mechanisms of post-operative adhesion are 
shown in Figures 6.1 and 6.2. Our results showed that IL-1 can cause cell detachment 
from basement membrane by suppressing integrin α6β4. Meanwhile, IL-1α and 
TGF-β1 were shown to cause EMT in PMC which further broke down the 
intercellular junction by reducing E-cadherin expression on cell membrane (Figure 
6.1A). EMT-transformed cells had enhanced cell motility and were more adherent to 
ECM components. In addition, TGF-β1 could facilitate the invasion of transformed 
PMC into ECM by inducing membrane-inserted MMP 14 and 16 (Figure 6.1B). 
These suggest a likely mechanism of the origin of free-floating PMC and their 
invasion into repairing tissue. Moreover, IL-1α is mainly involved in the disruption 
of tissue homeostasis by inducing MMPs production. In contrast, TGF-β1 is involved 
in the reconstruction of damaged tissue by inducing the production of collagens and 
other ECM-related proteins, but not laminins (Figure 6.2). Thus, the balance between 
IL-1 and TGF-β effects is crucial for the remodeling of ECM. However, both IL-1α 
and TGF-β1 are able to upregulate some key pro-fibrotic factors in adhesion 
formation such as collagen VII and fibronectin, which might account for irreversible 
adhesion formation. This mechanism can be further enhanced by an autocrine circuit 
of TGF-β1 action in PMC induced by IL-1α and TGF-β1 (Figure 6.2).  
 
In this Chapter, we discussed some possible underlying mechanisms involved in 
peritoneal repair based on the microarray results. Since the results only reflect the 
regulation at the mRNA level, other studies looking at the same genes in other cell 
types are referenced to help us understand the consequences of these changes. 
Therefore, some concepts need further confirmation, while the roles of a number of 
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Figure 6.1. Underlying mechanism for recruiting PMC to repairing tissue 
during peritoneal healing. A: Origin of free-floating PMC by reducing cell-cell 
contact and cell-basement attachment. B: recruitment of EMT-transformed PMC to 




Figure 6.2. Regulation of ECM remodelling by EMT-transformed PMC and 





















Chapter 7  











7.1 Major findings of the thesis 
 
The work presented in this thesis has provided new insights into both the 
physiological and pathological roles of peritoneal mesothelial cells (PMC) in the 
progression of post-operative peritoneal adhesion.  
 
First, in vivo peritoneal fibrosis was induced by i.p injection of carbon nanotubes 
(NT), which adopted from the published work of Poland et al (Poland et al., 2008). 
We found that lysyl oxidase (LOX), a critical enzyme for collagen crosslinking, 
played an important role in the development of peritoneal fibrosis. In our in vivo 
fibrosis model, inhibition of LOX activity reduced collagen deposition, which further 
minimized the granuloma lesions on the peritoneal side of diaphragm. Subsequent 
studies confirmed PMC as a major source of LOX in the abdominal cavity; and the 
expression of LOX can be regulated by several inflammatory cytokines, including 
IL-1, IL-4, TNF-α, and TGF-β. Upregulation of LOX by IL-1 was confirmed at both 
mRNA and protein levels, whereas the effects of other cytokines were found not as 
potent as IL-1. In contrast, collagen expression in PMC was induced by TGF-β, but 
not by IL-1. These data provide a likely fundamental mechanism for collagen 
deposition which needs the presence of both IL-1 and TGF-β. Therefore, the 
combination of IL-1 and TGF-β was used to mimic the complicated inflammatory 
environment during peritoneal fibrosis. Results showed that, in the presence of IL-1 
and TGF-β, PMC underwent a dramatic cell morphologic change, in terms of an 
epithelial-mesenchymal-transition (EMT). These EMT-transformed PMC had 
enhanced cell motility and were more adherent to ECM component (fibronectin) 
compared to normal PMC.  
 
A real-time quantitative PCR-based microarray was used for genomic analysis of 
ECM-adhesion-related PMC genes in response to IL-1 and TGF-β treatments. The 
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results showed that IL-1 was more involved in regulating ECM degradation by 
inducing expression of matrix metalloproteinase (MMP) genes, including MMP 1, 3, 
8, 9, and 13. In contrast, TGF-β mainly affected genes involved in ECM deposition, 
including collagens (collagens I, IV, V, VI, VIII) and other ECM components 
(Versican, ECM1). However, both cytokines were shown to regulate some key genes 
involved in the development of adhesion, including COL16A1, COL7A1, FN1, and 
ITGA5. In addition, the combination of IL-1 and TGF-β was shown to induce an 
autocrine circuit of TGF-β production from PMC by increasing TGFB1 and THBS1 
expression (Figure 6.2). Furthermore, IL-1 reduced ITGA4 and ITGB6 expression 
affecting adherence of PMC to basement membrane; while TGF-β increased MMP14 
and MMP16 expression, which could facilitate invasion of EMT-transformed PMC 
to the site of tissue repair. 
 
Inflammatory cytokines were strongly associated with these studies. We first 
identified that NT-treated macrophages can release TNF-α, but not IL-1α. 
Meanwhile, results also showed that the cell-associated form of IL-1α (CA-IL-1α) 
was produced by PMC in response to TNF-α. Moreover, the combination of TNF-α 
and TGF-β1 synergistically induced both secreted IL-1α and CA-IL-1α expression 
from PMC. In addition, TNF-α-induced LOX expression in PMC was inhibited by 
the addition of the IL-1 receptor antagonist (IL-1ra). This is suggestive that TNF-α 
signalling network could be partially mediated by the elevation of IL-1.   
 
In the thesis, we also showed that application of dexamethasone (DEX) reduced 
NT-induced fibrosis on mouse diaphragms. Our in vitro results showed that DEX can 
suppress TNF-α production from NT-treated macrophages. In addition, addition of 
cortisol reduced IL-1-induced LOX production from ovarian surface epithelial (OSE) 
cells. A similar suppression of cortisol had been observed on PMC, but this was not 
as effective as that on OSE cells. Furthermore, cortisol suppressed both secreted 
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IL-1α and CA-IL-1α production from PMC in response to TNF-α and TNF-α+TGF-β 
treatments. However, no interaction between cortisol and TGF-β was found in either 
PMC or OSE cells.  
 
7.2 Prospective pathology of peritoneal repair and peritoneal adhesion. 
 
The unique mechanism of peritoneal repair is the incorporation of free-floating PMC 
into the regenerating mesothelium, to reconstitute an intact mesothelial monolayer 
(Foley-Comer et al., 2002). However, how these cells become detached from the 
basement membrane and appear on regenerating peritoneum still requires further 
investigation. Our result showed that, these free-floating PMC could be a 
consequence of downregulation of integrin α6β4 expression induced by IL-1. Since 
integrin α6β4 plays an important role in the adherence of cells to laminin (Lee et al., 
1992; Sonnenberg et al., 1990), reduction of integrin α6β4 could lead to the 
dissociation of PMC from the basement membrane. Moreover, our results showed 
that PMC underwent EMT in response to inflammatory stimuli, which broke down 
the intercellular junction by reducing E-cadherin expression on cell membrane. This 
process may further disrupt the mesothelial monolayer and result in more 
free-floating PMC (Figure 6.1A). In addition, the results showed that 
EMT-transformed cells had enhanced cell motility and were more adherent to ECM 
components. Therefore, EMT can promote the centripetal migration of PMC from 
the wound edge, as well as the reattachment of free-floating PMC to the regenerating 
peritoneum covered with ECM components, including collagen, fibronectin and 
fibrin. In the meantime, TGF-β was shown to induce the MMP 14 and MMP 16 
expression on the cell membrane, which may promote the invasion of PMC into the 
underlying connective tissue or the fibrin clot (Figure 6.1B). This could explain the 
presence of cells with epithelial-like characteristics in the subserosal layer of biopsies 
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from various pathological conditions (Bolen et al., 1986; Bolen et al., 1987; Davila 
and Crouch, 1993; Dobbie, 1990).  
 
Furthermore, these EMT-transformed cells can contribute to the peritoneum repair by 
producing several ECM components, including collagens, fibronectin, versican, and 
tenascin C. As we discussed previously, collagen crosslinking and deposition can be 
enhanced by the increased PMC-derived LOX expression in response to IL-1. Fibril 
and network collagen growth can be promoted by the production of collagens I, IV, 
V, VI, and VIII; while fibril fusion can be enhanced by reduction of collagen XIV. 
The increasing level of collagen XVI may further recruit more EMT-transformed 
PMC and myofibroblast into the injured areas. Meanwhile, the upregulation of 
collagen VII could promote hemidesmosome formation which could eventually lead 
to adhesions forming between the wounded area and the opposing mesothelium. 
Moreover, CTGF and ECM1 were also found produced by the transformed cells, 
which synergistically promote EMC synthesis and deposition together with TGF-β. 
Therefore, EMT-transformed PMC not only reconstitute the mesothelium monolayer 
by cell proliferation, they also contribute to the repair process by increasing ECM 
deposition (Figure 6.2). Interestingly, laminin α3 expression was reduced in the 
EMT-transformed cells, indicating a possible delayed repair of the damaged 
basement membrane (Figure 6.1A).  
 
Although these transformed PMC can promote ECM synthesis and deposition, our 
results also showed they played an important role in ECM degradation. 
EMT-transformed PMC was shown to secrete various MMPs in response to IL-1. 
These MMPs, including collagenase and gelatinase, are highly involved in the 
degradation of ECM components, especially for collagen, fibronectin and fibrin 
(Figure 6.2). Therefore, EMT-transformed PMC are able to initiate both ECM 
deposition and degradation within the injured tissue or the fibrin clot. During a 
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normal peritoneal repair, the balance of such ECM remodelling mechanism of PMC 
might be well controlled, leading to tissue repair without any fibrosis. However, as is 
well known, serious surgical damage can cause a chronic inflammation in the 
abdominal cavity, causing a persisted activation of inflammatory factors and a 
significant delay in fibrinolysis (Holmdahl et al., 1996). Therefore, chronic 
inflammation may cause a persisting EMT process on normal PMC, which facilitates 
more EMT-transformed PMC recruitment into the fibrin clot. The delayed 
fibrinolysis can further provide a platform for PMC to deposit ECM components, 
which makes the fibrin clot become a precursor for an adhesion. In addition, the 
fibrin tissue might also provide a barrier for the infiltrated PMC, separating these 
cells from outside inflammatory stimuli, including IL-1 and TGF-β. However, our 
results indicated an autocrine circuit of TGF-β production of PMC (Figure 6.2). 
Therefore, after infiltration into the fibrin, the IL-1-induced ECM degradation might 
become weaker, whereas the TGF-β-induced ECM deposition can persist by its own 
autocrine feedback circuit. The balance of the ECM remodelling will shift to the 
synthesis and deposition site, eventually leading to adhesion formation replacing the 
fibrin.  
 
7.3 Anti-inflammatory steroid treatments for peritoneal adhesion. 
 
In the thesis, we already showed that anti-inflammatory steroid (DEX) can reduce 
peritoneal fibrosis induced by carbon nanotubes. The underlying mechanism 
involved a suppression of DEX on the NT-induced TNF-α production from 
macrophages. As we discussed previously, anti-inflammatory steroid environment 
seemed to play an important role in ovary scar-free repair. Results showed that 
cortisol can significantly suppress IL-1-induced LOX rise in OSE cells, while its 
effect on PMC was similar albeit less effective. It suggested a more sensitive 
responding model might present in OSE cells compared to PMC. However, cortisol 
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was shown to reduce both secreted IL-1α and CA-IL-1α production from PMC in 
response to TNF-α and TGF-β. Since both types of IL-1α have biological activity, 
the suppression of cortisol not only reduced secreted IL-1α levels to avoid a systemic 
inflammation, but also minimized any local inflammatory response by reducing 
CA-IL-1α levels. Interestingly, cortisol alone had no interaction with TGF-β 
signalling pathways. Therefore, the application of DEX or cortisol treatment may not 
be able to prevent TGF-β-induced ECM deposition effectively.   
 
7.4 Future work 
 
In this thesis, I tried to draw a picture of the pathology of peritoneal repair and 
peritoneal adhesion, aiming to find potential therapeutic methods to treat 
post-operative adhesion. However, most of the data presented in the chapters are 
restricted to the gene level. Functional studies for particular genes are needed to 
confirm the conclusions. Single dose and time-point may not represent the real 
effects of selected cytokines. Quantification on a single section for each diaphragm 
sample could also generate inconsistent results for further experiments. Therefore, 
some of the conclusions still need further consolidation and investigation. The 
mechanism for MMP-mediated PMC invasion needs to be confirmed by in vitro cell 
invasion assays used in other studies (Hotary et al., 2002; Sabeh et al., 2009). An in 
vitro adhesion model could be developed by seeding EMT-transformed PMC onto 
fibrin clots. ECM remodelling within the fibrin can then be examined by 
immunohistochemistry.  Localization of infiltrating cells into the fibrin clot or 
pre-adhesion sites can be putatively identified by immunohistochemistry, staining 
with a specific PMC marker, such as HBME-1 (Foley-Comer et al., 2002). 
Meanwhile, blocking of membrane-associated MMPs can be conducted to inhibit cell 
invasion and prevent adhesion formation in animal models. Collagens involved in 
adhesion formation, especially collagen VII, can be indentified by specific antibody 
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for individual collagen member. Moreover, signalling pathways regulating the 
autocrine production circuit of TGF-β1 require confirmation and more detailed 
investigation. In addition, we also showed a possible manner for the PMC to 
manipulate local inflammation and systemic inflammation by secreted IL-1α and 
CA- IL-1α. However, levels of IL-1β secreted by PMC were not investigated in the 
studies. The actually amount of membrane-associated IL-1α (MA-IL-1α) derived 
from CA-IL-1α still requires determination. Flow cytometric and bioactivity analysis 
described in other studies can be used to identify the level of MA-IL-1α present in 
PMC (Niki et al., 2004).  
 
The underlying mechanism elucidated above indicated that the treatment of 
post-operative adhesion might not be simply by inhibiting any single factor. Instead, 
a combined treatment is more likely to aid the healing process before control is lost. 
First, application of an anti-inflammatory steroid, such as DEX, should help to 
suppress any excess inflammatory response. In addition, the suppression of 
inflammation may further facilitate fibrinolysis by preventing inflammation-induced 
plasminogen activator inhibitor expression (see section 1.3.3). Secondly, specific 
inhibition of MMP 14 and 16 activities may prevent EMT-transformed PMC or 
myofibroblasts infiltrating into the fibrin clot and promoting adhesion formation. 
Lastly, inhibition of LOX activity can be used to prevent collagen deposition and to 
minimize further adhesion formation. Alternatively, selective suppression of TGF-β1 
action could also help to prevent excess ECM deposition.  
 
In summary, the work in this thesis provides an underlying mechanism for peritoneal 
repair and peritoneal adhesion. The concepts of the thesis also offer some therapeutic 
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Histology sections of mouse diaphragm stained with picrosirius red 
Diaphrams were recovered from mice following 7 days treatment of the following 
groups: A: BAPN, animal treated with 0.5ml saline on day 1 and daily 200μl i.p. 
injections of BAPN (1g/kg) for 7 days. B: DEX, animal treated with 0.5ml saline on 
day 1 and daily 200μl i.p. injections of DEX (1mg/kg) for 7 days. or C: BAPN+DEX 
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